<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:m="http://schemas.microsoft.com/office/2004/12/omml"
xmlns="http://www.w3.org/TR/REC-html40">

<head>   <meta charset="utf-8" />
<meta http-equiv=Content-Type content="text/html; charset=Windows-1254">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 14">
<meta name=Originator content="Microsoft Word 14">
<link rel=File-List href="geriyatri2_dosyalar/filelist.xml">
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>Microsoft Office Kullan�c�s�</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>Bono</o:LastAuthor>
  <o:Revision>5</o:Revision>
  <o:TotalTime>47</o:TotalTime>
  <o:Created>2018-12-30T15:01:00Z</o:Created>
  <o:LastSaved>2019-01-18T17:29:00Z</o:LastSaved>
  <o:Pages>48</o:Pages>
  <o:Words>15495</o:Words>
  <o:Characters>88328</o:Characters>
  <o:Company>UNUN</o:Company>
  <o:Lines>736</o:Lines>
  <o:Paragraphs>207</o:Paragraphs>
  <o:CharactersWithSpaces>103616</o:CharactersWithSpaces>
  <o:Version>14.00</o:Version>
 </o:DocumentProperties>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=themeData href="geriyatri2_dosyalar/themedata.thmx">
<link rel=colorSchemeMapping href="geriyatri2_dosyalar/colorschememapping.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Print</w:View>
  <w:Zoom>124</w:Zoom>
  <w:GrammarState>Clean</w:GrammarState>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:HyphenationZone>21</w:HyphenationZone>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>TR</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
  </w:Compatibility>
  <w:DocumentVariables>
   <w:__Grammarly_42____i>H4sIAAAAAAAEAKtWckksSQxILCpxzi/NK1GyMqwFAAEhoTITAAAA</w:__Grammarly_42____i>
   <w:__Grammarly_42___1>H4sIAAAAAAAEAKtWcslP9kxRslIyNDa0MDczMTUwtTA1NDY1NDJS0lEKTi0uzszPAymwrAUAvOBBxiwAAAA=</w:__Grammarly_42___1>
  </w:DocumentVariables>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
  DefSemiHidden="true" DefQFormat="false" DefPriority="99"
  LatentStyleCount="267">
  <w:LsdException Locked="false" Priority="0" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 1"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 2"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 3"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 4"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 5"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 6"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 7"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 8"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 9"/>
  <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
  <w:LsdException Locked="false" Priority="10" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Title"/>
  <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
  <w:LsdException Locked="false" Priority="11" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
  <w:LsdException Locked="false" Priority="22" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
  <w:LsdException Locked="false" Priority="20" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="false"
   UnhideWhenUsed="false" Name="Table Grid"/>
  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
  <w:LsdException Locked="false" Priority="1" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 1"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
  <w:LsdException Locked="false" Priority="34" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
  <w:LsdException Locked="false" Priority="29" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
  <w:LsdException Locked="false" Priority="30" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 1"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 2"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 2"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 3"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 3"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 4"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 4"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 5"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 5"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 6"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 6"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="19" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
  <w:LsdException Locked="false" Priority="21" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
  <w:LsdException Locked="false" Priority="31" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
  <w:LsdException Locked="false" Priority="32" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
  <w:LsdException Locked="false" Priority="33" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
  <w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
  <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;
	mso-font-charset:162;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536859905 -1073732485 9 0 511 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:162;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520081665 -1073717157 41 0 66047 0;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:162;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610610945 1073750107 16 0 415 0;}
@font-face
	{font-family:MyriadPro-Light;
	mso-font-alt:"Arial Unicode MS";
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:auto;
	mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
	{font-family:"\@MyriadPro-Light";
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:auto;
	mso-font-signature:1 134676480 16 0 131072 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Ba�l�k 1 Char";
	mso-style-next:Normal;
	margin-top:24.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:0cm;
	margin-bottom:.0001pt;
	line-height:115%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:14.0pt;
	font-family:"Cambria","serif";
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#365F91;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-font-kerning:0pt;
	font-weight:bold;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"A��klama Metni Char";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Calibri","sans-serif";
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:minor-fareast;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"�stbilgi Char";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Altbilgi Char";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
span.MsoCommentReference
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-ansi-font-size:8.0pt;
	mso-bidi-font-size:8.0pt;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-noshow:yes;
	mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Konu Ba�l��� Char";
	mso-style-next:Normal;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:15.0pt;
	margin-left:0cm;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	border:none;
	mso-border-bottom-alt:solid #4F81BD 1.0pt;
	mso-border-bottom-themecolor:accent1;
	padding:0cm;
	mso-padding-alt:0cm 0cm 4.0pt 0cm;
	font-size:26.0pt;
	font-family:"Cambria","serif";
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#17365D;
	mso-themecolor:text2;
	mso-themeshade:191;
	letter-spacing:.25pt;
	mso-font-kerning:14.0pt;}
p.MsoTitleCxSpFirst, li.MsoTitleCxSpFirst, div.MsoTitleCxSpFirst
	{mso-style-noshow:yes;
	mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Konu Ba�l��� Char";
	mso-style-next:Normal;
	mso-style-type:export-only;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	border:none;
	mso-border-bottom-alt:solid #4F81BD 1.0pt;
	mso-border-bottom-themecolor:accent1;
	padding:0cm;
	mso-padding-alt:0cm 0cm 4.0pt 0cm;
	font-size:26.0pt;
	font-family:"Cambria","serif";
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#17365D;
	mso-themecolor:text2;
	mso-themeshade:191;
	letter-spacing:.25pt;
	mso-font-kerning:14.0pt;}
p.MsoTitleCxSpMiddle, li.MsoTitleCxSpMiddle, div.MsoTitleCxSpMiddle
	{mso-style-noshow:yes;
	mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Konu Ba�l��� Char";
	mso-style-next:Normal;
	mso-style-type:export-only;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	border:none;
	mso-border-bottom-alt:solid #4F81BD 1.0pt;
	mso-border-bottom-themecolor:accent1;
	padding:0cm;
	mso-padding-alt:0cm 0cm 4.0pt 0cm;
	font-size:26.0pt;
	font-family:"Cambria","serif";
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#17365D;
	mso-themecolor:text2;
	mso-themeshade:191;
	letter-spacing:.25pt;
	mso-font-kerning:14.0pt;}
p.MsoTitleCxSpLast, li.MsoTitleCxSpLast, div.MsoTitleCxSpLast
	{mso-style-noshow:yes;
	mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Konu Ba�l��� Char";
	mso-style-next:Normal;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:15.0pt;
	margin-left:0cm;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	border:none;
	mso-border-bottom-alt:solid #4F81BD 1.0pt;
	mso-border-bottom-themecolor:accent1;
	padding:0cm;
	mso-padding-alt:0cm 0cm 4.0pt 0cm;
	font-size:26.0pt;
	font-family:"Cambria","serif";
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#17365D;
	mso-themecolor:text2;
	mso-themeshade:191;
	letter-spacing:.25pt;
	mso-font-kerning:14.0pt;}
a:link, span.MsoHyperlink
	{mso-style-noshow:yes;
	mso-style-priority:99;
	color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{mso-style-noshow:yes;
	mso-style-priority:99;
	color:purple;
	mso-themecolor:followedhyperlink;
	text-decoration:underline;
	text-underline:single;}
p
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
pre
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"HTML �nceden Bi�imlendirilmi� Char";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
	font-size:10.0pt;
	font-family:"Courier New";
	mso-fareast-font-family:"Times New Roman";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"A��klama Metni";
	mso-style-link:"A��klama Konusu Char";
	mso-style-next:"A��klama Metni";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Balon Metni Char";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-fareast-language:EN-US;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{mso-style-noshow:yes;
	mso-style-priority:1;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{mso-style-noshow:yes;
	mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{mso-style-noshow:yes;
	mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{mso-style-noshow:yes;
	mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{mso-style-noshow:yes;
	mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
span.MsoSubtleEmphasis
	{mso-style-priority:19;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	color:gray;
	mso-themecolor:text1;
	mso-themetint:127;
	font-style:italic;}
span.Balk1Char
	{mso-style-name:"Ba�l�k 1 Char";
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Ba�l�k 1";
	mso-ansi-font-size:14.0pt;
	mso-bidi-font-size:14.0pt;
	font-family:"Cambria","serif";
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#365F91;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-fareast-language:TR;
	font-weight:bold;}
span.HTMLncedenBiimlendirilmiChar
	{mso-style-name:"HTML �nceden Bi�imlendirilmi� Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"HTML �nceden Bi�imlendirilmi�";
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";
	mso-fareast-language:TR;}
span.AklamaMetniChar
	{mso-style-name:"A��klama Metni Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"A��klama Metni";
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:minor-fareast;
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:TR;}
span.stbilgiChar
	{mso-style-name:"�stbilgi Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:�stbilgi;
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:TR;}
span.AltbilgiChar
	{mso-style-name:"Altbilgi Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:Altbilgi;
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:TR;}
span.KonuBalChar
	{mso-style-name:"Konu Ba�l��� Char";
	mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Konu Ba�l���";
	mso-ansi-font-size:26.0pt;
	mso-bidi-font-size:26.0pt;
	font-family:"Cambria","serif";
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#17365D;
	mso-themecolor:text2;
	mso-themeshade:191;
	letter-spacing:.25pt;
	mso-font-kerning:14.0pt;
	mso-fareast-language:TR;}
span.AklamaKonusuChar
	{mso-style-name:"A��klama Konusu Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"A��klama Metni Char";
	mso-style-link:"A��klama Konusu";
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:TR;
	font-weight:bold;}
span.BalonMetniChar
	{mso-style-name:"Balon Metni Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Balon Metni";
	mso-ansi-font-size:9.0pt;
	mso-bidi-font-size:9.0pt;
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.msonormal0, li.msonormal0, div.msonormal0
	{mso-style-name:msonormal;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.headinganchor, li.headinganchor, div.headinganchor
	{mso-style-name:headinganchor;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.bulletindent1, li.bulletindent1, div.bulletindent1
	{mso-style-name:bulletindent1;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	mso-layout-grid-align:none;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	color:black;
	mso-fareast-language:EN-US;}
span.stBilgiChar0
	{mso-style-name:"�st Bilgi Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"�st Bilgi";
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:TR;}
p.stBilgi, li.stBilgi, div.stBilgi
	{mso-style-name:"�st Bilgi";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-link:"�st Bilgi Char";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
span.AltBilgiChar0
	{mso-style-name:"Alt Bilgi Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Alt Bilgi";
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:TR;}
p.AltBilgi, li.AltBilgi, div.AltBilgi
	{mso-style-name:"Alt Bilgi";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-link:"Alt Bilgi Char";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
span.glyph
	{mso-style-name:glyph;
	mso-style-unhide:no;}
span.h1
	{mso-style-name:h1;
	mso-style-unhide:no;}
span.headingendmark
	{mso-style-name:headingendmark;
	mso-style-unhide:no;}
span.nowrap
	{mso-style-name:nowrap;
	mso-style-unhide:no;}
span.apple-converted-space
	{mso-style-name:apple-converted-space;
	mso-style-unhide:no;}
span.GramE
	{mso-style-name:"";
	mso-gram-e:yes;}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	font-size:10.0pt;
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Calibri","sans-serif";
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-fareast-language:EN-US;}
@page WordSection1
	{size:612.0pt 792.0pt;
	margin:70.85pt 70.85pt 70.85pt 70.85pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 @list l0
	{mso-list-id:155583761;
	mso-list-type:hybrid;
	mso-list-template-ids:786570436 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:38.45pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l0:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:74.45pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l0:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:110.45pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l0:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:146.45pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l0:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:182.45pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l0:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:218.45pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l0:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:254.45pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l0:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:290.45pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l0:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:326.45pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l1
	{mso-list-id:213203066;
	mso-list-type:hybrid;
	mso-list-template-ids:-1184039740 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l1:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l1:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l1:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l1:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l1:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l1:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l1:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l1:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l1:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l2
	{mso-list-id:290791737;
	mso-list-type:hybrid;
	mso-list-template-ids:-363569078 1593456880 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l2:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:14.0pt;
	font-family:Symbol;}
@list l2:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l2:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l2:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l2:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l2:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l2:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l2:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l2:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l3
	{mso-list-id:426654361;
	mso-list-type:hybrid;
	mso-list-template-ids:-1535328612 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l3:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l3:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l3:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l3:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l3:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l3:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l3:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l3:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l3:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l4
	{mso-list-id:835070106;
	mso-list-type:hybrid;
	mso-list-template-ids:-1822249982 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l4:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l4:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l4:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l4:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l4:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l4:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l4:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l4:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l4:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l5
	{mso-list-id:882134769;
	mso-list-type:hybrid;
	mso-list-template-ids:1663064120 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l5:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l5:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l5:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l5:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l5:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l5:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l5:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l5:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l5:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l6
	{mso-list-id:898243831;
	mso-list-type:hybrid;
	mso-list-template-ids:-1483986816 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l6:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l6:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l6:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l6:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l6:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l6:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l6:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l6:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l6:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l7
	{mso-list-id:1084113065;
	mso-list-type:hybrid;
	mso-list-template-ids:-1054206956 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l7:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l7:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l7:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l7:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l7:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l7:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l7:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l7:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l7:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l8
	{mso-list-id:1096711148;
	mso-list-type:hybrid;
	mso-list-template-ids:876135142 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l8:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l8:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l8:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l8:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l8:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l8:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l8:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l8:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l8:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l9
	{mso-list-id:1218130015;
	mso-list-type:hybrid;
	mso-list-template-ids:-633699172 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l9:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l9:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l9:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l9:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l9:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l9:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l9:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l9:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l9:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l10
	{mso-list-id:1221287162;
	mso-list-type:hybrid;
	mso-list-template-ids:-630536060 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l10:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l10:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l10:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l10:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l10:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l10:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l10:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l10:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l10:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l11
	{mso-list-id:1240866410;
	mso-list-type:hybrid;
	mso-list-template-ids:-603551838 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l11:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l11:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l11:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l11:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l11:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l11:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l11:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l11:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l11:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l12
	{mso-list-id:1260723200;
	mso-list-type:hybrid;
	mso-list-template-ids:-1059832774 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l12:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:53.4pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l12:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:89.4pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l12:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:125.4pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l12:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:161.4pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l12:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:197.4pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l12:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:233.4pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l12:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:269.4pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l12:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:305.4pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l12:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:341.4pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l13
	{mso-list-id:1424692309;
	mso-list-type:hybrid;
	mso-list-template-ids:1648648058 1028531424 837055474 -1526458792 1927164286 640699860 438439470 1682710464 1605390978 -988150456;}
@list l13:level1
	{mso-level-number-format:bullet;
	mso-level-text:�;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Arial","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
@list l13:level2
	{mso-level-number-format:bullet;
	mso-level-text:�;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Arial","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
@list l13:level3
	{mso-level-number-format:bullet;
	mso-level-text:�;
	mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Arial","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
@list l13:level4
	{mso-level-number-format:bullet;
	mso-level-text:�;
	mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Arial","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
@list l13:level5
	{mso-level-number-format:bullet;
	mso-level-text:�;
	mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Arial","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
@list l13:level6
	{mso-level-number-format:bullet;
	mso-level-text:�;
	mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Arial","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
@list l13:level7
	{mso-level-number-format:bullet;
	mso-level-text:�;
	mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Arial","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
@list l13:level8
	{mso-level-number-format:bullet;
	mso-level-text:�;
	mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Arial","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
@list l13:level9
	{mso-level-number-format:bullet;
	mso-level-text:�;
	mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Arial","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
@list l14
	{mso-list-id:1575505450;
	mso-list-type:hybrid;
	mso-list-template-ids:1864788114 1111110392 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l14:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l14:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l14:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l14:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l14:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l14:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l14:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l14:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l14:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l15
	{mso-list-id:1590115035;
	mso-list-type:hybrid;
	mso-list-template-ids:-1660671460 -329737276 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l15:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:12.0pt;
	font-family:Symbol;}
@list l15:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l15:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l15:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l15:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l15:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l15:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l15:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l15:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l16
	{mso-list-id:1595629179;
	mso-list-type:hybrid;
	mso-list-template-ids:-1738529938 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l16:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l16:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l16:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l16:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l16:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l16:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l16:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l16:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l16:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l17
	{mso-list-id:1629625867;
	mso-list-type:hybrid;
	mso-list-template-ids:-1557993258 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l17:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l17:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l17:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l17:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l17:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l17:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l17:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l17:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l17:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l18
	{mso-list-id:1765370467;
	mso-list-type:hybrid;
	mso-list-template-ids:1757575586 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l18:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l18:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l18:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l18:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l18:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l18:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l18:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l18:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l18:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l19
	{mso-list-id:1814785034;
	mso-list-type:hybrid;
	mso-list-template-ids:187487254 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l19:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l19:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l19:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l19:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l19:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l19:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l19:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l19:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l19:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l20
	{mso-list-id:1826506151;
	mso-list-type:hybrid;
	mso-list-template-ids:-677095888 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l20:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l20:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l20:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l20:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l20:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l20:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l20:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l20:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l20:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l21
	{mso-list-id:1851405966;
	mso-list-type:hybrid;
	mso-list-template-ids:1771352722 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l21:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l21:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l21:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l21:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l21:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l21:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l21:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l21:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l21:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l22
	{mso-list-id:2020303116;
	mso-list-type:hybrid;
	mso-list-template-ids:-1534320572 69140481 69140483 69140485 69140481 69140483 69140485 69140481 69140483 69140485;}
@list l22:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:71.4pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l22:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:107.4pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l22:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:143.4pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l22:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:179.4pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l22:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:215.4pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l22:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:251.4pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l22:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:287.4pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l22:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:323.4pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l22:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:359.4pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Normal Tablo";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Calibri","sans-serif";
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-fareast-language:EN-US;}
table.MsoTableGrid
	{mso-style-name:"Tablo K�lavuzu";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:39;
	mso-style-unhide:no;
	border:solid windowtext 1.0pt;
	mso-border-alt:solid windowtext .5pt;
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-border-insideh:.5pt solid windowtext;
	mso-border-insidev:.5pt solid windowtext;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Calibri","sans-serif";
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-fareast-language:EN-US;}
table.TabloKlavuzuAk1
	{mso-style-name:"Tablo K�lavuzu A��k1";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-priority:40;
	mso-style-unhide:no;
	border:solid #BFBFBF 1.0pt;
	mso-border-themecolor:background1;
	mso-border-themeshade:191;
	mso-border-alt:solid #BFBFBF .5pt;
	mso-border-themecolor:background1;
	mso-border-themeshade:191;
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-border-insideh:.5pt solid #BFBFBF;
	mso-border-insideh-themecolor:background1;
	mso-border-insideh-themeshade:191;
	mso-border-insidev:.5pt solid #BFBFBF;
	mso-border-insidev-themecolor:background1;
	mso-border-insidev-themeshade:191;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Calibri","sans-serif";
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-fareast-language:EN-US;}
table.DzTablo11
	{mso-style-name:"D�z Tablo 11";
	mso-tstyle-rowband-size:1;
	mso-tstyle-colband-size:1;
	mso-style-priority:41;
	mso-style-unhide:no;
	border:solid #BFBFBF 1.0pt;
	mso-border-themecolor:background1;
	mso-border-themeshade:191;
	mso-border-alt:solid #BFBFBF .5pt;
	mso-border-themecolor:background1;
	mso-border-themeshade:191;
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-border-insideh:.5pt solid #BFBFBF;
	mso-border-insideh-themecolor:background1;
	mso-border-insideh-themeshade:191;
	mso-border-insidev:.5pt solid #BFBFBF;
	mso-border-insidev-themecolor:background1;
	mso-border-insidev-themeshade:191;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Calibri","sans-serif";
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-fareast-language:EN-US;}
table.DzTablo11FirstRow
	{mso-style-name:"D�z Tablo 11";
	mso-table-condition:first-row;
	mso-style-priority:41;
	mso-style-unhide:no;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;}
table.DzTablo11LastRow
	{mso-style-name:"D�z Tablo 11";
	mso-table-condition:last-row;
	mso-style-priority:41;
	mso-style-unhide:no;
	mso-tstyle-border-top:1.5pt double #BFBFBF;
	mso-tstyle-border-top-themecolor:background1;
	mso-tstyle-border-top-themeshade:191;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;}
table.DzTablo11FirstCol
	{mso-style-name:"D�z Tablo 11";
	mso-table-condition:first-column;
	mso-style-priority:41;
	mso-style-unhide:no;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;}
table.DzTablo11LastCol
	{mso-style-name:"D�z Tablo 11";
	mso-table-condition:last-column;
	mso-style-priority:41;
	mso-style-unhide:no;
	mso-ansi-font-weight:bold;
	mso-bidi-font-weight:bold;}
table.DzTablo11OddColumn
	{mso-style-name:"D�z Tablo 11";
	mso-table-condition:odd-column;
	mso-style-priority:41;
	mso-style-unhide:no;
	mso-tstyle-shading:#F2F2F2;
	mso-tstyle-shading-themecolor:background1;
	mso-tstyle-shading-themeshade:242;}
table.DzTablo11OddRow
	{mso-style-name:"D�z Tablo 11";
	mso-table-condition:odd-row;
	mso-style-priority:41;
	mso-style-unhide:no;
	mso-tstyle-shading:#F2F2F2;
	mso-tstyle-shading-themecolor:background1;
	mso-tstyle-shading-themeshade:242;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1026"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=TR link=blue vlink=purple style='tab-interval:35.4pt'>

<div class=WordSection1>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<div style='mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;mso-border-alt:solid windowtext .5pt;
padding:0cm;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style='mso-bidi-font-weight:
normal'><span style='font-size:16.0pt;mso-bidi-font-size:12.0pt;font-family:
"Tahoma","sans-serif"'>YA�L<span style='mso-no-proof:yes'>I</span> N�ROLOJ�K
HASTAYA YAKLA�IM <o:p></o:p></span></b></p>

<p class=MsoNormal style='border:none;mso-border-alt:solid windowtext .5pt;
padding:0cm;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:"Tahoma","sans-serif"'>Yazanlar: G�listan
Bahat, Tu�ba Erdo�an, Mehmet Akif Karan <o:p></o:p></span></b></p>

<p class=MsoNormal style='border:none;mso-border-alt:solid windowtext .5pt;
padding:0cm;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:"Tahoma","sans-serif"'>Son g�ncelle�tirme
tarihi: 22.12.2018<o:p></o:p></span></b></p>

</div>

<p class=MsoNormal><span style='font-size:16.0pt;mso-bidi-font-size:12.0pt;
font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black;mso-bidi-font-style:italic'>Ya�l�l�k pek �ok sa�l�k probleminin bir
araya gelebildi�i ka��n�lmaz bir s�re�tir. Bu s�recin herhangi bir d�neminde,
doktorlar ve di�er sa�l�k �al��anlar� mutlaka ya�l� hastayla kar��la��r.</span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>
Baz� n�rolojik hastal�klar�n g�r�lme s�kl��� ya�lanma ile birlikte belirgin
art�� g�sterir. Bu hastal�klar�n ba��nda inme ve n�rodejeneratif hastal�klar
gelmektedir. Ya�, Alzheimer hastal��� (AH) i�in en �nemli risk fakt�r�d�r ve
hastal���n prevalans� 65 ya��ndan sonra her 5 y�lda bir katlanarak artmaktad�r.
Parkinson hastal���n�n (PH) prevalans� ya�la birlikte artmaktad�r. Progresif
supran�kleer fel� (PSP), Lewy cisimcikli demans (LCD), frontotemporal demans
(FTD), amiyotrofik lateral skleroz (ALS) gibi bir�ok n�rodejeneratif hastal���n
prevalans�n�n ya�la birlikte artt��� bilinmektedir. �nme ge�irenlerin %70�i 65
ya��n �zerindedir. Epilepsi insidans�n�n y�ksek oldu�u iki d�nem ya�am�n ilk
y�l� ve 60 ya� sonras�d�r. Ya�l�larda metastatik beyin t�m�rleri,
serebrovask�ler hastal�klar (SVH) ve dejeneratif beyin hastal�klar�n�n daha s�k
g�r�lmesi epilepsi insidans�n�n da artmas�na katk�da bulunur. N�rolojik
hastal�klar�n �nemli bir k�sm�n�n ya�l�larda g�r�lmesi nedeniyle, bu hastalar�
de�erlendirme a�amas�nda ya�l� hastan�n de�erlendirilmesindeki farkl�l�klar�n
bilinmesi g�nl�k pratikte �nem ta��r. Ya�l�n�n karma��k ve birbirini etkileyen
sorunlar� nedeniyle ayr�nt�l� bir geriatrik de�erlendirme yo�un bir
interdisipliner s�re� olup �ok miktarda verinin elde edilmesi ile
sonu�lanacakt�r. Geriatrik de�erlendirme ile mevcut hastal�klar ortaya
��kar�labilir, ila�lar ve tedaviler ile ili�kili yan etkiler, hastaneye ba�vuru
ve hastanede yat�� s�resi, bak�mevlerinde kal�� ihtiyac� ve sa�l�k ve bak�m
maliyetleri azalt�labilir.<span style='mso-spacerun:yes'>� </span>Ya�l�
bireylerin b�y�k bir k�sm� geriatrik de�erlendirmeden anlaml� fayda g�r�r.
Bununla birlikte kapsaml� geriatrik de�erlendirmeden; e�lik eden komorbidite ve
kullan�lan ila� say�s� d���k olan �sa�l�kl�� ya�l�lardan ziyade, �k�r�lgan�
veya kuruma yerle�tirilme riski y�ksek, fonksiyonel durumunda gerileme olan
veya olma riski ta��yan ya�l�lar en y�ksek fayday� g�recektir. Bu nedenle
�zellikle bu hasta grubunda kapsaml� geriatrik de�erlendirme yap�lmal�d�r. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Ya�lanma
ile baz� n�rolojik hastal�klardaki art���n yan� s�ra toplumda en s�k g�r�len
kronik hastal�klar olan hipertansiyon ve diabetes mellitus gibi <span
class=GramE>dahili</span> hastal�klar�n prevalans� artar. Buna paralel olarak
kullan�lan ila� say�s�, d��meler, inkontinans, maln�trisyon, sarkopeni,
konstipasyon, deliryum vb. gibi geriatrik tablolar�n prevalans� da artar. Bu
durum ya�l� hastan�n klinik y�netimini daha karma��k hale getirir. Kapsaml�
geriatrik de�erlendirme ile ya�l� hastan�n klinik y�netimden en fazla fayda ve
en az zarar g�rmesinin sa�lanmas� ama�lan�r. N�rolojik hastal��� olan
ya�l�larda bu hastal���n klinik k�t�le�mesine katk�da bulunabilecek
d�zeltilebilir bir�ok <span class=GramE>dahili</span> fakt�r mevcuttur. Ya�l�
hastalarda s�k kar��la��lan ve yukarda say�lan geriatrik tablolar i�levsellikte
bozulmaya ve mevcut n�rolojik hastal���n k�t�le�mesine katk�da bulunabilir.
Ayr�ca bu hastalarda n�rolojik hastal���n tedavisinde kullan�lan ila�lar�n
sebep olabilece�i <span class=GramE>dahili</span> yan etkiler ve ila�-ila�
etkile�imleri de s�z konusudur. �te yandan <span class=GramE>dahiliyede</span>
s�k kullan�lan ila�lar�n baz�lar� mevcut n�rolojik hastal���n klinik
k�t�le�mesine neden olabilmektedir. N�rolojik hastal��� olan ya�l�larda
diyabet, hipertansiyon, hiperlipidemi ve hipo-hipertiroidi gibi sistemik hastal�klarla
s�kl�kla kar��la��lmaktad�r; bu ba�l�klar�n her birine �zel yakla��m g�zden
ge�irilecektir.<b style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b
style='mso-bidi-font-weight:normal'><span style='font-size:16.0pt;mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";text-transform:uppercase'>N�rolojik
hastal���n klinik k�t�le�mesine katk�da bulunabilecek d�zeltilebilir <span
class=GramE>DAH�L�</span> fakt�rlerin tan�nmas� ve tedavisi<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>N�rolojik
hastal��� olan ya�l�da klinik k�t�le�me 4 farkl� �ekilde ortaya ��kabilir.<span
style='mso-spacerun:yes'>� </span>�zg�n n�rolojik hastal���n belirtilerinde
k�t�le�me, kognitif bozulma, davran��sal bozulma ve/veya i�levsel bozulma.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Bir
ya�l�da normal n�ronal i�levlerin s�rd�r�lebilmesi i�in yeterli makro ve mikro
besinlerin al�nmas�, yeterli oksijenizasyonun sa�lanmas�, uygun hormonal
durumun olmas�, dengeli elektrolit ve pH�a sahip olunmas� ve toksik olmayan
ortamda bulunulmas� gereklidir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-bidi-font-weight:bold'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-bidi-font-weight:bold'>Normal n�ronal i�levi bozabilecek bir�ok sistemik
veya metabolik bozukluk mevcuttur. Ya�l�da hiperglisemi, hipoglisemi, hipoksi,
hiperkarbi, hipotansiyon, hipertansiyon, dehidratasyon, elektrolit
dengesizlikleri, asidoz, alkoloz, b�brek yetersizli�i, karaci�er yetersizli�i,
maliniteler, sistemik infeksiyonlar, anemi, n�trisyonel eksiklikler,
hipotiroidi, hipertiroidi, toksik ajanlar ve ila� yan etkileri gibi bir�ok
fakt�r tek ba��na veya beraber n�ronal i�levlerde bozuklu�a neden olabilir.
Ya�l�lar�n komorbid hastal�klar�n�n �oklu�u nedeniyle bu mevcut bozukluklarla
kar��la�ma oran� olduk�a y�ksektir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:408.4pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-bidi-font-weight:bold'><span style='mso-tab-count:1'>������������������������������������������������������������������������������������������������������������ </span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-bidi-font-weight:bold'>N�ronal i�lev bozuklu�u ger�ekle�en hastada ilk
yap�lmas� gereken ad�m ayr�nt�l� anamnez al�nmas�d�r. Ya�l�da geli�en yeni <span
class=GramE>semptom</span> ve bulgular�n yakla��k 1/3��nden ila�lar�n sorumlu
oldu�u bilinmekte, bu nedenle �zellikle ald��� ila�lar�n yan etki profili,
ila�-ila� etkile�imleri ve endikasyonlar� a��s�ndan g�zden ge�irilmesi �ok
�nemlidir. Anamnez sonras� <span class=GramE>dahili</span> fizik muayeneden
sonra laboratuvar de�erlendirilmesi yap�lmal�d�r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-bidi-font-weight:bold'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-bidi-font-weight:bold'>Birinci basamakta istenecek laboratuvar tetkikleri;
akut faz reaktanlar�n�n d�zeyleri, kan �ekeri, b�brek fonksiyon testleri,
karaci�er fonksiyon testleri, elektrolitler, kalsiyum, tam kan say�m�, O<sup>2</sup>-CO<sup>2</sup>
d�zeyi, pH, EKG, tiroid fonksiyon testleri ve B12 vitamin d�zeyidir. Hastan�n
klini�ine g�re istenebilecek ileri tetkikler aras�nda kortizol d�zeyi, amonyak
d�zeyi, ileri g�r�nt�lemeler ve EEG say�labilir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-bidi-font-weight:bold'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b><span
style='font-size:16.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Deliryum <o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-bidi-font-weight:bold'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-bidi-font-weight:bold'>Deliryum; ya�l� hastalarda s�k kar��la��lan, <span
class=GramE>dahili</span> problemlerin sebep olabilece�i kognitif bozukluklar
aras�nda olup �nlenebilir olmas� nedeniyle geriatri prati�inde �zellikle �nemli
bir yere sahiptir. </span><span style='font-family:"Tahoma","sans-serif";
mso-bidi-font-weight:bold'>Kognitif fonksiyonlarda, dikkatte ve duygudurumda
akut ba�lang��l�, g�n i�inde dalgalanmalarla seyreden bozuklu�u ifade
etmektedir. Hastane d���nda ya�ayan ya�l�larda deliryum s�kl��� %1 ile %2
aras�nda iken hastanelere kabul s�ras�nda deliryum %10 ile %40 aras�nda bir
s�kl�kta g�r�lmektedir. Operasyon ge�iren ve �zellikle kal�a k�r��� olan
ya�l�larda deliryum g�r�lme s�kl��� %15-%53 aras�ndad�r.</span><span
style='font-family:"Tahoma","sans-serif";color:black'> </span><span
style='font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1'>Yo�un
bak�m �nitelerinde yatan ya�l� hastalarda ise bu oranlar %70 ile %87�ye kadar
��kmaktad�r. </span><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";mso-bidi-font-weight:bold'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>Deliryum i�in tan� <span class=GramE>kriterleri</span>
mevcut olmas�na ve tan� kondu�unda komplikasyonlar�n�n �nlenebilir olmas�na
ra�men, s�kl�kla g�zden ka�abilmekte, hastalar�n %30-60�� tan� almamaktad�r. </span><span
style='font-family:"Tahoma","sans-serif"'>Deliryum geli�en hastalarda hastane
yat�� su&#776;resi uzamakta, fonksiyonel kapasite azalmakta, maliyet
artmaktad�r. Ayr�ca deliryum, kal�c� kognitif bozukluk, bas� yaralar�, du&#776;�me,
pn�moni, mortalite art��� (%10-65) ve bak�mevine yerle�tirilmeye neden olabilmektedir.
<span style='color:black;mso-themecolor:text1;mso-bidi-font-weight:bold'>Deliryum,
hastalarda deliryumu kolayla�t�r�c� fakt�rler (predispozan) ile deliryumu
tetikleyici fakt�rlerin (presipite edici) etkile�mesi ile olu�maktad�r.
Predispozan fakt�rler aras�nda en s�k kar��la��lan durum demans varl���d�r.
Demans� olan ya�l� hastalarda deliryum s�kl��� 2 ila 5 kat daha fazla
g�r�lebilmektedir. </span></span><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:black;mso-themecolor:
text1;mso-bidi-font-weight:bold'>En s�k kar��la��lan deliryumu tetikleyici
fakt�r ise ila�lard�r. </span><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>�la�lar�n deliryumda �nemli
bir rolu&#776; vard�r. �lac�n tu&#776;ru&#776;nden ba��ms�z olarak 4 ve u&#776;zerinde
ila� kullanmak (polifarmasi) deliryum i�in bir risk fakt�ru&#776;yken, 24 saat
i�inde u&#776;� taneden fazla ila� ba�lanmas� da deliryumu presipite edebilir. <span
style='color:#212121'>Son �al��malarda ila�lar�n deliryum vakalar�n�n %22 ile
%39'una katk�da bulundu�u saptanm��t�r. Her hastada re�etesiz ila�lar da <span
class=GramE>dahil</span> olmak �zere mevcut ila�lar�n listesi g�zden
ge�irilmelidir. Deliryum riski olan bir hastada altta yatan predispozan ve
presipite eden fakt�rlerin (<b style='mso-bidi-font-weight:normal'>Tablo 1</b>)
sorgulanmas� ve d�zeltilebilecek fakt�rlerin ortadan kald�r�lmas� ile deliryum
geli�im riskini azaltmak m�mk�nd�r. <o:p></o:p></span></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>Ya�l� hastalarda deliryumda dikkat
edilmesi gereken di�er bir nokta infeksiyonlard�r. Ya�l� hastada infeksiyonun
di�er bulgular� ortaya ��kmadan ilk belirti deliryum olabilir. Bu nedenle
deliryum tablosu ile ba�vuran her ya�l� hastada muhtemel bir infeksiyon oda��
a��s�ndan mutlaka gerekli de�erlendirmeler yap�lmal�d�r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;color:black;mso-themecolor:
text1;mso-bidi-font-weight:bold'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Tablo 1. </span></b><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>Deliryumda predizpozan ve presipite edici fakt�rler</span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black;mso-themecolor:text1;mso-bidi-font-weight:bold'><o:p></o:p></span></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
  <td width=318 valign=top style='width:238.65pt;border:solid windowtext 1.0pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:150%'><b><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
  color:black;mso-themecolor:text1;mso-fareast-language:EN-US'>Deliryumda
  predizpozan fakt�rler<o:p></o:p></span></b></p>
  </td>
  <td width=318 valign=top style='width:238.65pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:150%'><b
  style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Deliryumu
  presipite eden fakt�rler<o:p></o:p></span></b></p>
  <p class=MsoNormal style='text-align:justify;line-height:150%'><b><u><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
  color:black;mso-themecolor:text1;mso-fareast-language:EN-US'><o:p><span
   style='text-decoration:none'>&nbsp;</span></o:p></span></u></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;mso-yfti-lastrow:yes'>
  <td width=318 valign=top style='width:238.65pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>�leri
  ya� (65 ya� ve �zeri)<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>K�r�lgan
  ya�l�<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Polifarmasi<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Kardiyopulmoner
  hastal�klar<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Organ
  yetmezlikleri (b�brek, karaci�er)<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Santral
  sinir sistemi hastal�klar�<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Kognitif
  bozukluk, demans<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Parkinson
  hastal���<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Depresyon<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>G�rme-i�itme
  sorunlar�<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Maln�trisyon<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Kontrol
  alt�nda olmayan birden fazla t�bbi sorun<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l3 level1 lfo2;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Sosyal
  <span class=GramE>izolasyon</span><o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l15 level1 lfo4'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:black;
  mso-themecolor:text1;mso-fareast-language:EN-US;mso-bidi-font-weight:bold'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Fonksiyonel
  yetersizlik<span style='color:black;mso-themecolor:text1;mso-bidi-font-weight:
  bold'><o:p></o:p></span></span></p>
  </td>
  <td width=318 valign=top style='width:238.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l8 level1 lfo6'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>�la�lar<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-left:53.4pt;mso-add-space:
  auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l12 level1 lfo8'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Antikolinerjikler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-left:53.4pt;mso-add-space:
  auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l12 level1 lfo8'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Trisiklik
  antidepresanlar<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-left:53.4pt;mso-add-space:
  auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l12 level1 lfo8'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Steroidler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-left:53.4pt;mso-add-space:
  auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l12 level1 lfo8'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Benzodiazepinler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-left:53.4pt;mso-add-space:
  auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l12 level1 lfo8'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Antihistaminikler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-left:53.4pt;mso-add-space:
  auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l12 level1 lfo8'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Antibiyotikler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-left:53.4pt;mso-add-space:
  auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l12 level1 lfo8'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Digoksin<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-left:53.4pt;mso-add-space:
  auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l12 level1 lfo8'><![if !supportLists]><span
  style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
  mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-fareast-language:
  EN-US'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>A�r�
  kesiciler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>�nfeksiyonlar<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Ate�,
  hipotermi, hipoksi, hiperkarbi, elektrolit bozukluklar�<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Kardiyovask�ler
  hastal�klar (akut miyokard infarkt�s�, kalp yetersizli�i, hipotansiyon)<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Hastaneye
  yatmak, yo�un bak�m �nitesine yatmak, invazif giri�imler, cerrahi giri�imler
  (�zellikle ortopedik)<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>A�r�<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Konstipasyon,
  fekal impakt<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>�riner
  retansiyon<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Fiziksel
  k�s�tlamalar (idrar yolu sondas� tak�lmas� gibi)<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>�mmobilizasyon<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Uyku
  uyan�kl�k siklusunun bozulmas�<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Kafa
  <span class=GramE>travmas�</span>, yan�k<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpLast style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l21 level1 lfo10;mso-layout-grid-align:none;
  text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;color:black;mso-themecolor:text1;mso-fareast-language:
  EN-US;mso-bidi-font-weight:bold'><span style='mso-list:Ignore'>�<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>�evresel
  fakt�rler<b><u><span style='color:black;mso-themecolor:text1'><o:p></o:p></span></u></b></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;line-height:150%'><sup><span
style='mso-bidi-font-size:10.0pt;line-height:150%;color:red;mso-bidi-font-weight:
bold'><o:p>&nbsp;</o:p></span></sup></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Deliryumda
Tan�sal Yakla��m<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>Deliryum tan�s�nda en �nemli nokta
detayl� anamnez, fizik, n�rolojik ve mental durum muayeneleri ile hastan�n
mevcut bazal durumunda bir de�i�iklik olup olmad���n�n anla��lmas�d�r. En s�k
kullan�lan tan� <span class=GramE>kriteri</span> Amerikan Psikiyatri Derne�inin
yay�nlad��� �The Diagnostic and Statistical Manual of Mental Disorders� (DSM)
kriteridir. DSM-5 kriterlerine g�re dikkati bir konu �zerinde odaklama,
s�rd�rme ya da yeni bir konuya kayd�rma yetisinde azalma ile giden bilin�
bozuklu�u olmas�, �evrede olup bitenin fark�nda olma d�zeyinde azalma olmas� ve
bu durumun k�sa bir s�re i�erisinde geli�mesi, dalgalanma e�ilimi g�stermesi;
bellek kayb�, <span class=GramE>oryantasyon</span> bozuklu�u, dil
fonksiyonlar�, g�rsel-mekansal i�levler ve alg� gibi kognitif fonksiyonlarda
bozukluk olmas� gerekmektedir. Kriterlere g�re bu durum daha �nceden var olan
bir n�rokognitif bozuklukla a��klanam�yor olmal� ve koma gibi ileri derecede
azalm�� uyan�kl�k d�zeyi ba�lam�nda ortaya ��kmamal�d�r. Anamnez, fizik muayene
ve laboratuvar bulgular�ndan elde edilen verilerde bu bozuklu�un genel t�bbi
durumun do�rudan etkilerine ba�l� oldu�una ili�kin kan�tlar olmal�d�r.<span
style='mso-spacerun:yes'>� </span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>Deliryum taramas�nda kullan�lan
�l�ekler aras�nda ��Mini Mental Durum De�erlendirme Testi�� (MMSE), ��Konfu&#776;zyon
De�erlendirme Metodu�� (CAM) yer almaktad�r. CAM %94-100 duyarl�l�k ve %90-95
�zg�ll��e sahiptir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>Ya�l� hastalarda deliryum
de�erlendirilmesinde ana basamaklar �unlard�r:<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>1. Kognitif durumun, mental durum ve
dikkatin test edilmesi ve bazal kognitif durumun saptanmas�.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>2. Kapsaml� <span class=GramE>hikaye</span>
ve fizik muayene, n�rolojik muayene yap�lmas�.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>3. �la� listesinin g�zden ge�irilmesi:
Tu&#776;m ila�lar�n yan etkilerinin g�zden ge�irilmesi. Tu&#776;m psikoaktif
ila�lar�n kesilmesi veya azalt�lmas�.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>4. Laboratuvar de�erlendirme: tam kan
say�m�, elektrolitler, BUN, kreatinin, glukoz, kalsiyum, fosfor, karaci�er
enzimleri, oksijen sat�rasyonu, tiroid fonksiyon testleri.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>5. �nfeksiyon aranmas�: fizik muayene,
idrar tetkiki, akci�er grafisi, ku&#776;ltu&#776;rler (endikasyon varsa).<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>6. Yukar�daki basamaklarda ili�kili
sebep bulunamazsa se�ilmi� hastalarda ileri de�erlendirme yap�lmas�. �leri
laboratuvar testleri; arteryel kan gaz�, EKG, kalp enzimleri, beyin
g�r�nt�lemesi, beyin omurilik s�v�s� incelemesi, elektroensefalogram.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>�nfeksiyonlar
<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;line-height:150%'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>K�t�
<span class=GramE>hijyen</span> ve maln�trisyon nedeniyle ya�l� n�rolojik
hastalar her t�rl� infeksiyon hastal���na a��kt�rlar. Terminal d�nem hastalarda
aspirasyon pn�monisi s�kl�kla kar��la��lan bir problemdir. Ya�l�larda
infeksiyon hastal�klar�n�n tipik semptom ve bulgular� (ate�, dispne, <span
class=GramE>l�kositoz ...</span> vb) olmayabilir. Kognitif fonksiyonda ve
i�levsellikte akut k�t�le�me durumunda infeksiyonlar mutlaka akla gelmelidir.
Uygun ve yeterli s�re antibiyoterapi uygulanmal�d�r. Ya�lanma ile birlikte
imm�n fonksiyonlarda de�i�iklik olur (imm�nosenesans). Ya�am�n imm�nolojik
olarak hassas d�nemlerinden olan �ocukluk �a��nda oldu�u gibi ileri ya�ta da
infeksiyon hastal�klar�ndan korunma amac�yla baz� �zg�n a��lar�n kullan�lmas�
ile ya�l�larda �nemli bir morbidite ve mortalite sebebi olan infeksiyon
hastal�klar�n�n azalt�lmas� sa�lanabilir. Ya�l�larda rutin olarak uygulanmas�
�nerilen a��lar a�a��da �zetlenmi�tir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Korunma
<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Pn�mokok
A��s�: Daha �nce pn�mokok a��s� yap�lmam�� 65 ya� ve �zeri bireylerde ilk doz
13 valan konjuge a��, takiben en az 1 y�l sonra 23 valan polisakkarid a��
�eklinde uygulanmal�d�r. �nceden 23 valan polisakkarid a�� ile a��lanm��sa 1
y�l sonra konjuge a�� yap�lmal�d�r. 23 valan a�� 65 ya� �ncesinde uygulanm��sa,
65 ya� �st�nde ilk a��dan en az 5 y�l sonra tekrarlanmal�d�r <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>�nfluenza
A��s�: 50 ya� �st� t�m eri�kinlere y�ll�k mevsimsel grip a��s� �nerilir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Tetanoz
A��s�: Her 10 y�lda bir eri�kin tipi difteri-tetanoz toksoidi �nerilir. Erken
eri�kinlik d�nemi veya �ocuklukta a��lananlar i�in ara a��labilir. Bu olgularda
50 ya� �st� yap�lan tek bir td toksoidi �m�r boyu imm�nite i�in yeterli
olabilir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Herpes
Zoster A��s�: Zoster infeksiyonu riski ya� ilerledik�e artmaktad�r Zoster
infeksiyonu ili�kili postherpetik nevralji, ensefalit, miyelit, kranyal ve
periferik sinir paralizileri ya�l�larda daha fazlad�r. Herpes zoster a��s� zona
riskinde ve postherpetik nevralji riskinde azalma sa�lar. Atm�� ya� �st� imm�n
sorunu olmayan t�m ya�l�lara �m�r boyu bir kez olmak �zere �nerilebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><u><span
style='mso-bidi-font-size:14.0pt;line-height:150%;background:white'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:"Tahoma","sans-serif";
text-transform:uppercase'>N�rolojik hastal�klarda i�levsellikte bozulmaya
katk�da bulunabilecek geriatrik sendromlar<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Ya�lanma
ile birlikte maln�trisyon, sarkopeni, d��me, inkontinans, konstipasyon gibi
sorunlar�n s�kl��� artar. Standart n�rolojik ve <span class=GramE>dahili</span>
de�erlendirmede bunlar g�zden ka�ar. Yukar�da say�lan durumlar ya�l� hastalarda
s�k olarak g�r�len, ya�am kalitesini bozup, morbidite ve mortaliteyi
artt�rabilen geriatrik <span class=GramE>sendrom</span> olarak nitelendirilen
durumlard�r. <span style='color:black;mso-themecolor:text1'>Ya�l�da �o�unlukla
atipik <span class=GramE>semptomlarla</span> kendini g�steren ve hastal�k
tan�m�</span></span><span style='font-family:"Tahoma","sans-serif";color:black;
mso-themecolor:text1'> ile tam olarak a��klanamayan klinik durumlar� ve
semptomlar� tan�mlamak i�in �Geriatrik Sendromlar� terimi
kullan�lmaktad�r.&nbsp;</span><span style='font-family:"Tahoma","sans-serif"'> </span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>N�rolojik
hastal��� olan ya�l�larda geriatrik <span class=GramE>sendromlar�n</span>
varl��� i�levselli�i bozacakt�r.<span style='mso-spacerun:yes'>� </span>Bu
nedenle s�k kar��la��lan geriatrik <span class=GramE>sendromlar�n</span>
varl���n�n sorgulanmas� ve gerekli �nlemlerin al�nmas� �nem arz etmektedir. Bu
geriatrik <span class=GramE>sendromlar�n</span> tan�s�, tedavisi a�a��da k�saca
�zetlenecektir. </span><span style='font-family:"Tahoma","sans-serif"'><o:p></o:p></span></p>

<p class=MsoNormal><span style='mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b><span
style='font-size:16.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Maln�trisyon<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif";color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif";color:black'>Malnu&#776;trisyona sebep
oldu�u bilinen n�rolojik hastal�klar aras�nda Alzheimer hastal���, Parkinson
hastal���, serebrovask�ler hastal�k, multipl skleroz ve motor n�ron hastal���
bulunur. N�rolojik hastal�klar�n seyrinde geli�en malnu&#776;trisyonun
nedenleri aras�nda depresyon, �z bak�m�n bozulmas�, orofarengial disfaji,
bilin� bozukluklar�, alg�lamada g��l�k, kognitif bozukluk, ila�lar ve artm��
ihtiya� say�labilir. Maln�trisyon sonucunda, kas atrofisi (ekstremite/solunum),
bas� yaralar�, du&#776;�meler, osteoporoz, infeksiyon riski ve sa�kal�mda
azalma g�ru&#776;lu&#776;r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif";color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>Maln�trisyon bir ya da daha fazla besin
maddesinin v�cut dengesini bozacak �ekilde yetersiz al�nmas�d�r. Metabolik
ihtiya�lar� kar��layacak kadar enerji ve/veya proteinin olmamas� maln�trisyonun
temel �zelli�idir. Ya�l�lar�n %37-40�� gu&#776;nlu&#776;k enerji ihtiyac�n�
kar��layacak du&#776;zeyde beslenememekte, u&#776;� ya�l�dan 2�si bir ��u&#776;n�
atlamaktad�r. 65 ya� �st� ayaktan hastalarda yetersiz beslenme s�kl��� %30-35
aras�ndad�r. Tahmini s�kl�k hastanede yatanlarda %70 civar�nda iken,
bak�mevlerinde kalanlarda %85�in �zerinde oldu�u tahmin edilmektedir. <span
style='color:black'>SVH varl���nda ba�vuru s�ras�nda %15 hastada, 2. haftada
%22-35 ve takip s�ras�nda %50 hastada malnu&#776;trisyon tan�s� konulmaktad�r. </span>Maln�trisyon,
s�k g�r�lmesinin yan� s�ra mortalitede art��a neden oldu�u i�in de �nem arz
etmektedir. Ya�l�l�kta herhangi sebeple kilo kayb�n�n ba�lang�c�n� takip eden
1�2,5 y�l i�inde, sadece bu sebeple ili�kili olarak mortalite oran� %9-38
artmaktad�r. <span style='color:black'><o:p></o:p></span></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>Beslenme durumunu olumsuz etkileyen
fakt�rler aras�nda ya�lanmayla birlikte ortaya ��kan fizyolojik de�i�iklikler,
akut ve kronik hastal�klar, di� ve a��z sa�l��� problemleri, polifarmasi,
ekonomik sorunlar, tek ba��na al��veri� yapamama, yemek haz�rlayamama ve
yiyememe gibi �evresel etkenler �nemli yer tutar. ��tah azalmas�n�n ya�lanma
ile ortaya ��kt���na dair baz� bulgular mevcuttur ki bu da ya�lanma anoreksisi
olarak bilinmektedir. Ya�lanmayla beraber a�l��a ve enerji ihtiyac�na v�cudun
verdi�i i�tah art��� cevab�n�n bozulmas�, tat ve koku duyular�ndaki
de�i�iklikler, ya�a ba�l� olarak geli�en mide bo�alma h�z�n�n yava�lamas�,
ghrelin gibi i�tahla ilgili hormonlar�n dengesindeki de�i�iklikler gibi bir�ok
fakt�r nedeniyle i�tahta azalma g�r�lebilir. Ayr�ca i�tah, inflamasyon (kanser,
KOAH, kalp yetmezli�i gibi) ile birlikte seyreden akut ve kronik hastal�klarda
azalmaktad�r. Ancak di�er taraftan, korku, depresyon, yaln�zl�k ve e� kayb�
gibi psikososyal sorunlar da i�tah�n azalmas�na sebep olan unsurlard�r.<span
style='color:black'> </span>K�r�lgan ya�l�larda �o�unlukla de�i�ik fakt�rler
ayn� anda ortaya ��kabilmekte ve kendi aralar�nda etkile�erek g�da al�m�n�
etkileyebilmekte ve g�da al�m� ile sindirimi su&#776;recinde akut ve kronik
d�nemde dengesizlikler, kilo kayb� ve fonksiyon kayb� gibi durumlar ortaya
��kabilmektedir.<span style='color:black'><o:p></o:p></span></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Maln�trisyon
Tan�s�<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'><span
style='mso-spacerun:yes'>�</span><o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif";color:#212121'>Maln�trisyon ya�l�
hastalarda s�k g�r�lmesine ra�men, klinisyenler taraf�ndan yeterince tan�nmaz
ve pek �ok olguda hasta ka�ektik d�zeye gelinceye kadar tan� ve tedavisi
yap�lamaz. 65 ya� ve �zeri bireylerde en az y�lda 1 kez ve hastaneye
yat�r�ld�klar� her durumda beslenme bozuklu�unun de�erlendirilmesi gereklidir
ve uluslararas� k�lavuzlarca �nerilmektedir. �te yandan maln�trisyon tan�s�nda
kullan�lmas� �nerilen �ok say�da de�i�ik ara�/test bulunmaktad�r. Burada
birincil ama� maln�trisyonun en pratik �ekilde saptanmas� olmal�d�r. Bu
ba�lamda </span><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif"'>ESPEN (</span><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>The European
Society of Clinical Nutrition and Metabolism) �nerilerine g�re </span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>v�cut</span><span
style='font-family:"Tahoma","sans-serif"'> kitle indeksi (VK�) &lt;18,5 kg/m<sup>2
</sup>ise veya herhangi bir zaman diliminde &gt;%10 istemsiz kilo <span
class=GramE>kayb�<span style='mso-spacerun:yes'>� </span>varsa</span>
maln�trisyon tan�s� konur. Ek olarak 3 ay i�inde %5 kilo kayb� olmas� ve
beraberinde 70 ya� alt�nda VK� &lt;20 kg/m<sup>2</sup>, 70 ya� ve �zerinde VK�
&lt;22 kg/m<sup>2</sup> ise veya ya�s�z VK� kad�nda 15 kg/m<sup>2</sup>,
erkekte 17 kg/m<sup>2</sup> ise maln�trisyon tan�s� yine konur.</span><span
style='font-size:9.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;text-indent:35.4pt;line-height:
150%;mso-layout-grid-align:none;text-autospace:none'><span style='font-size:
10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Tan� ve tedavideki gecikmelerin �n�ne ge�ebilmek ve maln�trisyon
tan�s�nda k�resel ge�erlili�i olan standart yakla��m� sa�layabilmek i�in Eyl�l
2018�de �Maln�trisyonda k�resel liderlik giri�im toplulu�u�� (Global Leadership
Initiative on Malnutrition - GLIM) yap�s�nda klinik beslenme
organizasyonlar�n�n bir�o�u bir araya gelmi� ve GLIM maln�trisyon <span
class=GramE>kriterlerini</span> yay�nlam��lard�r.<span
style='mso-spacerun:yes'>� </span>GLIM �nerilerine g�re birinci basamakta
riskli hastalar� saptamak �zere valide edilmi� tarama testlerinden birinin
kullan�lmas� �nerilir. Bu basamakta Mini-N�trisyonel De�erlendirme- K�sa form
(MNA-SF), N�trisyonel Risk Taramas� (NRS) veya Malnutrition Universal Screening
Tool (MUST) uygulanabilir. Mini N�trisyonel De�erlendirme testi (<b
style='mso-bidi-font-weight:normal'>Tablo 2</b>) ya�l� popu&#776;lasyona �zg�n
geli�tirilmi� bir testtir. �lk k�sm� 6 sorudan olu�ur ve h�zl� bir tarama
testidir. MNA k�sa formdan 12-14 puan alanlarda n�trisyonel durumun normal
oldu�u 11 alt�nda puan alanlarda ise maln�trisyon riski oldu�u s�ylenir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;text-indent:35.4pt;line-height:
150%;mso-layout-grid-align:none;text-autospace:none'><b style='mso-bidi-font-weight:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;text-indent:35.4pt;line-height:
150%;mso-layout-grid-align:none;text-autospace:none'><b style='mso-bidi-font-weight:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Tablo 2.<span style='mso-spacerun:yes'>� </span></span></b><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";background:white'>Mini N�trisyonel De�erlendirme testi</span><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'><o:p></o:p></span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=533
 style='width:399.95pt;margin-left:5.4pt;border-collapse:collapse;border:none;
 mso-border-alt:solid windowtext .5pt;mso-yfti-tbllook:160;mso-padding-alt:
 0cm 5.4pt 0cm 5.4pt;mso-border-insideh:.5pt solid windowtext;mso-border-insidev:
 .5pt solid windowtext'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:9.05pt'>
  <td width=533 colspan=2 valign=top style='width:399.95pt;border:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:9.05pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0cm;
  margin-bottom:3.0pt;margin-left:0cm;text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none'><b><span style='font-size:
  10.0pt;mso-bidi-font-size:12.0pt;letter-spacing:.2pt;background:#D9D9D9;
  mso-shading:windowtext;mso-pattern:gray-15 auto;mso-fareast-language:EN-US'>M</span></b><b><span
  style='font-size:10.0pt;mso-bidi-font-size:12.0pt;letter-spacing:-.05pt;
  background:#D9D9D9;mso-shading:windowtext;mso-pattern:gray-15 auto;
  mso-fareast-language:EN-US'>in</span></b><b><span style='font-size:10.0pt;
  mso-bidi-font-size:12.0pt;background:#D9D9D9;mso-shading:windowtext;
  mso-pattern:gray-15 auto;mso-fareast-language:EN-US'>i <span
  style='letter-spacing:-.05pt'>N</span><span style='letter-spacing:.15pt'>�</span><span
  style='letter-spacing:-.05pt'>trisyone</span>l <span style='letter-spacing:
  -.05pt'>D</span>e�<span style='letter-spacing:.2pt'>e</span><span
  style='letter-spacing:-.05pt'>rlend</span><span style='letter-spacing:.3pt'>i</span><span
  style='letter-spacing:-.05pt'>rm</span>e <span style='letter-spacing:-.05pt'>(</span></span></b><span
  style='font-size:10.0pt;mso-bidi-font-size:12.0pt;letter-spacing:.3pt;
  background:#D9D9D9;mso-shading:windowtext;mso-pattern:gray-15 auto;
  mso-fareast-language:EN-US;mso-bidi-font-weight:bold'>M</span><span
  style='font-size:10.0pt;mso-bidi-font-size:12.0pt;letter-spacing:-.05pt;
  background:#D9D9D9;mso-shading:windowtext;mso-pattern:gray-15 auto;
  mso-fareast-language:EN-US;mso-bidi-font-weight:bold'>N</span><span
  style='font-size:10.0pt;mso-bidi-font-size:12.0pt;letter-spacing:-.25pt;
  background:#D9D9D9;mso-shading:windowtext;mso-pattern:gray-15 auto;
  mso-fareast-language:EN-US;mso-bidi-font-weight:bold'>A</span><b><span
  style='font-size:10.0pt;mso-bidi-font-size:12.0pt;background:#D9D9D9;
  mso-shading:windowtext;mso-pattern:gray-15 auto;mso-fareast-language:EN-US'>)
  1.K�s�m<span style='letter-spacing:.2pt;background:lightgrey;mso-highlight:
  lightgrey'><o:p></o:p></span></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:47.0pt'>
  <td width=264 valign=top style='width:197.75pt;border:solid windowtext 1.5pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.5pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:47.0pt'>
  <p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
  text-autospace:none'><b><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  mso-fareast-language:EN-US'>1. Son �� a<span style='letter-spacing:-.25pt'>y</span>da
  i�tahs�zl��a, sindi<span style='letter-spacing:-.3pt'>r</span><span
  style='letter-spacing:.25pt'>i</span>m <span style='letter-spacing:-.3pt'>s</span><span
  style='letter-spacing:.25pt'>o</span><span style='letter-spacing:-.3pt'>r</span>un<span
  style='letter-spacing:-.15pt'>l</span><span style='letter-spacing:.25pt'>a</span><span
  style='letter-spacing:-.25pt'>r�</span><span style='letter-spacing:.3pt'>n</span>a,
  �i�neme ya da yutma <span style='letter-spacing:-.25pt'>z</span>or<span
  style='letter-spacing:-.25pt'>l</span><span style='letter-spacing:.3pt'>u</span>kla<span
  style='letter-spacing:-.2pt'>r�</span>na b<span style='letter-spacing:.1pt'>a�l�
  </span>o<span style='letter-spacing:-.2pt'>l</span><span style='letter-spacing:
  .25pt'>a</span><span style='letter-spacing:-.3pt'>r</span><span
  style='letter-spacing:.25pt'>a</span>k besin <span style='letter-spacing:
  .05pt'>a</span><span style='letter-spacing:-.25pt'>l�m�n</span><span
  style='letter-spacing:.05pt'>d</span>a <span style='letter-spacing:.05pt'>bi</span>r
  <span style='letter-spacing:.25pt'>a</span><span style='letter-spacing:-.3pt'>z</span><span
  style='letter-spacing:.25pt'>a</span><span style='letter-spacing:.05pt'>l</span><span
  style='letter-spacing:-.15pt'>m</span>a <span style='letter-spacing:.05pt'>o</span><span
  style='letter-spacing:-.25pt'>l</span><span style='letter-spacing:.05pt'>d</span>u
  <span style='letter-spacing:.05pt'>m</span><span style='letter-spacing:.2pt'>u</span></span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'>?
  <o:p></o:p></span></p>
  <p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
  text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>�����������������
  </span>0 = C<span style='letter-spacing:-.45pt'>i</span>d<span
  style='letter-spacing:.25pt'>d</span>i i�tah k<span style='letter-spacing:
  .2pt'>a</span><span style='letter-spacing:-.25pt'>y</span><span
  style='letter-spacing:.05pt'>b�</span><o:p></o:p></span></p>
  <p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
  text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>�����������������
  </span>1 = O<span style='letter-spacing:-.2pt'>r</span><span
  style='letter-spacing:.25pt'>t</span>a d�ze<span style='letter-spacing:-.55pt'>y</span><span
  style='letter-spacing:.25pt'>d</span>e i�tah k<span style='letter-spacing:
  .2pt'>a</span><span style='letter-spacing:-.25pt'>y</span><span
  style='letter-spacing:.05pt'>b�</span><o:p></o:p></span></p>
  <p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
  text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>�����������������
  </span>2 = ��tah k<span style='letter-spacing:.2pt'>a</span><span
  style='letter-spacing:-.25pt'>y</span><span style='letter-spacing:.05pt'>b�</span><span
  style='letter-spacing:-.3pt'> y</span><span style='letter-spacing:.25pt'>o</span>k<o:p></o:p></span></p>
  </td>
  <td width=270 valign=top style='width:202.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  mso-border-top-alt:solid windowtext 1.5pt;mso-border-left-alt:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:47.0pt'>
  <p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
  text-autospace:none'><b><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  mso-fareast-language:EN-US'>4. Son 3 a<span style='letter-spacing:-.2pt'>y</span>da
  psiko<span style='letter-spacing:-.35pt'>l</span>ojik stres ya da akut hasta<span
  style='letter-spacing:-.2pt'>l�k</span>tan <span class=GramE>�i<span
  style='letter-spacing:-.2pt'>k</span>ayet</span> o<span style='letter-spacing:
  -.35pt'>l</span>du mu?</span></b><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><o:p></o:p></span></p>
  <p class=MsoNormal style='line-height:6.5pt;mso-line-height-rule:exactly;
  mso-pagination:none;mso-layout-grid-align:none;text-autospace:none'><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;letter-spacing:-.05pt;mso-fareast-language:EN-US'><span
  style='mso-spacerun:yes'>��������� </span>0 </span><span style='font-size:
  8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'>= <span
  style='letter-spacing:.15pt'>E</span><span style='letter-spacing:-.25pt'>v</span><span
  style='letter-spacing:-.05pt'>et</span><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>���������
  </span>2 = <span style='letter-spacing:-.05pt'>H</span><span
  style='letter-spacing:.2pt'>a</span><span style='letter-spacing:-.2pt'>y�r</span><o:p></o:p></span></p>
  <p class=MsoNormal><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:38.85pt'>
  <td width=264 valign=top style='width:197.75pt;border:solid windowtext 1.5pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.5pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:38.85pt'>
  <p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
  text-autospace:none'><b><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  letter-spacing:.05pt;mso-fareast-language:EN-US'>2</span></b><b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'>.
  <span style='letter-spacing:.05pt'>So</span>n <span style='letter-spacing:
  .05pt'>�</span>� <span style='letter-spacing:.05pt'>a</span>y <span
  style='letter-spacing:.05pt'>i�inde</span><span style='letter-spacing:-.3pt'>k</span>i
  <span style='letter-spacing:-.2pt'>k</span><span style='letter-spacing:.05pt'>i</span><span
  style='letter-spacing:-.2pt'>l</span>o <span style='letter-spacing:-.2pt'>k</span><span
  style='letter-spacing:.05pt'>ay</span>b� <span style='letter-spacing:.05pt'>du</span><span
  style='letter-spacing:-.25pt'>r</span><span style='letter-spacing:.3pt'>u</span><span
  style='letter-spacing:-.15pt'>m</span>u</span></b><span style='font-size:
  8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span
  style='mso-spacerun:yes'>������������� </span>0 = �� kg<span
  style='letter-spacing:.1pt'>�</span>dan <span style='letter-spacing:-.4pt'>f</span>azla
  ki<span style='letter-spacing:-.3pt'>l</span>o k<span style='letter-spacing:
  .2pt'>a</span><span style='letter-spacing:-.25pt'>y</span>b�<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span
  style='mso-spacerun:yes'>������������� </span>1 = <span style='letter-spacing:
  .25pt'>B</span><span style='letter-spacing:-.3pt'>i</span>l<span
  style='letter-spacing:-.2pt'>i</span><span style='letter-spacing:.25pt'>n</span><span
  style='letter-spacing:-.2pt'>m</span>i<span style='letter-spacing:-.5pt'>y</span><span
  style='letter-spacing:.25pt'>or</span><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span
  style='mso-spacerun:yes'>������������� </span>2 = 1 <span style='letter-spacing:
  -.3pt'>v</span>e 3kg ara<span style='letter-spacing:-.15pt'>s�</span><span
  style='letter-spacing:-.25pt'>n</span>da <span style='letter-spacing:.2pt'>k</span>i<span
  style='letter-spacing:-.45pt'>l</span>o k<span style='letter-spacing:.2pt'>a</span><span
  style='letter-spacing:-.25pt'>y</span><span style='letter-spacing:.05pt'>b�</span><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span
  style='mso-spacerun:yes'>������������� </span>3 = Ki<span style='letter-spacing:
  -.6pt'>l</span>o k<span style='letter-spacing:.35pt'>a</span><span
  style='letter-spacing:-.25pt'>y</span>b� <span style='letter-spacing:-.3pt'>y</span><span
  style='letter-spacing:.25pt'>o</span>k<o:p></o:p></span></p>
  </td>
  <td width=270 valign=top style='width:202.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  mso-border-top-alt:solid windowtext 1.5pt;mso-border-left-alt:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:38.85pt'>
  <p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
  text-autospace:none'><b><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  mso-fareast-language:EN-US'>5. N�<span style='letter-spacing:-.3pt'>r</span>o-ps<span
  style='letter-spacing:.2pt'>i</span><span style='letter-spacing:-.2pt'>k</span>o<span
  style='letter-spacing:-.2pt'>l</span>oj<span style='letter-spacing:.35pt'>i</span>k
  p<span style='letter-spacing:-.25pt'>r</span>o<span style='letter-spacing:
  .3pt'>b</span><span style='letter-spacing:-.2pt'>l</span><span
  style='letter-spacing:.2pt'>e</span>mle<span style='letter-spacing:-.25pt'>r</span>:</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>��������
  </span>0 = C<span style='letter-spacing:-.4pt'>i</span>d<span
  style='letter-spacing:.25pt'>d</span>i <span style='letter-spacing:-.25pt'>b</span><span
  style='letter-spacing:.25pt'>u</span><span style='letter-spacing:-.25pt'>n</span><span
  style='letter-spacing:.2pt'>a</span><span style='letter-spacing:-.2pt'>m</span>a
  ve depre<span style='letter-spacing:.25pt'>s</span><span style='letter-spacing:
  -.5pt'>y</span><span style='letter-spacing:.45pt'>o</span>n<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>��������
  </span>1 = Haf<span style='letter-spacing:-.35pt'>i</span>f d�zeyde <span
  style='letter-spacing:-.25pt'>b</span><span style='letter-spacing:.25pt'>u</span><span
  style='letter-spacing:-.25pt'>n</span><span style='letter-spacing:.2pt'>a</span><span
  style='letter-spacing:-.2pt'>m</span>a ve depresyon<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>��������
  </span>2 = H<span style='letter-spacing:-.35pt'>i</span><span
  style='letter-spacing:.2pt'>�</span>b<span style='letter-spacing:-.45pt'>i</span>r
  n�ropsik<span style='letter-spacing:.4pt'>o</span><span style='letter-spacing:
  -.45pt'>l</span><span style='letter-spacing:.45pt'>o</span><span
  style='letter-spacing:-.2pt'>ji</span>k pr<span style='letter-spacing:.25pt'>o</span>b<span
  style='letter-spacing:-.45pt'>l</span><span style='letter-spacing:.2pt'>e</span>m
  <span style='letter-spacing:-.5pt'>y</span><span style='letter-spacing:.25pt'>o</span>k<o:p></o:p></span></p>
  <p class=MsoNormal><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;height:44.2pt'>
  <td width=264 valign=top style='width:197.75pt;border:solid windowtext 1.5pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.5pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:44.2pt'>
  <p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
  text-autospace:none'><b><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  letter-spacing:.1pt;mso-fareast-language:EN-US'>3</span></b><b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'>.
  <span style='letter-spacing:.1pt'>Mobilite</span></span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;letter-spacing:-.05pt;mso-fareast-language:EN-US'><span
  style='mso-spacerun:yes'>������������� </span>0 </span><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'>=
  <span style='letter-spacing:-.05pt'>Ya</span><span style='letter-spacing:
  .25pt'>t</span><span style='letter-spacing:-.05pt'>a</span>k <span
  style='letter-spacing:-.45pt'>y</span>a <span style='letter-spacing:-.05pt'>d</span>a
  <span style='letter-spacing:-.05pt'>sanda</span><span style='letter-spacing:
  .15pt'>l</span><span style='letter-spacing:-.25pt'>y</span><span
  style='letter-spacing:.2pt'>e</span><span style='letter-spacing:-.25pt'>y</span>e
  <span style='letter-spacing:-.05pt'>b</span>a��ml�<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span
  style='mso-spacerun:yes'>������������� </span>1 = Yataktan, s<span
  style='letter-spacing:-.2pt'>a</span><span style='letter-spacing:-.25pt'>n</span>d<span
  style='letter-spacing:.2pt'>a</span>l<span style='letter-spacing:-.2pt'>y</span>eden
  kalkabili<span style='letter-spacing:-.35pt'>y</span><span style='letter-spacing:
  .25pt'>o</span>r<span style='letter-spacing:.1pt'> </span><span class=GramE><span
  style='letter-spacing:.25pt'>a</span><span style='letter-spacing:-.45pt'>m</span>a<span
  style='mso-spacerun:yes'>� </span>d��ar�ya</span> ��kam�yor<span
  style='letter-spacing:.1pt'><o:p></o:p></span></span></p>
  <p class=MsoNormal><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  mso-fareast-language:EN-US'><span
  style='mso-spacerun:yes'>������������������� </span>2 = D��ar� <span
  style='letter-spacing:.3pt'>��</span><span style='letter-spacing:.25pt'>ka</span><span
  style='letter-spacing:-.05pt'>b</span><span style='letter-spacing:-.2pt'>i</span>li<span
  style='letter-spacing:-.5pt'>y</span><span style='letter-spacing:.25pt'>or</span><o:p></o:p></span></p>
  </td>
  <td width=270 valign=top style='width:202.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  mso-border-top-alt:solid windowtext 1.5pt;mso-border-left-alt:solid windowtext 1.5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:44.2pt'>
  <p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
  text-autospace:none'><b><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;
  letter-spacing:-.05pt;mso-fareast-language:EN-US'>6</span></b><b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'>.
  V�cut <span style='letter-spacing:.3pt'>B</span><span style='letter-spacing:
  -.05pt'>ede</span>n k<span style='letter-spacing:-.05pt'>i</span><span
  style='letter-spacing:.15pt'>t</span><span style='letter-spacing:-.05pt'>l</span>e
  i<span style='letter-spacing:-.05pt'>n</span><span style='letter-spacing:
  .15pt'>d</span><span style='letter-spacing:-.05pt'>ek</span><span
  style='letter-spacing:-.25pt'>s</span>i <span style='letter-spacing:.25pt'>(</span><span
  style='letter-spacing:-.05pt'>B</span><span style='letter-spacing:.25pt'>K</span><span
  style='letter-spacing:-.1pt'>�</span>) <span style='letter-spacing:-.05pt'>(kg/m2)<span
  style='mso-spacerun:yes'>���� </span></span></span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;letter-spacing:.55pt;
  mso-fareast-language:EN-US'>veya</span><span style='font-size:8.0pt;
  mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>���������
  </span>0 = <span style='letter-spacing:.1pt'>&lt;</span>19<span
  style='mso-spacerun:yes'>������������������������������ </span><span
  style='mso-spacerun:yes'>����������</span>Bald�r �evresi<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>���������
  </span>1 = <span style='letter-spacing:.1pt'>&#8805;</span>19 ve &lt;21<span
  style='mso-spacerun:yes'>����������������������������������� </span>�l��m�<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>���������
  </span>2 = <span style='letter-spacing:.1pt'>&#8805;</span>21 ve &lt;23<span
  style='mso-spacerun:yes'>���������������������������������� </span>&#8805;<span
  style='mso-spacerun:yes'>�� </span><span class=GramE>31 : 3</span><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:9.6pt;mso-pagination:none;mso-layout-grid-align:
  none;text-autospace:none'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>���������
  </span>3 = <span style='letter-spacing:.1pt'>&#8805;</span>23<span
  style='mso-spacerun:yes'>����������������������������������������������
  </span>&lt;<span style='mso-spacerun:yes'>� </span><span class=GramE>31 : 0</span><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;mso-yfti-lastrow:yes;height:5.4pt'>
  <td width=533 colspan=2 valign=top style='width:399.95pt;border:solid windowtext 1.5pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.5pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:5.4pt'>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0cm;margin-bottom:
  2.0pt;margin-left:0cm;mso-layout-grid-align:none;text-autospace:none'><b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'>Toplam
  Puan<span class=GramE><span style='letter-spacing:-.05pt'>:</span><span
  style='letter-spacing:-.05pt;font-weight:normal'>����.��.�</span></span></span></b><b
  style='mso-bidi-font-weight:normal'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;letter-spacing:-.05pt;mso-fareast-language:EN-US'>/14</span></b><b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;letter-spacing:.15pt;
  mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>������ </span>�</span></b><b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;letter-spacing:-.05pt;
  mso-fareast-language:EN-US'>zle</span></b><b><span style='font-size:8.0pt;
  mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'>m <span
  style='letter-spacing:-.05pt'>D</span>e�<span style='letter-spacing:.2pt'>e</span><span
  style='letter-spacing:-.05pt'>rlen</span><span style='letter-spacing:.2pt'>d</span><span
  style='letter-spacing:-.05pt'>irm</span><span style='letter-spacing:.15pt'>e</span><span
  style='letter-spacing:-.05pt'>si :<span style='mso-spacerun:yes'>��� </span></span></span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;font-family:Wingdings;
  mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman";
  mso-fareast-language:EN-US;mso-char-type:symbol;mso-symbol-font-family:Wingdings;
  mso-bidi-font-weight:bold'><span style='mso-char-type:symbol;mso-symbol-font-family:
  Wingdings'>o</span></span><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt;mso-fareast-language:EN-US'> </span><span style='font-size:8.0pt;
  mso-bidi-font-size:10.0pt;mso-fareast-font-family:MyriadPro-Light;mso-fareast-language:
  EN-US'>0-7<span style='mso-spacerun:yes'>� </span>maln�trisyon<span
  style='mso-spacerun:yes'>�������� </span></span><span style='font-size:8.0pt;
  mso-bidi-font-size:10.0pt;font-family:Wingdings;mso-ascii-font-family:"Times New Roman";
  mso-hansi-font-family:"Times New Roman";mso-fareast-language:EN-US;
  mso-char-type:symbol;mso-symbol-font-family:Wingdings;mso-bidi-font-weight:
  bold'><span style='mso-char-type:symbol;mso-symbol-font-family:Wingdings'>o</span></span><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'>
  </span><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-font-family:
  MyriadPro-Light;mso-fareast-language:EN-US'>8-11 maln�trisyon riski<span
  style='mso-spacerun:yes'>�������� </span></span><span style='font-size:8.0pt;
  mso-bidi-font-size:10.0pt;font-family:Wingdings;mso-ascii-font-family:"Times New Roman";
  mso-hansi-font-family:"Times New Roman";mso-fareast-language:EN-US;
  mso-char-type:symbol;mso-symbol-font-family:Wingdings;mso-bidi-font-weight:
  bold'><span style='mso-char-type:symbol;mso-symbol-font-family:Wingdings'>o</span></span><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'>
  </span><span style='font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-fareast-font-family:
  MyriadPro-Light;mso-fareast-language:EN-US'>&gt;11 normal<span
  style='mso-spacerun:yes'>��� </span><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;text-indent:35.4pt;line-height:
150%;mso-layout-grid-align:none;text-autospace:none'><span style='font-size:
10.0pt;line-height:150%'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";background:white'>Riskli bireyler saptand�ktan sonra
maln�trisyon tan�s�n� de�erlendirmek �zere fenotipik ve etyolojik <span
class=GramE>kriterlerin</span> varl��� ara�t�r�l�r. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";background:white'>Fenotipik <span class=GramE>kriterler</span>:
Son alt� ay i�inde %5 veya 6 aydan uzun s�rede %10 kilo kayb�n�n olmas�, d���k
VKݒnin olmas� (&lt;70 ya�: &lt;20 kg/m2 veya &gt;70 ya� : &lt;22 kg/m2 Asya�da
&lt;70 ya� : &lt;18,5 kg/m2 veya &gt;70 ya� &lt;20 kg/m2) ve/veya azalm�� kas
k�tlesi olmas� (Valide edilmi� v�cut bile�eni �l��m teknikleri ile): �rne�in
bioimpedans DXA, MRI, BT gibi<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";background:white'>Etyolojik kriterler: azalm�� besin
al�m�/sindirimi (&gt;1 hafta &lt;=%50 enerji ihtiyac� veya &gt;2 hafta herhangi
bir <span class=GramE>azalma,</span> veya g�dalar�n sindirimini ya da emilimini
olumsuz etkileyen kronik bir gastrointestinal durum) ve/veya inflamasyon (Akut
hastal�k/yaralanma veya kronik hastal��a ba�l�). Maln�trisyon tan�s� koyabilmek
i�in etyolojik <span class=GramE>kriterlerden</span> en az biri ve fenotipik
kriterlerden en az birinin var olmas� gerekir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";background:white'>Maln�trisyonun ciddiyetini belirlemek
i�in fenotipik <span class=GramE>kriterler</span> kullan�l�r. Bu basamakta kilo
kayb� son 6 ay i�inde %5-10 veya 6 aydan uzun s�rede %10-20 ise evre 1 (�l�ml�
maln�trisyon), son 6 ay i�inde &gt;%10 veya 6 aydan uzun s�rede &gt;%20 ise
evre 2 (�iddetli maln�trisyondan) bahsedilir. E�er hastan�n VK� &lt;70 ya�ta
&lt;20 kg/m2,&gt;=70 ya�ta &lt;22 kg/m2 ise evre 1 maln�trisyon, &lt;70 ya�ta
&lt;18,5 kg/m2 &gt;=70 ya�ta &lt;20 kg/m2 ise evre 2 maln�trisyon olarak
derecelendirilir. Kas k�tlesinde hafif ila orta azalma var ise evre 1
maln�trisyon, �iddetli azalma var ise evre 2 maln�trisyon olarak
de�erlendirilir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'>Beslenme yetersizli�i sorgulanan bir
hastada bireyin beslenme al��kanl��� nitelik ve i�erik a��s�ndan sorgulanmal�, ishal
kusma gibi sindirim sistemi bulgular� sorulmal� ve hastan�n kulland��� ila�lar,
mevcut hastal�klar�, al��kanl�klar� ��renilmelidir. Kilo kayb� olanlarda altta
yatan sebebi ara�t�rmak i�in tam kan say�m�, glukoz, elektrolitler, b�brek ve
karaci�er fonksiyon testleri, tiroid fonksiyon testi, sedimentasyon, tam idrar
tahlili ve akci�er grafisi rutin istenmesi gereken testlerdir. Bu testler
d���nda hastan�n bulgular�na g�re daha ileri tetkikler planlanabilir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black;mso-themecolor:text1'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black;mso-themecolor:text1'>ESPEN �nerilerine g�re PH olanlarda hastal�k
s�resince beslenme ve vitamin durumunun d�zenli olarak izlenmesi tavsiye
edilir. Kilo kayb�, d���k VK�, demans veya disfaji bulgular� olan Parkinson
hastalar�nda �on� faz�nda iken disfaji varl��� taranmal�d�r. Taramada PH�na
�zel anketler </span><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:Symbol;mso-ascii-font-family:Tahoma;mso-hansi-font-family:Tahoma;
mso-bidi-font-family:Tahoma;color:black;mso-themecolor:text1;mso-char-type:
symbol;mso-symbol-font-family:Symbol'><span style='mso-char-type:symbol;
mso-symbol-font-family:Symbol'>[</span></span><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:black;
mso-themecolor:text1'>�rne�in SDQ (swallowing disturbance questionnaire) veya
MDT-PD (<span style='background:white'>Munich Dysphagia Test</span>)</span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
mso-ascii-font-family:Tahoma;mso-hansi-font-family:Tahoma;mso-bidi-font-family:
Tahoma;color:black;mso-themecolor:text1;mso-char-type:symbol;mso-symbol-font-family:
Symbol'><span style='mso-char-type:symbol;mso-symbol-font-family:Symbol'>]</span></span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black;mso-themecolor:text1'> ve yutma tarama testleri �nerilir. Yutma
tarama testlerinden akut inmede kullan�lmas� �nerilen su yutma testinin PH�de
orofaringeal disfajiyi �ng�remedi�i saptanm��t�r. �stanbul T�p Fak�ltesi
Geriatri Bilim Dal� prati�inde de kullan�lmakta olan Vol�m-Viskozite Yutma
Testi (VVST) ise PH�de valide edilmi�tir. Taramada disfaji saptanan, hastal���n
h�zl� k�t�le�mesi olan, pn�monisi olan veya disfajinin di�er bulgular� olan
hastalarda enstr�mental disfaji testi yap�lmal�d�r. De�erlendirme fiberoptik
endoskopik yutma de�erlendirmesi (fiberoptic endoscopic evaluation of
swallowing) (FEES) <span class=GramE>ile,</span> e�er bu yap�lam�yor ise
Videofluoroscopic assessment of swallowing (VFA) ile yap�lmal�d�r. Enstr�mental
de�erlendirme yap�lam�yorsa klinik de�erlendirme yap�lmal�d�r. PH i�in
kullan�lan ila�lar�n yan etkileri beslenme durumunu etkileyebilir. Levodopa
kullananlarda homosistein ve B6 vitamini durumuna �zellikle dikkat edilmelidir.
Levodopa homosistein d�zeyinde art��a neden olur. Parkinson hastalar�nda
dopaminerjik ila�lar�n bulant� kusma yapabilece�i, vitamin deste�i alt�ndaki
hastalarda B6 vitamininin levodopa emilimini bozabilece�i, insu&#776;lin
sal�n�m�n�n levodopan�n kan beyin bariyerini ge�mesini kolayla�t�rd���, bu
nedenle diyetteki karbonhidrat oran�n�n yu&#776;ksek olmas�n�n faydal�
olabilece�i unutulmamal�d�r. Ayr�ca PH tedavisinde kullan�lan levadopa a�
karn�na (yemeklerden en az 1 saat �nce ya da yemeklerden 2-3 saat sonra)
al�nmal�d�r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;background:white'>T�m <b style='mso-bidi-font-weight:normal'>inme</b>
hastalar� disfaji, bilin� bozuklu�u, alg� bozuklu�u ve kognitif i�lev bozuklu�u
nedeniyle maln�trisyon ve dehidratasyona yatk�n olabilir. Maln�trisyonda ya da
maln�trisyon riski alt�nda olma, artm�� mortalite riski ve di�er k�t�
sonu�larla ili�kilidir.</span><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'> Ayr�ca, inme
hastalar� hayat� tehdit eden bir <span class=GramE>komplikasyon</span> olan
aspirasyon pn�monisi i�in de y�ksek risk alt�ndad�r. </span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>ESPEN
�nerilerine g�re t�m inme ge�iren hastalarda m�mk�n olan en k�sa s�rede disfaji
taramas� <span style='color:black;mso-themecolor:text1'>yap�lmal�d�r. Disfaji
taramas� yap�lamayan veya �ks�rme, bo�ulma, �slak ses, a��z i�inde yiyecek
kal�nt�lar� kalmas� veya pn�moni varl��� gibi disfaji <span class=GramE>semptomlar�</span>
g�steren veya dizartri, afazi, fasyal paralizi, kognitif bozukluk, bilin�
bozuklu�u gibi disfaji risk fakt�rleri olan t�m inme hastalar�n�n yutma
fonksiyonu m�mk�n olan en erken zamanda de�erlendirilmelidir. <o:p></o:p></span></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Tan�sal
yakla��m aspirasyon taramalar�ndan olan su yutma testi <span style='color:#212121'>ile
ba�lar. <span style='background:white'>Daha kapsaml� bir de�erlendirme s�z
konusu oldu�unda enstr�mental de�erlendirmelerden</span></span><span
style='color:black;mso-themecolor:text1;background:white'> VFA </span><span
style='color:#212121;background:white'>veya FEES ger�ekle�tirilebilir. FEES�in
baz� avantajlar� vard�r. Bu testte hastan�n minimum i�birli�ine ihtiya�
duyulur.</span> T�m inmeli hastalar hastane ba�vurusunda (ilk 48 saat i�inde)
maln�trisyon riski a����ndan de�erlendirilmelidir. Bu ama�la t�bbi beslenme
tedavisinden yararlanma olas�l��� daha y�ksek olan hastalar� belirlemek i�in<span
style='color:red'> </span><span style='color:black;mso-themecolor:text1'>MUST
testi </span>kullan�labilir. Disfajisi olmayan ve yeterli beslenen hastalara
rutin oral n�trisyon deste�i �nerilmez. Yemek yiyebilen ve maln�trisyon veya
maln�trisyon riski olanlarda oral n�trisyon deste�i �nerilir. Disfaji saptanan
hastalarda k�vam� de�i�tirilmi� g�dalar veya kat�la�t�r�lm�� s�v�lar aspirasyon
pn�monisi insidans�n� azalt�r. D<span style='color:#212121'>isfajinin
de�erlendirilmesi ve tedavisi konusunda deneyimli profesyoneller taraf�ndan
standart bir protokole g�re aspirasyon riskini de i�eren yutma i�levinin
de�erlendirilmesinden sonra </span>k�vam� de�i�tirilmi� g�dalar <span
style='color:#212121'>ve koyula�t�r�lm�� s�v�lar verilmelidir. Bu de�erlendirme
normal yutma fonksiyonu tekrar elde edilinceye kadar d�zenli aral�klarla
tekrarlanmal�d�r. </span><span style='color:black;mso-themecolor:text1'>Gazl�
i�ecekler koyula�t�r�lm�� s�v�lara k�yasla farengeal art��� azaltabilir. Gazl�
i�eceklerin kullan�m�, farengeal kal�nt� te�hisi konan inme hastalar� i�in bir
se�enek olabilir. <span style='background:white'>�nme sonras� uzam�� �iddetli
disfajisi olan ve disfajinin 7 g�nden uzun s�rmesi beklenen hastalarda 3 g�n
i�inde enteral t�p beslenmesi �nerilir. </span></span>Bilin� seviyesi d���k
olan ve mekanik ventilasyon ihtiyac� olan kritik inme hastalar�nda enteral
t�ple beslenmeye <span style='color:black;mso-themecolor:text1'>3 g�n i�inde
ge�ilmelidir. </span><span style='color:#212121;background:white'>E�er inmenin
akut faz� s�ras�nda yeterli oral besin al�m� m�mk�n de�ilse, enteral n�trisyon
tercihen nazogastrik t�p ile verilmelidir. </span><span
style='mso-spacerun:yes'>�</span><span style='color:#212121;background:white'>E�er
enteral beslenme daha uzun bir s�re i�in gerekliyse (&gt; 28 g�n), PEG
se�ilmeli ve PEG <span class=GramE>stabil</span> bir klinik d�nemde
yerle�tirilmelidir (14-28 g�n sonra).</span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>ESPEN
�nerilerine g�re <b style='mso-bidi-font-weight:normal'>demans</b>�<b
style='mso-bidi-font-weight:normal'> </b>olan her hasta maln�trisyon a��s�ndan
taranmal�d�r. Demansl� hastalar�n kilosu yak�n takip edilmeli ve
belgelenmelidir. <span style='color:#212121;background:white'>Ki�isel
tercihlere �nem vererek bireysel ihtiya�lara g�re yeterli yiyecek tedariki
�nerilmektedir.</span> <span style='color:#212121'>��tah uyar�c�lar�n kullan�m�
�nerilmez.</span> Demansl� hastalarda <span style='color:#212121;background:
white'>maln�trisyonun olas� nedenlerinin olabildi�ince ortadan kald�r�lmas�
gerekir.</span> <span style='color:black;mso-themecolor:text1'>Diyet</span>
k�s�tlamalar�ndan uzak durulmal�d�r. <span style='color:#212121'>Demansl�
ki�ilerde kognitif bozuklu�a y�nelik omega-3-ya� asidi, B1 vitamini, B12
vitamini, B6 vitamini ve/veya folik asit takviyelerinin kullan�lmas� �nerilmez.</span>
<span style='color:#212121;background:white'>Kognitif y�k�m�n �nlenmesi veya
d�zeltilmesi i�in bunama hastalar�nda E vitamini, selenyum, bak�r, D vitamini
takviyelerinin kullan�lmas� �nerilmez. Demans� olan ki�ilere kognitif bozuklu�u
d�zeltmek veya kognitif gerilemeyi �nlemek i�in �zel t�bbi g�dalar�n kullan�m�
da �nerilmez. Bununla birlikte </span><span style='color:#212121'>yap�lan
�al��malarda<span style='background:white'> </span>Multinutrient Fortasyn
Connect (</span><span style='color:#333333;background:white'>Omega-3 (g�nl�k
1500 mg d</span><em><span style='font-family:"Tahoma","sans-serif";color:black;
mso-themecolor:text1;background:white;mso-bidi-font-weight:bold;font-style:
normal'>okosaheksaenoik asit</span></em><span style='color:black;mso-themecolor:
text1'> </span><span style='color:#333333;background:white'>eikosapentaenoik asit),
fosfolipidler, kolin, y�ksek doz vitamin B (B12, <span class=GramE>B6,</span>
ve folik asit), vitamin E, vitamin C, selenyum, ve uridin monofosfat) </span><span
style='color:#212121'>alan Alzheimer hastalar�nda kognitif i�levlerde g�receli
bir iyilik ve beyin atrofi h�z�nda azalma olabilece�i �ne s�r�lm��t�r. <span
style='background:white'>Maln�trisyon riski veya maln�trisyonu olan </span>demansl�
hastalarda </span><span style='color:black;mso-themecolor:text1'>beslenme
durumunu iyile�tirmek i�in </span><span style='color:#212121'>oral n�trisyonel
ek kullan�m� �nerilir.</span> E�er d���k besinsel al�m b�y�k �l��de <span
style='color:black;mso-themecolor:text1'>d�zeltilebilir </span>bir durumdan
kaynaklan�yorsa, akut duru<span style='color:black;mso-themecolor:text1'>mun</span>
�stesinden gelmek i�in maln�trisyonu olan hafif-orta <span class=GramE>demansl�<span
style='mso-spacerun:yes'>� </span>hastalarda</span> s�n�rl� bir s�re i�in t�ple
beslenme �nerilir. <span style='color:#212121;background:white'>�leri evre
demansl� hastalarda ise t�p beslenmesi �nerilmez.</span> E�er yapay beslenme
endikasyonu var fakat t�ple beslenme kontrendike ise veya tolere edilemiyorsa
parenteral n�trisyon �nerilir. Hayat�n terminal d�neminde yapay beslenme
(enteral beslenme, parenteral beslenme ve parenteral s�v�) �nerilmez.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Maln�trisyonda
tedavi<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Tarama
ve de�erlendirme sonucunda malnu&#776;trisyon veya malnu&#776;trisyon riski
tespit edilen hastalara beslenme destek tedavisi planlanmal�d�r. Hastalar�n
metabolik gereksinimine g�re kalori al�m�n�n yeterli olup olmad���na
bak�lmal�d�r. �ncelikle oral g�da <span class=GramE>al�m� mu</span>&#776;mku&#776;n
olanlarda gu&#776;nlu&#776;k kalori ihtiyac� do�rultusunda diyet du&#776;zenlenir.
Diyet ile yeterli kalori al�m� sa�lanamaz ise enteral ve/veya parenteral
beslenme u&#776;ru&#776;nleri ile destek tedavi ba�lanabilir. Bu tedavi
modalitesinde as�l olan enteral beslenmedir, fakat bu her zaman yeterli veya
uygulanabilir olamayabilir, dolay�s�yla bazen parenteral nu&#776;trisyon
tedavisi ile destek gerekmektedir. Enteral beslenme yollar� oral enteral,
nazoenteral ve enteroku&#776;tan yollard�r. Enteral beslenmede kullan�lacak
y�ntem beklenen beslenme s�resi, aspirasyon riski ve sindirim sisteminin
durumuna g�re belirlenmelidir. Nazoenteral yol i�in nazogastrik veya
nazointestinal �feeding� tu&#776;p kullan�labilir. Bu tu&#776;plerin silikon
veya poliu&#776;retan olanlar� tercih edilmelidir. Enteroku&#776;tan yollar
ise, perku&#776;tan endoskopik gastrostomi (PEG) ve perku&#776;tan endoskopik
jejunostomidir (PEJ). Otuz g�nden k�sa beslenme i�in nazogastrik ve
nazointestinal t�pler kullan�labilir. K���k �apl� �feeding� t�pleri nazogastrik
t�plere g�re daha iyi tolere edilir. N�rolojik disfaji varl���nda enteral
beslenme yollar�ndan birinin tercih edilmesi, lif i�erikli u&#776;ru&#776;nlerin
se�ilmesi, bas� yaralar� varl���nda yu&#776;ksek protein i�erikli u&#776;ru&#776;nlerin
verilmesi �nerilmektedir. Erken ve orta evredeki demans hastalar�nda oral veya
tu&#776;ple beslenme tedavisi verilmesi, ileri evre demans hastalar�nda tu&#776;ple
beslenmenin tercih edilmemesi gerekir. Terminal evre kanser hastalar�nda da tu&#776;ple
beslenmenin uygulanmamas� �nerilmektedir. Uzun su&#776;reli tu&#776;ple
beslenme gereken hastalarda (&gt;4 hafta) PEG uygulanmas� tavsiye edilmektedir.
PEG i�leminin <span class=GramE>komplikasyon</span> riski azd�r, infeksiyon,
kanama ve peritonit %1-3 aras�nda rapor edilmi�tir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Beslenme
yolu se�ildikten sonra gu&#776;nlu&#776;k enerji ihtiyac� (GE�) hesaplanmal� ve
ard�ndan oral g�da al�m� da g�z �n�nde bulundurularak gu&#776;nlu&#776;k
verilecek destek miktar� hesaplanmal�d�r. GEݒn�n ortalama 25-30 kcal/kg/g�n,
obezlerde 20-25 kcal/kg, stres durumunda 30-40 kcal/kg, sepsis durumunda 40-50
kcal/kg �eklinde hesaplanmas� �nerilir. Hafif �iddette hastal�kta bazal
metabolizma h�z�n�n 1,3 kat�, orta �iddette hastal�kta 1,5 kat� ve ciddi
�iddette hastal�kta 1,7-1,8 kat� kadar enerji al�m�na ihtiya� vard�r. GE�
hesapland�ktan sonra hastaya yediklerini listelemesi istenir ve bu liste u&#776;zerinden
gu&#776;nlu&#776;k almakta oldu�u kalori miktar� hesaplan�r. G�nl�k enerji
ihtiyac�ndan almakta oldu�u kalori miktar� ��kar�larak enerji a���� hesaplan�r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Ya�l�larda
fiziksel fonksiyonu yerine getirmek i�in gen�lere g�re daha fazla protein
ihtiyac� vard�r.<span style='mso-spacerun:yes'>� </span>PROT-AGE Grubu g�nl�k
ortalama protein gereksinimi 1-1,2 g/kg aras�nda olmas� gerekti�ini bildirmi�tir.
Akut veya kronik hastal��� olan ya�l�larda ise daha fazla proteine ihtiya�
oldu�u (�rn: 1,2-1,4 g/kg) ciddi hastal��� olan, yaralanma veya belirgin
maln�trisyonu olanlarda 2 g/kg�a kadar ihtiya� olabilece�i belirtilmi�tir.
Ciddi b�brek yetmezli�i olan ve diyalize girmeyen hastalarda (�rn, eGFR &lt;30
mL/min/1,73m2) protein al�m� k�s�tlanmal�d�r (0,8 g/kg/g). Orta b�brek
yetmezli�inde (GFR 30-60 mL/min/1,73m 2) &gt; 0,8 g/kg/g g�venlidir fakat GFR
y�lda iki defa takip edilmelidir. Hemodiyaliz ve periton diyalizine girenlerde
protein al�m�&gt; 1,2 g/kg/g olmal�d�r, e�er ula��labiliyorsa 1,5 g/kg/ g� e
kadar ��kar�labilir.<span style='mso-spacerun:yes'>� </span>PROT-AGE �al��ma
grubu, egzersizden hemen sonra <span class=GramE>amino</span> asitlere kas
duyarl�l��� artt��� i�in, fiziksel egzersizden hemen sonra protein al�m�n� �nerir.<span
style='mso-spacerun:yes'>� </span>G�z ard� edilmemesi gereken bir di�er �nemli
nokta da ya�l�lar�n yemeklerindeki dengesiz protein da��l�m� ve s�k s�k ���n
atlanmas�d�r. G�nl�k protein al�m�n�n, al�nan proteinden <span class=GramE>optimal</span>
fayda sa�lamak i�in, g�n boyunca yemeklerle orant�l� olarak da��t�lmas�
gerekir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
none;text-autospace:none'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Oral
beslenmede �ncelikle oral g�da al�m� artt�r�lmal�d�r. Yap�lan �neriler ya�l�n�n
al��kanl�klar�na uygun olmal�d�r. Enerji ve protein i�eri�i d���k g�dalar
kaliteli g�dalarla de�i�tirilmelidir. Yemek aralar�nda at��t�rmal�klar �nerilmelidir.
Oral g�da al�m�n� artt�rmaya y�nelik �nlemler ba�ar�s�z olursa oral n�trisyonel
�r�nlere vakit kaybetmeden ba�lanmal�d�r.<span style='mso-spacerun:yes'>�
</span>Enteral beslenme �r�nlerinin hepsi protein, karbonhidrat ve ya�lardan
olu�ur. �r�nler aras�ndaki farkl�l�klar sindirilebilirlik, k�vam, ozmolarite,
i�eriklerin miktar� ve fiyat�na g�redir. �zotonik form�ller (1-1,2 kcal/ml)
genelde ba�lang��ta kullan�lan �r�nlerdir. Daha yo�un (1,5-2 kcal/ml) formlar
s�v� k�s�tlamas� gerekti�inde yararl� olabilir, ancak bu �r�nler y�ksek ozmolariteden
dolay� ishal ve t�p�n t�kanmas� gibi <span class=GramE>komplikasyonlara</span>
neden olabilir. �shali �nlemek i�in y�ksek lif i�erikli �r�nler tercih
edilebilir. B�brek yetmezli�i, karaci�er yetmezli�i, diabetes mellitus ve
akci�er hastal��� varl���nda kullan�labilecek �zel �r�nler mevcuttur. Bu �zel
�r�nlerin kullan�m� mutlak endike de�ildir. Pek �ok hastada standart �r�nlerle
de gerekli beslenme tedavisi yap�labilir. B�brek yetmezli�inde d���k proteinli,
d���k elektrolitli ve kalorisi y�ksek �r�nler tercih edilebilir. Karaci�er
yetmezli�inde hepatik ensefalopati riskini artt�rmamak i�in �zel aminoasitleri
i�eren formlar tercih edilebilir. Akci�er hastal��� olanlarda karbondioksit
�retimini azaltmak i�in y�ksek ya�l� formlar kullan�labilir. Sindirim sistemi
fonksiyon bozuklu�u olanlarda karbonhidratlar ve proteinler oligosakkarit ve
aminoasit gibi yap�ta�lar� �eklinde verilerek emilim ve sindirim
kolayla�t�r�labilir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:14.0pt;line-height:150%;
background:white'><span style='mso-spacerun:yes'>�</span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Sonu�
olarak maln�trisyon n�rolojik hastal��� olan ya�l�larda s�k g�r�l�r ve<span
style='color:black'> kas atrofisi (ekstremite/solunum), bas� yaralar�, du&#776;�meler,
osteoporoz, infeksiyon riski ve sa� kal�mda azalma gibi bir�ok olumsuz duruma</span>
neden olabilir. Ya�l�da beslenme durumunu olumsuz etkileyen bir�ok fakt�r
vard�r. Maln�trisyonun ilk a�amada tan�nmas� b�y�k �nem arz etmektedir. Her
hasta mutlaka maln�trisyon a��s�ndan de�erlendirilmeli ve yeterli beslenemeyen
hastaya h�zla gerekli �nerilerde bulunulmal�d�r. �htiya� halinde uygun beslenme
yolu se�ilerek beslenme �r�nleri ile beslenme deste�i vakit kaybetmeden
ba�lanmal�d�r. <b style='mso-bidi-font-weight:normal'><span style='color:black'><o:p></o:p></span></b></span></p>

<p class=MsoNormal style='text-align:justify;text-indent:35.4pt;line-height:
150%'><span style='mso-bidi-font-size:10.0pt;line-height:150%'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='font-size:16.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";color:#212121'>Sarkopeni</span></b><span
style='font-size:16.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";color:#212121'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1'>Sarkopeni
ya�lanma ile birlikte ilerleyici kas kitle ve fonksiyon kayb�d�r. N�rolojik
hastal�klarda ya�am kalitesini bozan �nemli bir i�levsel kay�p sebebidir.
Sarkopeni, d��me, k�r�klar fiziksel k�s�tl�l�k ve mortalite gibi olumsuz sonu�larda
artmaya neden olabilen ilerleyici ve jeneralize iskelet kas� rahats�zl���d�r.
Klinik pratikte en s�k kullan�lan sarkopeni tan� <span class=GramE>kriterleri</span>
EWGSOP (<span style='background:white'>European Working Group on Sarcopenia in
Older People) </span>kriterleridir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Sarkopeni
riski olan hastalar, d��en, y�r�me h�z� yava� olan, sandalyeden kalkmakta
zorlanan, kilo kayb�/kas erimesi olan hastalard�r. Formal bir risk
de�erlendirmesi i�in SARC-F testi kullan�labilir. SAR?-F testi pozitif saptanan
veya sarkopeni klinik ��phesi olanlarda sarkopeni varl���n� saptamak i�in kas
g�c� de�erlendirilmelidir. Kas g�c�n� saptamak i�in el dinamometresi ile elin
kavrama g�c�n�n de�erlendirilmesi �nerilir. Kas g�c� d���k olanlarda muhtemel
(probable) sarkopeni tan�s� konur. Bu olgularda sarkopeninin etyolojik tan�s�
ve tedavisine y�nelik giri�imler ba�lamal�d�r. Kas g�c� d���k olanlarda
sarkopeni tan�s�n� do�rulamak i�in ikinci basamakta kas miktar� ve/veya
kalitesi klinik pratikte DXA ve B�A <span class=GramE>ile,</span> �al��malarda
ise DXA, B�A, BT veya MRI ile de�erlendirilebilir. Kas k�tlesi
de�erlendirilirken �l��len kas k�tlesinin boy, kilo veya VKݒne g�re
d�zeltilmesi gerekir. D���k kas g�c�, d���k kas miktar�/kalitesi olanlarda
sarkopeninin ciddiyetini saptamak i�in fiziksel performans
de�erlendirilmelidir. Fiziksel performans de�erlendirmesinde kullan�lan testler
aras�nda ola�an y�r�me h�z�, k�sa fiziksel performans bataryas� (SPPB), 6
dakika y�r�me testi ve merdiven t�rmanma g�c� testi say�labilir. Y�r�menin
de�erlendirilmesinde s�kl�kla 4 metre ola�an y�r�me h�z� kullan�l�r. D���k kas
g�c�, d���k kas miktar�/kalitesi ve d���k fiziksel performans tespit
edildi�inde, sarkopeni ciddi kabul edilir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1;background:
yellow;mso-highlight:yellow;mso-shading:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:9.3pt;text-align:justify;line-height:
150%;mso-pagination:none;tab-stops:11.0pt 36.0pt;mso-layout-grid-align:none;
text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1'>Sarkopeni;
fiziksel kapasitede azalma, g��s�zl�k, denge problemleri, hareket bozuklu�u,
k�s�tl�l�k, solunum fonksiyonunda bozulma, kardiopulmoner performansta azalma,
olumsuz metabolik etkiler, ba����kl�k sisteminde bozukluk, ya�am kalitesinde
azalma, k�r�lganl�k, g�nl�k ya�am aktiviteleri ve enstr�mental g�nl�k ya�am
aktivitelerinde azalma, osteoporoz, d��meler, hastane yat�� s�resinde uzama ve
�l�mle ili�kilidir.<span style='mso-spacerun:yes'>� </span><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:9.3pt;text-align:justify;line-height:
150%;mso-pagination:none;tab-stops:11.0pt 36.0pt;mso-layout-grid-align:none;
text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1'>Sarkopeni
etyolojisinde en �nemli risk fakt�rleri mobilizasyonun azalmas� ve
maln�trisyondur. �zellikle eklem, kas, sinir ve kemikleri etkileyen
hastal�klar, kronik <span class=GramE>dahili</span> hastal�klar (karaci�er
yetersizli�i, kalp yetersizli�i, b�brek yetersizli�i, solunum sistemi
problemleri, kanser, t�berk�loz gibi kronik infeksiyonlar, ba� dokusu
hastal�klar�), demans, depresyon, a�r� varl���, sosyoekonomik yoksunluk ve
bunun gibi durumlar ba�l�ca sarkopeni risk fakt�rleridir. Ya�lanma ile testosteron,
�strojen ve b�y�me hormonu azal�r, bunlar da sarkopeni olu�umuna katk�da
bulunur. Kad�n cinsiyet, d���k do�um a��rl���, alkol, sigara kullan�m� ve
kal�tsal �zellikler sarkopeni i�in di�er risk fakt�rleridir. Sarkopeninin kesin
bir tedavisi yoktur fakat baz� �nerilerle ve giri�imlerle mevcut sarkopeniyi
iyile�tirmek ve ilerlemesini �nlemek m�mk�nd�r. Sarkopeninin �nlenmesi ve
tedavisinde ba�l�ca egzersiz, yeterli beslenme ve baz� besinsel destekler
�nerilmektedir. Sarkopeni a��s�ndan risk alt�nda olan bireylerin erken
tan�nmas� ve �nlem al�nmas� d�zeltilebilir risk fakt�rlerinin ortadan
kald�r�lmas� olduk�a �nemlidir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:9.3pt;text-align:justify;line-height:
150%;mso-pagination:none;tab-stops:11.0pt 36.0pt;mso-layout-grid-align:none;
text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1'>Egzersiz
sarkopeni tedavisinin temelini olu�turmaktad�r. Egzersiz mutlaka yeterli
beslenme ile kombine edilmelidir. Egzersiz �e�itleri aras�nda diren�
egzersizleri, hem kas k�tlesi hem de kas fonksiyonlar�n� iyile�tirmek i�in
g�venli ve en etkili y�ntemdir. Diren� egzersizleri ile kas yap�m�nda olumlu
etkileri oldu�u bilinen testosteron ve b�y�me hormonu gibi anabolizan
hormonlar�n seviyesi artar. Ya�l�larda diren� egzersizleri olarak duvar� itme,
sandalyeden kalkma, lastik germe, hafif a��rl�klar kald�rma yap�labilir. Esneme
ve germe egzersizleri, hareket a��kl���n�n idamesini sa�layarak; denge
egzersizleri ise dengeyi iyile�tirerek ya�l�larda fonksiyonellikte olumlu
etkilere neden olur. En ideal egzersiz program� diren�, esneme, germe, denge ve
aerobik egzersizlerin <span class=GramE>kombinasyonu</span> ile olacakt�r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:9.3pt;text-align:justify;line-height:
150%;mso-pagination:none;tab-stops:11.0pt 36.0pt;mso-layout-grid-align:none;
text-autospace:none'><span style='font-size:9.0pt;mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:black;mso-themecolor:
text1'><a href="http://www.itfnoroloji.org/geriyatri/Sarkopeni.pdf">�stanbul
T�p Fak�ltesi Geriyatri Bilim Dal� taraf�ndan olu�turulan �sarkopeni egzersizi
bro��r��n� buradan indirebilirsiniz.</a><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:9.3pt;text-align:justify;line-height:
150%;mso-pagination:none;tab-stops:11.0pt 36.0pt;mso-layout-grid-align:none;
text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1'>Beslenme
deste�i sarkopeni tedavisinin �nemli bir par�as�d�r. Ya�lanmayla birlikte kas
y�k�m�n�n artmas�, e�lik eden hastal�klar ve bu hastal�klar�n alevlenme
d�nemleri ya�l�da protein ihtiyac�n� artt�rmaktad�r. G�ncel klavuzlarda
ya�l�larda proteinin 1-1,5g/kg/g�n al�nmas�n�n daha uygun oldu�u ifade
edilmektedir. Diyetteki proteinin miktar� ve 3 ���nde dengeli olarak al�n�yor
olmas�n�n yan� s�ra kalitesi ve t�ketim zaman� da �nemlidir. Baz� elementer
proteinlerin kas �zerine daha etkili oldu�u bilinmektedir. �zellikle l�sin ve
metaboliti olan beta-hidroksi-metilbutirat (HMB)��n kas �zerinde yap�m� uyar�c�
etkiye sahip oldu�u bilinmektedir. HMB, kas k�tlesi ve fonksiyonunda d�zelme
sa�lamaktad�r. Protein al�m�ndan en etkili faydan�n sa�lanmas� i�in egzersiz
sonras� ilk saatte al�nmas� �nerilmektedir. Ayr�ca egzersiz sonras� erken ve
yeterli proteinin yan� s�ra yeterli karbonhidrat al�m� da sa�lanmal�d�r. </span><span
style='font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1'>D
vitamini kas-iskelet sistemi sa�l��� i�in �nemli bir besin ��esidir. </span><span
style='font-family:"Tahoma","sans-serif";color:#212121'>D���k D vitamini
seviyeleri, d���k kas g�c� ile ili�kili bulunmu�tur. D vitamininin d���k
seviyeli ki�ilerde replasman�, kas g�c� ve i�levini artt�r�r ve d��meleri
azalt�r.<span style='mso-spacerun:yes'>� </span>Vitamin D replasman�
mortalitede azalma ile ili�kilidir.</span><span style='font-size:11.0pt;
mso-bidi-font-size:12.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'> </span><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:black;mso-themecolor:text1'><o:p></o:p></span></p>

<pre style='text-align:justify;line-height:150%;background:white'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";color:#212121'>B�y�me hormonu, testosteron ve �strojen kas fonksiyonu ve k�tlesini etkileyebilen hormonlard�r. Testosteron tedavisinin sadece laboratuvar olarak testosteron eksikli�i tan�s� kesinle�mi� ve klinik bulgular� olan ya�l�lara uygulanmas� �nerilir. Testosteronun kas k�tlesinde art��a neden oldu�u bilinmektedir kas fonksiyonu ve performans� �zerine olumlu etkisi olabilir. Fakat bunun yan� s�ra �nemli yan etkilere (kardiovask�ler risk art���, polisitemi, uyku apnesi, prostat b�y�mesi/prostat kanseri, karaci�er toksisitesi, �dem, jinekomasti gibi) neden olabilece�i unutulmamal�d�r. </span><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><span style='mso-spacerun:yes'>�</span><o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%;background:white'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></pre><pre style='text-align:
justify;line-height:150%;background:white'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;background:white'>Sonu� olarak sarkopeni ya�l�larda s�kl�kla kar��m�za ��kan;</span><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";color:black;mso-themecolor:text1'> fiziksel kapasitede, fonksiyonel kapasitede, kardiopulmoner performansta ve ya�am kalitesinde azalma, k�r�lganl�k, hastane yat�� s�resinde uzama ve �l�mle ili�kili bir geriatrik <span
class=GramE>sendromdur</span>. Sarkopeni a��s�ndan riskli olabilecek hastalar bu y�nden de�erlendirilmeli ve gerekli tedbirler al�nmal�d�r. </span><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";color:#212121;background:white'>Sarkopeni tedavisinde ve �nlenmesinde multimodal tedavi yakla��m�n�n bir par�as� olarak dengeli protein, enerji ve D vitamini al�m�, �zellikle d�zenli egzersizle birlikte kullan�ld���nda yararl� olabilir.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%;background:white'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Times New Roman","serif";color:#212121;background:white'><o:p>&nbsp;</o:p></span></pre>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='font-size:16.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";color:#212121'>D��meler<o:p></o:p></span></b></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>D��meler,
ya�l� <span class=GramE>pop�lasyonda</span> s�kl�kla kar��m�za ��kan, ancak
ya�lanman�n ka��n�lmaz bir sonucu gibi g�r�lmemesi gereken t�bbi ve ekonomik
sonu�lar� a��s�ndan �nemli bir halk sa�l��� sorunudur. Mortalite ve morbidite
art���n�n yan� s�ra, uzun s�reli immobilizasyon ve buna ba�l� <span
class=GramE>komplikasyonlara</span> neden olmaktad�r. D��meye ba�l� geli�en
yaralanma ve k�r�klar�n yan� s�ra ki�ide geli�en d��me korkusu; hareketlili�i
olumsuz y�nde etkileyerek fonksiyonel kay�p, ba��ms�zl�kta azalma, depresyon ve
sosyal <span class=GramE>izolasyona</span> neden olabilir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Ya�l�
<span class=GramE>pop�lasyonda</span> ya��n ilerlemesi ve artan fiziksel
�z�rl�l�k ile d��me insidans� ve ciddiyeti artar. Toplumda ya�ayan 65 ya�
�zerindeki bireylerin %30-40�� her y�l d��er.<sup> </sup>Seksen ya� ve �zeri
i�in bu oran yakla��k %50�ye y�kselmi�tir. Uzun s�reli bak�m evinde kalan
bireylerin %50�si her y�l d��er ve d��me �yk�s� olanlar�n yakla��k %60�� daha
sonra tekrar d��ecektir. Demans, n�ropatik ve miyopatik hastal�klar gibi
n�rolojik hastal�klar�n �o�u d��meler i�in ba��ms�z risk fakt�r�d�r ve bu
nedenle n�rolojik hastal��� olan ya�l�larda d��me olduk�a s�kt�r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><sup><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></sup></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>D��melerin
%10-15�i b�y�k yaralanmalara neden olurken %37-56�s� hafif yaralanmalarla
sonu�lan�r. Atm�� be� ya� ve �zeri ya�taki ki�ilerde yaralanma ile ilgili hastaneye
yat��lar�n ba�l�ca nedenidir ve bu ya� grubundaki acil ba�vurular�n %14��n� ve
hastaneye kabullerinin %4��n� olu�turmaktad�r. Ya�l� hastalarla ilgilenen
klinisyenler, d��meleri rutin olarak sorgulamal�, d��me riskini de�erlendirmeli
ve altta yatan de�i�tirilebilir risk fakt�rleri varsa d�zeltmelidir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><b style='mso-bidi-font-weight:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>D��me Risk Fakt�rleri<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:10.0pt;text-align:justify;line-height:
150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Ya�l�larda
d��me nedenleri ara�t�r�ld���nda ilk s�rada �evresel fakt�rler nedeniyle
ya�anan kazalar (%30-50), ikinci s�rada ise denge ve y�r�y�� bozukluklar�
(%10-25) gelmektedir. Denge ve normal y�r�me bir�ok sistemin birlikte
�al��mas�yla sa�lan�r. G�rme fonksiyonu (g�rme keskinli�i, derinlik alg�lama, <span
class=GramE>kontrast</span> duyarl�l���, karanl��a uyum) i� kulakta bulunan
denge sistemi, y�zeyel ve derin duyu, eklemlerin serbest hareketi, kas g�c� ile
kas koordinasyonu denge ve y�r�meyi etkileyen ba�l�ca fakt�rlerdir. Denge ve
normal y�r�mede etkili olan bu sistemlerin hepsinde ya�lanmayla birlikte baz�
de�i�iklikler olur. <span class=GramE>Denge problemi olmayan ve normal y�r�yen
bir ya�l�da dahi, araya giren ate�li bir hastal�k, ishal, kusma, a��r� terleme,
di�retik kullan�m� gibi nedenlerle meydana gelen dehidratasyon, yeni ortaya
��kan aritmi, ani tansiyon de�i�iklikleri, uyku bozukluklar� (gece s�k s�k
uyanma, uykuya dalmada ve/veya s�rd�rmede g��l�k, toplam uyku s�resinde
k�salma, g�n i�inde k�sa s�reli uyuklamalar, s�rekli uykuya meyilli olma), yeni
ba�lanan veya pozolojisi de�i�tirilen ila� veya bir �evre de�i�ikli�i ard�ndan
d��me olabilir. </span>Ba�l�ca d��me risk fakt�rleri a�a��da �zetlenmi�tir.<sup><span
style='color:red'><o:p></o:p></span></sup></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Ya�l�
bireylerde meydana gelen d��meler �o�unlukla birden fazla nedenden
kaynaklanmaktad�r.<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-bottom:10.0pt;mso-add-space:
auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l18 level1 lfo12;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><u><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Psikososyal ve demografik
fakt�rler:</span></u><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif"'> ileri ya�, kad�n cinsiyet, yaln�z ya�amak,
inaktivite, d��me <span class=GramE>hikayesi</span><o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l18 level1 lfo12;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><u><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Medikal fakt�rler</span></u><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>:
inme, Parkinson hastal���, kognitif bozukluklar, inkontinans, akut hastal�klar,
vestib�ler bozukluklar, artrit, ayak problemleri, ba� d�nmesi, senkop,
ortostatik hipotansiyon, D vitamin eksikli�i, depresyon<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l18 level1 lfo12;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><u><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>�la�lar:</span></u><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>
Antihipertansifler, psikoaktif ila�lar, nonsteroidal anti-inflamatuar ila�lar
ve 4�den fazla ila� kullan�m� <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l18 level1 lfo12;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><u><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Denge ve mobilite
fakt�rleri</span></u><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif"'>: Denge kayb�, duru� ve mobilite bozuklu�u<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l18 level1 lfo12;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><u><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Duyusal ve n�rom�sk�ler
fakt�rler:</span></u><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif"'> G�rme bozuklu�u, g�rme alan� kayb�,
vestib�ler fonksiyonlarda azalma, kas g��s�zl���, azalm�� periferik duyu <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l18 level1 lfo12;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><u><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>N�ropsikolojik fakt�rler</span></u><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>:
Depresyon, kognitif bozukluklar, d��me korkusu<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-bottom:10.0pt;mso-add-space:
auto;text-align:justify;text-indent:-18.0pt;line-height:150%;mso-list:l18 level1 lfo12;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><u><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>�evresel fakt�rler:</span></u><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>
Uygun olmayan g�zl�kler, evde meydana gelebilecek tehlikeler, d�� tehlikeler<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>D��me riskini tarama<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Basit
kullan�m� kolay bir tarama, ya�l�larda son y�ldaki d��me anamnezini al�p, denge
ve hareketlilik durumlar�n� de�erlendirmektir. Daha �nceki d��meler ertesi y�l
tekrar d��me y�n�ndeki en g��l� predikt�rlerden biridir<b style='mso-bidi-font-weight:
normal'>.</b> T�m ya�l� bireylere (veya bak�c�lar�na), �zellikle n�rolojik
hastal��� olanlarda d��me riski fazla oldu�u i�in, en az y�lda bir; d��me,
d��me s�kl���, y�r�y�� veya denge bozuklu�u sorulmal�d�r. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>De�erlendirme<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Tekrarlayan
d��meleri olan, y�r�y�� ve denge ile ilgili sorunlar� olan, d��me sebebiyle
medikal yard�m isteyen ve acile ba�vuran ya�l� bireyler i�in multifakt�ryel
d��me de�erlendirmesi yap�lmal�d�r. De�erlendirmede d��me ile ilgili ayr�nt�l�
anamnez al�nmal� ve ayr�nt�l� fizik muayene yap�lmal�d�r. Fizik muayenede
y�r�me h�z�, post�r, kas g�c�, post�ral instabilite, Romberg ve �k�sa fiziksel
performans testi�, �time up and go testi� gibi post�ral stabilite testleri
yap�lmal�d�r. Ayr�ca g�rme keskinli�i de�erlendirmesi, f�s�lt� i�itme testi,
ekstremitelerin muayenesi yap�lmal�d�r. <b style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Tan�sal
Testler<o:p></o:p></span></b></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif"'>Anemi, dehidratasyon ve otonom n�ropatiyi
saptamak �zere tam kan say�m�, BUN, kreatinin, glukoz d�zeyleri bak�lmal�d�r.
Ayr�ca D vitamini, vitamin B12 d�zeyi de�erlendirilmelidir. Holter,
ekokardiyografi ve radyolojik incelemeler yaln�zca muayenedeki bulgular ve
anamnez neticesinde endike oldu�u durumlarda �nerilir.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>D��meyi
�nleme Yakla��mlar�<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'>D��melerden korunmak i�in at�lmas�
gereken ilk ad�m risk fakt�rlerini belirlemek ve m�mk�n olanlar�
de�i�tirmektir. Ya�l�da d��meye yol a�an fakt�rlerin �o�unlu�u d�zeltilebilir risk
fakt�rleridir. D��meyi �nleme ve s�kl���n� azaltmada; t�bbi giri�imler,
�evresel d�zenlemeler, e�itim ve egzersiz programlar� ve yard�mc� aletler
kullan�labilmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'>D��meyi �nlemeye y�nelik
yap�labilecek basit t�bbi giri�imler; <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='text-align:justify;line-height:150%;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Vitamin
B12 eksikli�ini de�erlendirmek <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Sedatif
hipnotik ve santral etkili ila�lar� kesmek<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Servikal
spondilosis y�n�nde ara�t�rma yapmak <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>�la�
say�s�n� azaltmak<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>�evresel
d�zenlemeler yapmak<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>E�itim
programlar�, egzersizler (denge, kas kuvvetlendirme ve diren� egzersizleri, g�zlem
alt�nda egzersiz) uygulamak<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Yard�mc�
aletlerden (sert tabanl� uygun �l��de ayakkab�, y�r�te�, kal�a koruyucular�)
klinik pratikte faydalanmak<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Post�ral
hipotansiyonu ara�t�rmak ve tespit edildi�inde etyolojisini ara�t�rmak <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>�la�lar
g�zden ge�irmek<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>A��r�
tuz k�s�tlamas� yapanlar�n diyetini g�zden ge�irmek <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Yeterli
s�v� al�nmas� sa�lamak (2-2,5 lt/g�n)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Beslenme
bozuklu�u varsa tedavi etmek, az ve s�k yemek yemek ve alkolden ka��nmas�n�
s�ylemek, karbonhidratl� yiyeceklerden uzak durulmas�n� �nermek<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Gerekti�i
durumda, antihipertansif ilac�n dozu azalt�lmak veya ba�ka grup ila�la
de�i�tirmek <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Yatak
ba��n�n y�kseltilmesi, yataktan yava� kalkma, dorsifleksiyon egzersizleri, alt
ekstremite diren� egzersizlerini �nermek<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Varis
�orab� giyilmesi �nermek<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>Bu
m�dahaleler yetersiz kal�rsa midodrin ve fludrokortizon uygulanabilir<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l19 level1 lfo14;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif"'>D
vitamini kullan�m�n�n ya�l�larda d��me say�s�n� azaltt��� saptanm��t�r. D
vitamini kullan�m�n�n kas g�c�n� artt�rarak bu azalmay� sa�lad���
d���n�lmektedir. �zellikle kad�nlarda yararl� oldu�u g�r�lm��t�r. Osteoporozu
olan ya�l�larda d��me sonras� k�r�k riski artt��� i�in osteoporoz tedavisi g�z
ard� edilmemelidir. <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='text-align:justify;line-height:150%;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><a
href="http://www.itfnoroloji.org/geriyatri/Dusme.pdf">�stanbul T�p Fak�ltesi Geriyatri
Bilim Dal� taraf�ndan olu�turulan d��meyi �nleme i�in yap�labilecekler
bro��r�n� buradan indirebilirsiniz.</a><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'>Sonu� olarak d��meler ya�l�larda s�k
g�r�l�r ve y�k�c� sonu�lara neden olabilir. D��melerin �o�u tek bir nedene
ba�l� de�ildir. Birbiriyle etkile�en birden �ok fakt�r�n sonucu olarak d��meler
ortaya ��kmaktad�r. D��meleri �nlemek i�in yap�lmas� gereken, risk
fakt�rlerinin belirlenmesi ve d�zeltilebilir fakt�rlerin d�zeltilmesidir.
Sonucu ne olursa olsun d��en ve s�k d��me tehlikesi ya�ayan bir ya�l� mutlaka
bir doktor taraf�ndan </span>de�erlendirilmeli, d��me nedenleri ara�t�r�lmal�
ve d��menin ya�l� �zerindeki etkileri analiz edilmelidir.<span
style='mso-spacerun:yes'>� </span><b style='mso-bidi-font-weight:normal'><o:p></o:p></b></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='font-size:16.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";color:#212121'>K�r�lganl�k<o:p></o:p></span></b></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>K�r�lganl�k, genellikle ileri ya�ta ortaya ��kan d��k�nl�k durumunu
tan�mlar. K�r�lgan bireylerin karakteristik �zellikleri infeksiyon, uygunsuz
ila� veya akut hastal�klar gibi stres fakt�r� varl���nda fiziksel ve kognitif
durumlar�nda ani ve dramatik de�i�iklik ve dekompansasyon riski ta��malar�d�r.
Ya�l�larda k�r�lganl���n olmas� alarm durumunu g�sterir. Bu hastalar her t�rl�
d�� etkene hassast�r. K�r�lgan ya�l� her an d��me, k�s�tl�l�k, hastaneye yat��
ve �l�m riski alt�ndad�r. K�r�lganl�k i�in standart bir tan�m yoktur.
K�r�lganl�k ya�l�y� fonksiyonel a��dan daha ba��ml� hale getiren, d��me,
deliryum ve immobilite riskini artt�ran, bak�m evine yerle�me olas�l���n�
art�ran, hastane yat��� ve mortalite art���na neden olan bir durumdur. </span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black;mso-themecolor:text1'>K�r�lganl�k tan�mlamas� ile ilgili tam bir
fikir birli�i olmad��� i�in k�r�lganl�k prevalans�n� belirlemek zordur.
K�r�lganl�k ile ilgili yap�lan epidemiyolojik �al��malarda farkl� k�r�lganl�k
�l�ekleri kullan�lm��t�r. Bu nedenle k�r�lganl�k prevalans� kullan�lan �l�e�e
ve <span class=GramE>pop�lasyona</span> g�re farkl�l�k g�stermektedir.
K�r�lganl�kta rol oynayan fakt�rler i�tahs�zl�k, sarkopeni, immobilite,
ateroskleroz, denge bozuklu�u, depresyon ve kognitif bozukluktur.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black;mso-themecolor:text1'><span style='mso-spacerun:yes'>�</span><o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><span
style='mso-spacerun:yes'>�</span>K�r�lganl�k Tarama Ara�lar�<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:black;
mso-themecolor:text1'><o:p>&nbsp;</o:p></span></b></p>

<pre style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>K�r�lganl��� de�erlendirmek i�in ge�erlili�i ve g�venilirli�i kan�tlanm�� bir�ok tarama arac� vard�r. En s�k kullan�lan tan� arac� Fried k�r�lganl�k indeksidir. K�r�lganl�k indeksine g�re 5 <span
class=GramE>kriterden</span> 3 ve �zerinin olmas� k�r�lganl�k olarak tan�mlan�r. Bir veya ikisinin olmas� ise k�r�lganl�k-�ncesini tan�mlar. Fried k�r�lganl�k indeksine g�re tan�mlanan <span
class=GramE>kriterler</span> �unlard�r: <o:p></o:p></span></pre><pre
style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;line-height:
150%;mso-list:l14 level1 lfo16'><![if !supportLists]><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Kilo kayb�: son 1 y�lda &gt; 4,5 kg istemsiz kilo kayb�<o:p></o:p></span></pre><pre
style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;line-height:
150%;mso-list:l14 level1 lfo16'><![if !supportLists]><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>G��s�zl�k: cinsiyet veya boya uygun olarak dinamometre ile �l��len kavrama kuvvetinin azalm�� olmas� <o:p></o:p></span></pre>

<p class=MsoListParagraph style='text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l14 level1 lfo16;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;line-height:150%;font-family:
Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Dayanma
g�c� ve enerjinin azalmas�: yorgunlukla ilgili �z raporlamada dayan�ks�zl�k ve
d���k enerji. CES-D �l��t�nden iki soruyla tan�mlanan �z raporlamadaki
yorgunluk, kademeli egzersiz testinde ula��lan egzersiz seviyesiyle
ili�kilidir; bu VO2 maks ve onun i�aret etti�i kardiyovask�ler hastal���n
habercisidir.</span></p>

<p class=Default style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l14 level1 lfo16;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:windowtext;
mso-fareast-language:TR'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
"Times New Roman";color:windowtext;background:white;mso-fareast-language:TR'>Yava�l�k:
cinsiyet ve boya uygun olarak 4 metre y�r�me s�resinin uzun olmas� (&#8804; 159
cm &#8805;7 sn,&gt; 159 cm &#8805; 6 sn) <o:p></o:p></span></p>

<pre style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;
line-height:150%;mso-list:l14 level1 lfo16'><![if !supportLists]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Azalm�� fiziksel aktivite: haftal�k kilo kalori harcamas�n�n d���k olmas� (erkek &lt; 383 kcal, kad�n &lt;270 kcal)<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Fried k�r�lganl�k indeksi en s�k kullan�lan �l�ek olsa da klinik pratikte daha h�zl� ve uygulamas� daha kolay olan ve s�kl�kla kullan�lan bir di�er tarama arac� ise FRAIL <span
class=GramE>skalas�d�r</span>. FRAIL <span class=GramE>skalas�na</span> g�re 5 kriterden 3 veya �zerinin olmas� k�r�lgan, bir veya ikisinin olmas� k�r�lganl�k-�ncesi olarak tan�mlan�r. FRAIL k�r�lganl�k <span
class=GramE>skalas�n�n</span> bile�enleri �unlard�r:<o:p></o:p></span></pre><pre
style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;line-height:
150%;mso-list:l10 level1 lfo18'><![if !supportLists]><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Yorgunluk: son 4 haftan�n hepsinde veya �o�unda yorgunluk hissi olmas�<o:p></o:p></span></pre><pre
style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;line-height:
150%;mso-list:l10 level1 lfo18'><![if !supportLists]><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Dayan�kl�l�k: 10 ad�m� dinlenmeden, tek ba��na ve yard�ms�z y�r�mekte zorluk �ekmesi<o:p></o:p></span></pre><pre
style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;line-height:
150%;mso-list:l10 level1 lfo18'><![if !supportLists]><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Ambulasyon: 200 metre veya �zeri mesafeyi tek ba��na, yard�ms�z ve g��l�k �ekmeden y�r�mekte zorluk �ekilmesi<o:p></o:p></span></pre><pre
style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;line-height:
150%;mso-list:l10 level1 lfo18'><![if !supportLists]><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Hastal�klar: 11 hastal�ktan 5 ve �zerinde olmas�. Hipertansiyon, diyabet, kronik obstruktif akci�er hastal���, miyokard enfarkt�s�, konjestif kalp yetersizli�i, angina, ast�m, artrit, inme, b�brek hastal���, kanser (k���k deri kanserleri d���nda)<o:p></o:p></span></pre><pre
style='margin-left:36.0pt;text-align:justify;text-indent:-18.0pt;line-height:
150%;mso-list:l10 level1 lfo18'><![if !supportLists]><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Kilo kayb�: son 1 y�l i�inde v�cut a��rl���n�n %5 veya �zerinin kaybedilmesi<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'><o:p>&nbsp;</o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Di�er tarama arac� osteoporotik frakt�rler �al��mas� (SOF) indeksidir. SOF indeksine g�re 3 bile�enden ikisinin olmas� k�r�lganl�k, bir bile�enin olmas� ise k�r�lganl�k-�ncesi olarak tan�mlan�r. SOF indeksinin i�erdi�i <span
class=GramE>kriterler</span> �unlard�r:<o:p></o:p></span></pre><pre
style='margin-left:38.45pt;text-align:justify;text-indent:-18.0pt;line-height:
150%;mso-list:l0 level1 lfo20'><![if !supportLists]><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Son 1 y�lda %5 veya �zeri kilo kayb�n�n olmas�<o:p></o:p></span></pre><pre
style='margin-left:38.45pt;text-align:justify;text-indent:-18.0pt;line-height:
150%;mso-list:l0 level1 lfo20'><![if !supportLists]><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Kollar� kullanmadan 5 kez sandalyeden desteksiz kalkamama<o:p></o:p></span></pre><pre
style='margin-left:38.45pt;text-align:justify;text-indent:-18.0pt;line-height:
150%;mso-list:l0 level1 lfo20'><![if !supportLists]><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>�Kendinizi enerji dolu hissediyor musunuz ?� sorusuna olumsuz yan�t verilmesi<o:p></o:p></span></pre>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:black;
mso-themecolor:text1'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:black;mso-themecolor:
text1'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>K�r�lgan
Ya�l�n�n Tedavisi <o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:#212121'>Hastalar ve aileleriyle
birlikte hedef belirleme; k�r�lgan bireylere bak�m sa�lama, bireysel
�ncelikleri belirleme, riskleri ve m�dahalelerin faydalar�n� tartma ve bak�m�n <span
class=GramE>agresifli�ine</span> ili�kin kararlar vermede �ok �nemlidir. Zinde
ya�l�lar i�in, bilinen kronik hastal�klar� uygun �ekilde tedavi edilmeli,
aral�kl� akut hastal�klar� ve olaylar� y�netilmeli ve ya�a uygun tarama
�nlemleri ve �nleyici bak�m sa�lanmal�d�r. Orta derecede ve ciddi derecede
k�r�lgan bir hastada, genellikle hayati tehlikesi olmayan durumlar i�in <span
class=GramE>agresif</span> tarama veya m�dahale komplikasyonlarla seyredebilir.
Giri�imsel i�lemler ya da hastanede yat��lar, zaten b�y�k bir morbidite ve
mortalite riski ta��yan k�r�lgan bir ya�l�ya gereksiz bir y�k getirebilir ve
ya�am kalitesini azaltabilir. Baz� durumlarda bu tip hastalara <span
class=GramE>palyatif</span> bak�m �nerisi en uygun yakla��m olabilir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:#212121'>K�r�lgan ya�l�larda koruyucu
yakla��mlar a�a��daki �ekilde s�ralanabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%;mso-list:l13 level1 lfo22;tab-stops:list 36.0pt left 45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Arial","sans-serif";
mso-fareast-font-family:Arial;color:#212121'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;mso-bidi-font-weight:bold'>Beslenme (<b>F</b></span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>ood intake maintained)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%;mso-list:l13 level1 lfo22;tab-stops:list 36.0pt left 45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Arial","sans-serif";
mso-fareast-font-family:Arial;color:#212121'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;mso-bidi-font-weight:bold'>Egzersiz (<b>R</b></span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>esistance exercises)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%;mso-list:l13 level1 lfo22;tab-stops:list 36.0pt left 45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Arial","sans-serif";
mso-fareast-font-family:Arial;color:#212121'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;mso-bidi-font-weight:bold'>Aterosklerozu �nleme (<b>A</b></span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>therosclerosis prevention)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%;mso-list:l13 level1 lfo22;tab-stops:list 36.0pt left 45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Arial","sans-serif";
mso-fareast-font-family:Arial;color:#212121'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;mso-bidi-font-weight:bold'>�zolasyondan ka��nma (<b>I</b></span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>solation avoidance)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%;mso-list:l13 level1 lfo22;tab-stops:list 36.0pt left 45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Arial","sans-serif";
mso-fareast-font-family:Arial;color:#212121'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;mso-bidi-font-weight:bold'>A�r� tedavisi (<b>L</b></span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>imit pain)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%;mso-list:l13 level1 lfo22;tab-stops:list 36.0pt left 45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Arial","sans-serif";
mso-fareast-font-family:Arial;color:#212121'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;mso-bidi-font-weight:bold'>Egzersizler (<b>T</b></span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>ai chi or other balance exercises)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;text-indent:
-18.0pt;line-height:150%;mso-list:l13 level1 lfo22;tab-stops:list 36.0pt left 45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><![if !supportLists]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Arial","sans-serif";
mso-fareast-font-family:Arial;color:#212121'><span style='mso-list:Ignore'>�<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;mso-bidi-font-weight:bold'>Testosteron eksikli�inin tedavisi (<b>Y</b></span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>early check for testosterone deficiency)<o:p></o:p></span></p>

<pre style='text-align:justify;line-height:150%'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></pre>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:#212121'>K�r�lgan ya�l�lar genel ya�l� <span
class=GramE>pop�lasyonunda</span> en y�ksek riskli bireylerdir ve bu grup
ya�l�lar�n kapsaml� geriatrik de�erlendirmeden (KGD) maksimum fayda elde
etmeleri beklenebilir. KGD�nin genel hedefleri �unlard�r:<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraph style='text-indent:-18.0pt;mso-list:l22 level1 lfo24;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><![if !supportLists]><span style='mso-bidi-font-size:10.0pt;
font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;
color:#212121'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
font-family:"Tahoma","sans-serif";color:#212121'>Fiziksel ve kognitif
fonksiyonu iyile�tirmek<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraph style='text-indent:-18.0pt;mso-list:l22 level1 lfo24;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><![if !supportLists]><span style='mso-bidi-font-size:10.0pt;
font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;
color:#212121'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
font-family:"Tahoma","sans-serif";color:#212121'>�la� re�etelenmesi ve ila�
kullan�m�n� optimize etmek <o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraph style='text-indent:-18.0pt;mso-list:l22 level1 lfo24;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><![if !supportLists]><span style='mso-bidi-font-size:10.0pt;
font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;
color:#212121'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
font-family:"Tahoma","sans-serif";color:#212121'>Bak�m evine yerle�tirmeyi,
hastaneye yat��� ve �l�m riskini azaltmak<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraph style='text-indent:-18.0pt;mso-list:l22 level1 lfo24;
tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><![if !supportLists]><span style='mso-bidi-font-size:10.0pt;
font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;
color:#212121'><span style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
font-family:"Tahoma","sans-serif";color:#212121'>Hasta memnuniyetini artt�rmak<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:#212121'>Sonu� olarak k�r�lgan ya�l�lar
�o�unlukla �oklu <span class=GramE>�ikayetlerle</span> ba�vurur; medikal
tedavilere ve t�bbi giri�imlere toleranslar� d���kt�r. K�r�lganl���n ve bunun
do�uraca�� k�t� sonu�lar�n fark�nda olmak, nedenlerini anlamak ve uygun tedavi
yakla��mlar� sunmak k�r�lgan ya�l� grubunda uygun bak�m olanaklar�n� sa�lamak
a��s�ndan b�y�k �nem ta��r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='font-size:16.0pt;mso-bidi-font-size:10.0pt;line-height:150%;color:#212121'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='font-size:16.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";color:#212121'>�riner �nkontinans <o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'>�riner inkontinans (��), miktar� ne
olursa olsun her t�rl� istemsiz idrar ka��rma olarak tan�mlanm��t�r</span><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>. </span></b><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'>�� ya�lanma ile birlikte s�kl��� artan �nemli geriatrik <span
class=GramE>sendromlardan</span> birisidir. N�rolojik hastal��� olan ya�l�larda
s�kl�kla kar��m�za ��kan bir sorundur. Ya�l�lar idrar ka��rmay� s�kl�kla <span
class=GramE>�ikayet</span> olarak belirtmedi�i i�in klinisyenler taraf�ndan
sorgulanmad��� s�rece tan� konulamayabilir. G�nl�k prati�imizde kar��la�t���m�z
her ya�l�ya �riner inkontinans sorgulamas� yap�lmal�d�r ve detayland�r�larak,
tipleri ve risk fakt�rleri sorulmal�d�r. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'>Toplumda ya�ayan 60 ya� ve �zeri ya�l�larda prevalans� kad�nlarda %30-35
erkeklerde %20-25�dir. Hastanede yatanlarda %40-70, bak�mevlerinde ya�ayanlarda
ise %60 d�zeyindedir. Ya� ve bozulmu� fonksiyonel durum, hem erkek hem de
kad�nlarda �� i�in ba��ms�z risk fakt�rleridir.</span><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'> </span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:
EN-US'>��, multifakt�riyel etyolojik sebeplere ba�l� olabilir. Ayn� olguda
birden fazla fakt�r �� etyolojisinde rol oynayabilir. �nkontinans ya�l�larda <span
class=GramE>kompleks</span> semptomlarla ortaya ��kabilen ve tedavi
edilebilmesi i�in multidisipliner yakla��ma gerek duyulan geriatrik bir
sendromdur.</span><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif"'> </span><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Hastada <span
class=GramE>hijyen</span> kayb�, kom�u b�lgede selu&#776;lit ve bas� yaras�
geli�imi, idrar yolu infeksiyonu, uyku bozukluklar�, seks�el disfonksiyon,
depresyon, sosyal izolasyon, kendine g�ven ve sayg� yitimi, k�r�k ile
sonu�lanacak du&#776;�me riskinde art��, ya�am kalitesinin d��mesi ve bak�m
evine yerle�tirilme riskinde art��a neden olmas� a��s�ndan ya�l�lar i�in �nemli
bir sorundur.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>SVH,
demans, deliryum, normal bas�n�l� hidrosefali, PH ve omurilik yaralanmas� gibi
bir�ok n�rolojik hastal�kta �� g�r�lmektedir. A�a��daki tabloda n�rolojik
hastal�klar ve inkontinansa neden olma mekanizmalar� bulunmaktad�r. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><b style='mso-bidi-font-weight:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'>Tablo 3.</span></b><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:
EN-US'> Ba�l�ca n�rolojik hastal�klarda inkontinans ve nedenleri<o:p></o:p></span></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='margin-left:36.0pt;border-collapse:collapse;border:none;mso-border-alt:
 solid windowtext .5pt;mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
  none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
  150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Serebrovasku&#776;ler
  hastal�klar ve demans <o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraph style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l17 level1 lfo26;mso-layout-grid-align:none;
  text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Fonksiyonel
  ve kognitif bozukluk<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraph style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l17 level1 lfo26;mso-layout-grid-align:none;
  text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>�st motor
  n�ron hasar� sonucunda detrusor a��r� aktivitesi<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
  none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
  150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Deliryum <o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraph style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l16 level1 lfo28;mso-layout-grid-align:none;
  text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Fonksiyonel
  ve kognitif bozukluk<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
  none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
  150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Normal
  bas�n�l� hidrosefali <o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l11 level1 lfo30;mso-layout-grid-align:
  none;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Frontal
  inhibit�r merkezlerin inhibisyonu<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpLast style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l11 level1 lfo30;mso-layout-grid-align:none;
  text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Fonksiyonel
  ve kognitif bozukluk<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
  none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
  150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Parkinson
  hastal��� <o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraph style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l6 level1 lfo32;mso-layout-grid-align:none;
  text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Pons <span
  class=GramE>i�eme</span> merkezine gelen inhibit�r impulslar�n kayb�<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraph style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l6 level1 lfo32;mso-layout-grid-align:none;
  text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Fonksiyonel
  ve kognitif bozukluk<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraph style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l6 level1 lfo32;mso-layout-grid-align:none;
  text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Konstipasyonun
  tetikledi�i retansiyon ve ta�ma tipi �riner inkontinans<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
  none;text-autospace:none'><span style='mso-bidi-font-size:10.0pt;line-height:
  150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Omurilik
  yaralanmas� <o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12;mso-yfti-lastrow:yes'>
  <td width=578 valign=top style='width:433.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraph style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l7 level1 lfo34;mso-layout-grid-align:none;
  text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='mso-bidi-font-size:10.0pt;
  line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Detrusor
  arefleksisi veya sfinkter dissinerjisi<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:
EN-US'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:
EN-US'>Ge�ici inkontinans<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'>�riner inkontinans� olan hasta hangi
prezentasyonla gelirse gelsin �ncelikle ge�ici ve d�zeltilebilir inkontinans
nedenleri a��s�ndan ara�t�r�lmal� ve tedavi edilmelidir. Ge�ici �riner
inkontinans nedenleri aras�nda ila�lar, infeksiyonlar, atrofik vajinit-�retrit,
psikojenik hastal�klar (depresyon, deliryum), endokrin hastal�klar (diabetes
mellitus, hiperkalsemi), hareket k�s�tl�l��� ve fekal impakt bulunmaktad�r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:
EN-US'>Tablo 4.</span></b><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'> �la�lar ve
inkontinans mekanizmalar�<o:p></o:p></span></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0 align=left
 width=635 style='width:476.1pt;border-collapse:collapse;border:none;
 mso-border-alt:solid windowtext .5pt;mso-yfti-tbllook:1024;mso-table-lspace:
 7.05pt;margin-left:4.8pt;mso-table-rspace:7.05pt;margin-right:4.8pt;
 mso-table-anchor-vertical:paragraph;mso-table-anchor-horizontal:margin;
 mso-table-left:left;mso-table-top:9.9pt;mso-padding-alt:0cm 5.4pt 0cm 5.4pt'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><b style='mso-bidi-font-weight:
  normal'><span style='font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>�la�lar<o:p></o:p></span></b></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><b style='mso-bidi-font-weight:
  normal'><span style='font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Etkileri
  <o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Di�retikler<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Poli�ri, s�k idrara ��kma, s�k��ma<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Antikolinerjikler<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>�riner retansiyon, ta�ma
  inkontinans�, </span><span style='mso-bidi-font-size:10.0pt;font-family:"Tahoma","sans-serif";
  mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
  mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>�</span>deliryum,
  sedasyon, konstipasyon, fekal t�ka�</span><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
  mso-fareast-language:EN-US'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Psikotroplar<o:p></o:p></span></p>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>�����
  </span>antidepresanlar<o:p></o:p></span></p>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>�����
  </span>antipsikotikler<o:p></o:p></span></p>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>�����
  </span>sedatif-hipnotikler<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Antikolinerjik etkiler, sedasyon<o:p></o:p></span></p>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Antikolinerjik etkiler, rijidite,
  sedasyon, immobilite<o:p></o:p></span></p>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Sedasyon, deliryum, immobilite,
  �retral relaksasyon<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='mso-bidi-font-size:
  10.0pt;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>GABAerjik
  ajanlar (gabapentin, pregabalin)</span><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
  mso-fareast-language:EN-US'><o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='mso-bidi-font-size:
  10.0pt;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Noktu&#776;rnal
  poliu&#776;riye yol a�an pedal �dem</span><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
  mso-fareast-language:EN-US'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='mso-bidi-font-size:
  10.0pt;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Kolinesteraz inhibit�rleri
  <span style='mso-tab-count:1'>� </span></span><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
  mso-fareast-language:EN-US'><o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='mso-bidi-font-size:
  10.0pt;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Antimuskarinik
  etkile�imle �riner inkontinans</span><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
  mso-fareast-language:EN-US'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Narkotik analjezikler<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>�riner retansiyon, gaita t�kac�,
  sedasyon, deliryum<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Alfa adrenerjik blokerler<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>�retral relaksasyon stres
  inkontinans�n� kolayla�t�r�r<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Alfa adrenerjik agonistler<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>�riner retansiyon<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Anjiotensin d�n��t�r�c� enzim
  inhibit�rleri<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>�ks�r�k ile tetiklenen stres
  inkontinans�<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Beta adrenerjik agonistler<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Nadiren �riner retansiyon<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Kalsiyum kanal blokerleri<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Bozulmu� detrusor kontraktilitesi,
  �riner retansiyon<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Alkol<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Poli�ri, s�k��ma, sedasyon, deliryum,
  immobilite<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Kafein<o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='font-family:
  "Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
  minor-latin;mso-fareast-language:EN-US'>Mesane iritasyonu<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14;mso-yfti-lastrow:yes;height:10.7pt'>
  <td width=283 valign=top style='width:212.4pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNoSpacing style='mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='mso-bidi-font-size:
  10.0pt;font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Nonsteroidal
  antiinflamatuar ila�lar <span style='mso-tab-count:1'>�������� </span></span><span
  style='font-family:"Tahoma","sans-serif";mso-fareast-font-family:Calibri;
  mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'><o:p></o:p></span></p>
  </td>
  <td width=352 valign=top style='width:263.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%;mso-layout-grid-align:
  none;text-autospace:none;mso-element:frame;mso-element-frame-hspace:7.05pt;
  mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
  margin;mso-element-top:9.9pt;mso-height-rule:exactly'><span style='mso-bidi-font-size:
  10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
  Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Noktu&#776;rnal
  poliu&#776;riye yol a�an pedal �dem <o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><span style='mso-bidi-font-size:
10.0pt;line-height:150%;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><b style='mso-bidi-font-weight:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><b style='mso-bidi-font-weight:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'>Kal�c� �riner �nkontinans Tipleri<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'>Ge�ici
inkontinans nedenleri d��land�ktan ve �artlar d�zeltildikten sonra inkontinans
devam ediyorsa kal�c� inkontinans nedenleri du&#776;�u&#776;nu&#776;lmelidir.
Kal�c� inkontinans nedenlerini be� ba�l�k alt�nda toplayabiliriz.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><i style='mso-bidi-font-style:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'>1. Fonksiyonel �nkontinans:</span></i><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:
EN-US'> Detrusor aktivitesi ile alt �riner sistem anatomi ve fonksiyonlar�
normal olmakla birlikte; demans, depresyon ve deliryum gibi kognitif ve
psikolojik problemleri olan ki�ilerin kontinans yetene�ini organize edememesinden
ya da ortopedik problemler nedeni ile hareket yetene�i k�s�tlanm�� ki�ilerin
zaman�nda tuvalete gitme becerilerinin azalmas�ndan kaynaklanmaktad�r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><i style='mso-bidi-font-style:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'>2. Stres �nkontinans�:</span></i><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:
EN-US'> Ya�l�larda ikinci en s�k kar��la��lan inkontinans tipidir. Pelvik taban
kaslar�n�n gev�emesi sonucu abdominal bas�n� u&#776;retral sfinkter kapanma
bas�nc�n� a�t���nda; �ksu&#776;rme, gu&#776;lme, hap��rma ve a��r kald�rma gibi
aktivitelerden sonra ku&#776;�u&#776;k hacimli idrar ka���� olmas�d�r. Genitou&#776;riner
atrofi veya prolapsus, <span class=GramE>travma</span>, ge�mi�teki �rolojik
operasyonlar, morbid obezite, multiparite ve travmatik do�umlar stres
inkontinans geli�imi i�in birer risk fakt�ru&#776;du&#776;r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><i style='mso-bidi-font-style:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'>3. S�k��ma Tipi �nkontinans:</span></i><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:
EN-US'> Ya�l�larda en s�k kar��la��lan �� tipidir. Detrusor a��r� aktivitesine
ba�l� olarak kontrol edilemeyen ani s�k��ma hissi ile idrar ka��r�lmas�d�r.
Mesaneyi irrite eden ta�, infeksiyon, tu&#776;m�r ve yabanc� madde varl��� ile
birlikte, fibrozis ya da ya�lanma ile detrusor kas�n�n kompliyans�n�n bozulmas�
sonucunda geli�ebilir. Ayr�ca birinci motor n�ron bozukluklar�, inme, omurilik
hasar�, multipl skleroz ve PH a��r� detrusor aktivitesine sebep olan
hastal�klardan baz�lar�d�r. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><i style='mso-bidi-font-style:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'>4. Ta�ma �nkontinans�:</span></i><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:
EN-US'> Bozulmu� mesane duvar kontraksiyonu ya da sfinkterin gev�eme kusurundan
dolay� artan mesane volu&#776;mu&#776;nu&#776;n ve intravezikal bas�nc�n;
mekanik bask� yaratarak su&#776;rekli bir idrar ka����na neden olmas�d�r.
Prostat hipertrofisi, u&#776;retral striktu&#776;r, genitou&#776;riner organ
prolapsusu, antimuskarinik ila�lar, n�ropati ve omurilik yaralanmas� bu tip
inkontinansa neden olabilmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><b style='mso-bidi-font-weight:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><i style='mso-bidi-font-style:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'>5. Mikst �nkontinans:</span></i><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:
EN-US'> Stres tipi ve s�k��ma tipi inkontinans�n bir arada oldu�u inkontinans
tipidir. Kad�nlar�n yar�s�ndan fazlas�nda mikst tip inkontinans g�ru&#776;lu&#776;rken,
erkeklerde s�k��ma tipi inkontinans daha s�k g�ru&#776;lmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
Calibri;mso-fareast-theme-font:minor-latin;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:#212121'>Di�er bir birliktelik a��r�
detrusor kas aktivitesine e�lik eden<b style='mso-bidi-font-weight:normal'> </b>bozulmu�
mesane kontraktilitesidir. �zellikle k�r�lgan ya�l�larda bu duruma e�lik eden
rezid� idrar varl���nda d�zensiz mesane kontraksiyonlar� olu�ur. Erkeklerde
daha s�k g�r�l�r. Klinik olarak s�k��ma, stres ve ta�ma inkontinans�n� taklit
etti�i i�in tan� konulmas� olduk�a zor olup iyi sorgulanmas� ve
de�erlendirilmesi gerekmektedir. <b style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='mso-bidi-font-size:10.0pt;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
mso-layout-grid-align:none;text-autospace:none'><b style='mso-bidi-font-weight:
normal'><span style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-fareast-language:EN-US'>Tedavi<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-family:"Tahoma","sans-serif"'><span
style='mso-spacerun:yes'>�</span><o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'>Tedavi y�netimi inkontinans�n tipine g�re
ve hasta ve yak�nlar�n�n tercihine g�re planlanmal�d�r. �� tedavisinde ilk ad�m
d�zeltilebilir sebeplerin saptanmas� ve ortadan kald�r�lmas� olmal�d�r.
Ya�l�larda inkontinans geli�iminin genelde multifakt�ryel oldu�u ve �riner
sistem d���ndaki sebeplerin ilk planda olabilece�i unutulmamal�d�r. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Davran��
ve ya�am tarz� de�i�iklikleri t�m hastalarda �ncelikli olarak �nerilmesi
gereken tedavi se�ene�idir. Ya�am tarz� de�i�ikli�inde </span><span
style='font-family:"Tahoma","sans-serif"'>sigara b�rakma, inkontinans tipinden
ba��ms�z olarak t�m �riner inkontinans� olan hastalara �nerilir. Di�er
�neriler; kafeini azaltmak, 2 lt�e kadar s�v� al�m� (120ml ���nlerle al�nmas�),
obezlerde kilo verme, 2-3 saatte bir tuvalete gidilmesi, egzersiz, g��l�
kan�tlar olmasa da �zellikle s�k��ma tipi �ݒde �nerilir.</span><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>
</span><span style='font-family:"Tahoma","sans-serif"'>�la� tedavisi ile bu
�nlemlerin birle�tirilmesinin tek ba��na ila� tedavisine g�re daha ba�ar�l�
(%58 vs %69) oldu�u g�sterilmi�tir. Davran��sal m�dahaleler pelvik taban kas
egzersizleri (kegel) ve mesane e�itimini i�erir. Mesane e�itimi daha �ok
s�k��ma tipi inkontinans tedavisinde �n plandad�r. Stres inkontinans� olan
kad�nlarda yaln�zca mesane <span class=GramE>vol�m�</span> y�ksek olanlarda
etkilidir. Mesane e�itimi y�ntemleri ve pelvik kas egzersizleri s�kl�kla bir
arada kullan�lmaktad�r. Kegel egzersizleri 3 set halinde 10 kontraksiyon (10sn)
�eklinde uygulan�r. Stres ve �urge� inkontinansta uygulanabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Farmakolojik tedavi<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><u><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Stres
inkontinans�n�n</span></u><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'> tedavisinde </span><span
style='font-family:"Tahoma","sans-serif"'>ila� tedavisi s�k��ma tipi
inkontinanstaki kadar etkin de�ildir. Uygulanabilecek ila� tedavileri aras�nda
imipramin, duloksetin, �strojen bulunmaktad�r. �mipramin, hem </span><span
style='font-family:Symbol;mso-ascii-font-family:Tahoma;mso-hansi-font-family:
Tahoma;mso-bidi-font-family:Tahoma;mso-char-type:symbol;mso-symbol-font-family:
Symbol'><span style='mso-char-type:symbol;mso-symbol-font-family:Symbol'>a</span></span><span
style='font-family:"Tahoma","sans-serif"'> adrenarjik hem de antikolinerjik
etkisi nedeniyle �zellikle kad�nlardaki mikst �ݒde kullan�lmaktad�r. Fakat
ya�l�larda antikolinerjik yan etkileri ve ortostatik hipotansiyon nedeniyle
kullan�lmas� �nerilmemektedir. Duloksetin, serotonin ve noradrenalin geri al�m
inhibit�r�d�r. Pudental siniri stimule ederek etki etmektedir. Yap�lan
�al��malarda stres �� s�kl���nda belirgin bir iyile�meye neden oldu�u
saptanm��t�r. Bulant� s�k g�r�len yan etkisidir. �strojen yaln�zca internal
sfinkter yetersizli�i bulunan kad�nlarda fayda sa�lar. Vaginal �strojen
tedavisinin inkontinans <span class=GramE>semptomlar�nda</span> iyile�me
sa�lad���na dair baz� kan�tlar vard�r.<span style='mso-spacerun:yes'>� </span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<pre style='text-align:justify;line-height:150%'><u><span style='font-size:
12.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>S�k��ma tipi inkontinans</span></u><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'> tedavisinde ama� istemsiz kas�lmalar� azaltarak ya da bloke ederek s�k��ma <span
class=GramE>semptomlar�n�n</span> aral�klar�n� uzatarak mesane kapasitesini iyile�tirmektir. Bu ama�la en �ok kullan�lan ila�lar antikolinerjiklerdir.<span style='mso-spacerun:yes'>� </span>Antikolinerjik ila� se�imi dozaj s�kl���, ila�-ila� etkile�imleri, yan etkiler, komorbiditeler ve maliyet g�z �n�nde bulundurularak yap�lmal�d�r. Antikolinerjik ila�lar a��z kurulu�u, kab�zl�k, bulan�k g�rme, uyku hali, ta�ikardi ve kognitif fonksiyonlarda bozulmaya neden olabilir. Antikolinerjik ila�lar gastrik retansiyon ve dar a��l� glokomda kontrendikedir. <o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Oksibutinin</span></i><span style='mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";background:white'>, en �ok tercih edilen ila�t�r. Oral ve transdermal uygulamas� mevcuttur. Oral formu a��z ve g�z kurulu�u, g�rme bozuklu�u, kab�zl�k, ba�a�r�s�, gastro�zefageal refl�, idrar retansiyonu ve konf�zyon gibi yan etkilere neden olmaktad�r. Daha az yan etki i�in ilac�n ba�lang�� dozu d���k tutulmal�d�r. Yan etki <span
class=GramE>profili</span> en d���k olan ila� oksibutinin transdermal formudur.<span style='mso-spacerun:yes'>� </span>Yap�lan �al��malarda bu formun kognitif yan etkisinin plasebo ile e� oldu�u, a��z kurulu�u ve konstipasyon yan etkisinin de di�er �riner antikolinerjiklerden daha d���k oldu�u g�sterilmi�tir. Oksibutinin kullan�m�nda mutlak kontrendikasyonlar obstr�ktif �ropati ve dar a��l� glokom, r�latif kontrendikasyon ise kardiyak aritmilerdir. <i
style='mso-bidi-font-style:normal'>Tolterodin</i>, oksibutin ile benzer etkilere sahip olmas�na ra�men yan etkiler daha azd�r. Renal ve hepatik sorunu olan hastalarda klirens de�i�ece�i i�in doz d���r�lmelidir. <i
style='mso-bidi-font-style:normal'>Trospiyum</i>, santral sinir sistemi yan etkisi olmayan antimuskarinik bir ila�t�r. Absorbsiyonun tam olmas� i�in a� karn�na al�nmal�d�r. Kreatin klirensi 30 ml/dak�dan d���k olanlarda g�nl�k tek doz �nerilmektedir. Polifarmasiye uygunlu�u, yan etki s�kl���n�n azl��� ve etkinli�i nedeniyle geriatrik olgularda iyi bir se�enektir. Yap�lan �al��malarda kognitif s�rece herhangi bir olumsuz etkisi olmad��� g�sterilmi�tir. <i
style='mso-bidi-font-style:normal'>Propiverin</i>, antikolinerjik ajan olmas�n�n yan� s�ra kalsiyum kanal <span
class=GramE>blokaj�</span> ve D1-D2 blokaj� da yapar. Dopamin blokaji yaparak parkinsonizme yol a�abilece�inden ya�l�larda kullan�l�rken dikkat edilmelidir. <i
style='mso-bidi-font-style:normal'>Darifenasin</i>, M3 selektif muskarinik resept�r <span
class=GramE>antagonistidir</span>. Oral yoldan ba�lang�� dozu g�nde 7,5 mg tek dozdur en erken 2 hafta sonra 15mg�a ��kar�labilir. Kognitif fonksiyonlara olumsuz etkisi yoktur. Kardiyak a��dan g�venlidir. <i
style='mso-bidi-font-style:normal'>Solifenasin</i>, �nerilen g�nl�k doz 5 mg�d�r, gerekli durumlarda 10 mg�a ��kar�labilir. A��z kurulu�u konstipasyon yan etkileri tolterodine g�re daha fazlad�r.<span style='mso-spacerun:yes'>� </span><o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'><o:p>&nbsp;</o:p></span></pre>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";background:white'>Ta�ma tipi �riner inkontinansta BPH�a
ba�l� hafif obstr�ksiyon durumunda </span><span style='font-size:10.0pt;
mso-bidi-font-size:8.0pt;line-height:150%;font-family:Symbol;mso-ascii-font-family:
Tahoma;mso-hansi-font-family:Tahoma;mso-bidi-font-family:Tahoma;background:
white;mso-char-type:symbol;mso-symbol-font-family:Symbol'><span
style='mso-char-type:symbol;mso-symbol-font-family:Symbol'>a</span></span><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";background:white'>-adrenerjik blokerler faydal�d�r. <i
style='mso-bidi-font-style:normal'>Prazosin, terazosin, doksazosin ve
tamsulosin</i>, trigon ve prostat d�z kaslar�nda relaksasyona neden olarak
mesane bo�almas�n� kolayla�t�r�r. <i style='mso-bidi-font-style:normal'>Doksazosin</i>,
etki s�resi en uzun ve yan etkileri en hafif olan etkin maddedir. Postural
hipotansiyon, kardiyovask�ler, dermatolojik, solunum ve genito�riner etkiler
nedeniyle geriatrik olgular takip edilmelidir. <i style='mso-bidi-font-style:
normal'>Prazosin</i>, esas olarak antihipertansif olarak kullan�lmaktad�r,
fakat tolerans geli�mesi nedeniyle seyrek kullan�l�r. <i style='mso-bidi-font-style:
normal'>Tamsulosin</i>, prostat bezinde bulunan </span><span style='font-size:
10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:Symbol;mso-ascii-font-family:
Tahoma;mso-hansi-font-family:Tahoma;mso-bidi-font-family:Tahoma;background:
white;mso-char-type:symbol;mso-symbol-font-family:Symbol'><span
style='mso-char-type:symbol;mso-symbol-font-family:Symbol'>a</span></span><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";background:white'>-adrenerjik resept�rler �zerine etki
g�sterdi�i i�in di�erlerine g�re daha <span class=GramE>spesifiktir</span>, bu
nedenle hipotansif etkisi azd�r. A� al�nmas� �nerilir. <i style='mso-bidi-font-style:
normal'>Terazosin</i>, i�in geriatrik olgularda postural hipotansif etkisi
nedeniyle doz ayar� �nerilmektedir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'>Sonu� olarak ya�l� hastalarda �� s�k
g�r�l�r, ilerleyen ya�la birlikte artar, tan� konulmaz ise bir�ok <span
class=GramE>komplikasyona</span> neden olur. �� hasta ve yak�nlar�n�n hayat
kalitesinde d��meye, mortalitede art��a, morbidite ve maliyette ciddi art��a
neden olmaktad�r. Bu nedenle </span><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:black'>g�nl�k
prati�imizde kar��la�t���m�z her ya�l�da �� sorgulanmal�, tipleri, risk
fakt�rleri belirlenmeli ve uygun davran�� ve medikal tedaviler �nerilmelidir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:16.0pt;mso-bidi-font-size:
14.0pt;line-height:150%;font-family:"Tahoma","sans-serif";background:white'>Konstipasyon<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>Kab�zl�k n�rolojik hastal�klarda s�k g�r�len bir belirti ve <span
class=GramE>komplikasyondur</span>; erken tedavi edilmezse ve relapslar�n
�nlenememesi durumunda hasta i�in ciddi sorun yaratabilir</span><span
style='font-family:"Tahoma","sans-serif";color:#212121;background:white'>.
Serebrovask�ler hastal�klar� olanlarda prevalans� %30 ile %60 aras�nda
de�i�mekte ve inme sonras� hastalar�n %55'inde yeni ba�lang��l� kab�zl�k
g�r�lmektedir. PH�de kab�zl�k, hastalar�n %50'sinden fazlas�nda meydana
geldi�ine inan�lan en s�k g�r�len non-motor bulgulardan biridir.</span><span
style='font-family:"Tahoma","sans-serif"'> </span><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Roma
IV <span class=GramE>kriterlerine</span> g�re, fonksiyonel kab�zl�k, a�a��daki
�zelliklerin herhangi ikisinin olmas� olarak tan�mlan�r: zorlama, topakl� sert
d��k�, tam bo�almama hissi, dijital manevralar kullan�m�, anorektal t�kan�kl�k
hissi veya ba��rsak hareketlerinin %25'inde azalma ile t�kan�kl�k ve d��k�
frekans�nda azalma (haftada �� ba��rsak hareketinden daha az). Tan�dan 6 ay
�nce yukar�daki <span class=GramE>semptomlar</span> ba�lam�� ve son 3 ayd�r
devam ediyor olmal�d�r. </span><span style='font-family:"Tahoma","sans-serif";
color:#212121;background:white'>Ya�l� eri�kinlerde kab�zl�k fonksiyonel kronik
kab�zl��a ba�l� veya di�er etyolojik fakt�rlere sekonder olabilir.</span><span
style='font-family:"Tahoma","sans-serif"'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif";color:#212121;background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif";color:#212121;background:white'>Primer
kolorektal disfonksiyon �� �rt��en alt tipten olu�ur: yava� ge�i� kab�zl���,
dissinerjik defekasyon ve kab�zl�k ile birlikte iritabl ba��rsak <span
class=GramE>sendromu</span>. Sekonder kab�zl�k nedenleri kapsaml� bir �yk� ve
fizik muayene ile takip edilmeli ve tan�sal testler yap�lmal�d�r.</span><span
style='font-family:"Tahoma","sans-serif"'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121;background:white'>Kronik fonksiyonel kab�zl�k tedavisinde ilk
ad�m ya�am tarz� ve diyet de�i�ikli�idir. Genellikle 20 ila 25 g/g�nl�k bir lif
al�m� tavsiye edilir.</span><span style='mso-bidi-font-size:10.0pt;line-height:
150%;font-family:"Tahoma","sans-serif"'> </span><span style='font-family:"Tahoma","sans-serif";
color:#212121;background:white'>Kronik kab�zl��� olan, diyet ve ya�am tarz�
de�i�ikliklerine cevap vermeyen ya�l� hastalarda fekal t�ka� varl��� d��lanarak
lif deste�i veya polietilen glikol ba�lanmas� �nerilmektedir.</span><span
style='font-family:"Tahoma","sans-serif"'> </span><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Ya�l�
yeti�kinlerde laksatif kullan�m�, hastan�n �yk�s�, komorbiditeleri, ila�
etkile�imleri ve yan etkilerine g�re bireyselle�tirilmelidir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:16.0pt;mso-bidi-font-size:
12.0pt;line-height:150%;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:16.0pt;mso-bidi-font-size:
10.0pt;font-family:"Tahoma","sans-serif";text-transform:uppercase'>N�rolojik
hastal�klar�n tedavisinde kullan�lan ila�lar�n�n sebep olabilece�i <span
class=GramE>DAH�L�</span> yan etkilerin ve ila�-ila� etkile�imlerinin y�netimi<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'>Ya�l� hastalar e�lik eden komorbidite
y�k� nedeniyle genellikle �ok say�da ila� kullan�rlar. �lkemizde grubumuz
taraf�ndan bildirilen �niversite geriatri poliklini�ine ba�vuran hastalar�n ilk
ba�vuruda kulland�klar� ortalama ila� say�s� 4,8�dir. �te yandan ya�lanmayla
ili�kili fizyolojik de�i�iklikler, e�lik eden hastal�klara ba�l� geli�en
problemler nedeniyle ya�l�lar ila�larla ili�kili yan etkilere daha duyarl�d�r.
Uygunsuz ila� kullan�m� ya�l�larda kognitif bozukluk, deliryum, maln�trisyon,
��, d��me, ya�am kalitesinde d��me, bak�m ihtiyac�nda art��, hospitalizasyon ve
�l�m ile ili�kilidir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'>Bu nedenle t�m d�nyada ya�l�larda
uygunsuz ila� kullan�m� ve polifarmasinin engellemesine y�nelik stratejiler
geli�tirilmektedir. Bu ba�lamda Akademik Geriatri Derne�i Ak�lc� �la� �al��ma
Grubu �nderli�inde T�rkiye�de alan�nda uzman ve ya�l� hasta klinik prati�inde
deneyimli ��retim �yelerinin geni� kat�l�m� ile T�rkiye Ya�l�da Uygunsuz �la�
Kullan�m Kriterleri (Turkish Inappropriate Medication Use in the Elderly)-(TIME
Kriterleri) olu�turulmu�tur. �la�lar�n etkili oldu�u sistemler esas al�narak
olu�turulan <span class=GramE>kriterler</span>, temel olarak ya�l�da
kullan�lmas� genelde veya baz� durumlarda uygun olmayan ancak klinik pratikte
s�kl�kla yanl�� kullan�lan ila�lar (TIME - to STOP) ve ya�l�da kullan�lmas�
genelde veya baz� durumlarda �zellikle yararl� olan ancak klinik pratikte
s�kl�kla kullan�lmayan ila�lardan (TIME -to START) olu�maktad�r. Bu ba�lamda
�stanbul T�p Fak�ltesi N�roloji Anabilim Dal� Davran�� N�rolojisi ve Hareket
Bozuklar� ve Beyin Damar Hastal�klar� birimleri ile Psikiyatri Anabilim Dal�
Geropsikiyatri biriminden ��retim �yelerinin katk� verdikleri TIME-Merkezi Sinir
Sistemi Kriterleri olu�turulmu�tur. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Kolinesteraz inhibit�rleri<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Artan ya� ve de�i�en fizyoloji ile birlikte geriatrik
olgularda komorbid durumlar ve geriatrik <span class=GramE>sendromlar</span>
artmaktad�r. Demans tedavisinde kullan�lan ila�lar baz� komorbid durumlarda etkile�ebilmektedir
ve �nemli yan etkilere neden olabilirler. Bu durumlar�n bilinmesi ve tedaviye
ba�lamadan �nce ve tedavi s�ras�nda her zaman g�z �n�nde bulundurulmas�
ya�l�n�n tedavisinin d�zenlenmesinde ciddi �nem arz etmektedir.<span
style='mso-spacerun:yes'>� </span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Gastrointestinal sistem
(G�S):</span></u></i><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'> Bulant�, kusma, ishal,
kar�n a�r�s�, �i�kinlik, dispepsi, i�tahs�zl�k ve kilo kayb� en s�k g�r�len
gastrointestinal sistem yan etkileridir. D���k kilolu (&lt;55 kg) olgularda,
d���k VK� olanlarda ve kad�nlarda G�S yan etkileri daha fazla g�r�lmektedir.
G�S yan etkileri doz ba��ml� olup birka� hafta i�erisinde tolerans geli�ir ve
azalarak kaybolur. E�er kaybolmazsa veya hasta tolere edemezse bir �nceki doza
d�n�lebilir. �la�lara yakla��k 3 g�nden fazla ara verilmi�se en d���k dozdan
ba�lamak gerekir, aksi halde G�S yan etkileri abart�l� �ekilde ortaya ��kabilir
ve tedaviye uyum bozulabilir. G�S tolerans� en iyi rivastigmin bant&gt;
donepezil &gt;galantamin &gt;oral rivastigmin (en k�t�) �eklindedir.
Asetilkolinesteraz (AChE) inhibit�rleri artm�� kolinerjik aktiviteye ba�l�
olarak gastrik asit sekresyonunu artt�rabilir. �zellikle gastrik �lser <span
class=GramE>hikayesi</span> olanlarda ve nonsteroid anti inflamatuar ila�
kullananlarda a�ikar veya gizli gastrointestinal kanama semptomlar� a��s�ndan
takip edilmelidir. Rivastigmin ile ilgili klinik �al��malar, peptik �lser
hastal��� veya gastrointestinal kanama insidans�nda plaseboya g�re anlaml� bir
art�� g�stermemi�tir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Kardiyovask�ler
sistem:</span></u></i><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'> <span style='color:black'>Kardiyak
ileti bozukluklar�, senkop, hipotansiyon, hipertansiyon, periferik �dem
kardiyovask�ler sistem yan etkileridir. Kolinerjik aktivitedeki art�� kalp
�zerinde vagotonik etkilere neden olabilir. </span>Persistan bradikardi
(&lt;50/dk), 2. veya 3. derece kalp blo�u veya a��klanamayan senkop olan
hastalarda, QTc uzamas� olan hastalarda (kad�n 470msn, erkekte 450 msn)
asetilkolinesteraz inhibit�r� kullan�m� uygun de�ildir (kalp iletim defekti,
senkop, yaralanma riski). Kalp tepe at�m� 50-60/dk olan ve asemptomatik olan
hastalarda, AChE inhibit�rleri ba�lanabilir. Tedavi ba�lang�c� veya doz
art�r�m�ndan 1 hafta sonra kalp tepe at�m� ve <span class=GramE>semptom</span>
a��s�ndan kontrol edilmelidir. E� zamanl� h�z k�s�tlay�c� ila� alanlarda kalp
tepe at�m� &lt;50/dk de�ilse ve <span class=GramE>semptom</span> yok ise,
dikkatle kullan�labilir. Sol dal blo�u ve atrial fibrilasyon olanlarda dikkatli
kullan�lmal�d�r, hastalar takip edilmelidir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Pulmoner sistem:</span></u></i><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'> Kronik obstr�ktif akci�er hastal��� veya ast�m gibi
hastal��� olanlarda dikkatli kullan�lmal�d�r. Bronkospazm �iddetini
artt�rabilir.<sup><span style='color:red'> </span></sup>Ayr�ca AChE
inhibit�rleri pn�moni riskini artt�rabilir �zellikle ilk ba�land��� d�nemde
tedavi ba�lanmadan ve tedavi s�ras�nda bu riskler g�z �n�nde bulundurulmal�d�r.
<u><o:p></o:p></u></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Santral sinir
sistemi:</span></u></i><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'> Ba�a�r�s�, ba� d�nmesi,
sersemlik hissi, d��me, <span class=GramE>ajitasyon</span>, agresyon,
anksiyete, depresyon, hal�sinasyonlar ve del�zyonlara neden olabilir. �nsomni,
somnolans, REM uyku davran�� bozuklu�u gibi uyku bozukluklar� g�r�lebilir.
Epilepsi �yk�s� olanlarda dikkatli kullan�lmal�d�r. Kolinomimetikler jeneralize
epileptik n�betlere neden olabilirler.<u><o:p></o:p></u></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>�riner sistem</span></u></i><i
style='mso-bidi-font-style:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>:</span></i><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'> Yap�lan �al��malarda g�zlenmemesine ra�men kolinerjik
aktivite art��� nedeniyle �riner obstr�ksiyona neden olabilirler. Benign
prostat hiperplazisi veya mesane ��k�� yolu obstr�ksiyonu olanlarda dikkatli
kullan�lmal�d�r. �riner inkontinansta art��a neden olabilir. �drar yolu
infeksiyonu ve s�k idrara ��kma gibi yan etkiler g�r�lebilir.<u><o:p></o:p></u></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>N�rom�sk�ler ve
kas-iskelet sistemi:</span></u></i><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'> Kas kramplar�
(donepezilde daha belirgin), artrit, artralji, s�rt a�r�s�, yorgunluk,
g��s�zl�k, tremor, kreatinin kinaz enzim y�ksekli�i ve paresteziye neden
olabilir.<u><o:p></o:p></u></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>�la�-ila�
etkile�imleri<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Antikolinerjikler ve AChE inhibit�rleri aras�nda
kar��l�kl� etkile�im vard�r. Birbirlerinin etkisini azaltabilirler.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Beta-blokerlerle, �zellikle kardiyoselektif beta
blokerlerle (atenolol <span class=GramE>dahil</span>) birlikte AChE
inhibit�rleri kullan�ld���nda, senkop ile sonu�lanan ilave bradikardi etkileri
olu�abilir AChE inhibit�rlerinin beta-blokerler ile birlikte kullan�lmas�
tavsiye edilmez. Steroidler AChE inhibit�rlerinin yan etkilerini art�rabilir,
kas g��s�zl���n� art�rabilir. Anestezide s�ksinil kolin tipi kas gev�emesini
art�rabilir. Donepezil: <span class=GramE>Karaci�er<span
style='mso-spacerun:yes'>� </span>ve</span> b�brek yetersizli�inde doz
ayarlamas� �nerilmez. Rivastigmin: Karaci�er ve b�brek yetersizli�inde doz
ayarlamas� �nerilmez. Galantamin: Ciddi karaci�er ve b�brek yetersizli�inde
kullan�lmas� �nerilmez. Child B ve orta d�zey b�brek yetersizli�inde maksimum
16 mg �nerilir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Memantin<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Kolinerjik ajanlardan daha az yan etkiye sahiptir, hatta
plaseboya benzer.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Kardiovask�ler
sistem:</span></u></i><u><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'> </span></u><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Hipertansiyon, kalp yetmezli�i, senkop, SVH ve T�A
�nemli yan etkilerdir. Bu vask�ler yan etkilerden dolay� kardiyovask�ler
hastal�k <span class=GramE>hikayesi</span> olanlarda dikkatli kullanmak
gerekir.<u><o:p></o:p></u></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Santral sinir
sistemi:</span></u></i><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'> </span></u><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Sersemlik en s�k g�r�len yan etkidir. Ba� d�nmesi, ba�a�r�s�,
<span class=GramE>hal�sinasyonlar</span>, somnolans, yorgunluk, agresyon,
ataksi ve vertigo g�r�lebilir. Ajitasyon �zellikle Lewy cisimcikli demans
hastalar�nda g�r�lebilir. Epilepsi �yk�s� olanlarda dikkatli kullan�lmal�d�r,
n�bet riskini artt�rabilir. <u><o:p></o:p></u></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>N�rom�sk�ler ve kas
iskelet sistemi:</span></u></i><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'> </span></u><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>S�rt a�r�s� ve hipokineziye neden olabilir.<u><o:p></o:p></u></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Gastrointestinal
sistem:</span></u></i><u><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'> </span></u><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Konstipasyon, kusma, kilo kayb� g�r�lebilecek yan
etkilerdir.<u><o:p></o:p></u></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Respiratuvar sistem</span></u></i><u><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>: </span></u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>�ks�r�k, dispne
g�r�lebilir.<u><o:p></o:p></u></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><u><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>G�z hastal�klar�: </span></u></i><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Katarakt ve konjuktivit olu�umunu att�rd��� i�in
oftalmik hastal��� olanlarda dikkatli kullanmak ve belirli aral�klarla g�z
muayenesi yapt�rmak gerekir. <u><o:p></o:p></u></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>�la� etkile�imi<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Karbonik anhidraz inhibit�rleri ve sodyum bikarbonat
memantinin ekskresyonunu azaltabilir. Trimetoprim memantinin yan etkilerini
artt�rabilir. �zellikle miyoklonus ve deliryum riski artabilir. Her iki ila� da
birbirlerinin serum d�zeyini artt�rabilir. Hafif -orta b�brek yetmezli�inde doz
ayarlamas� �nerilmez. Glomer�ler filtrasyon h�z� 30mL/dk�n�n alt�nda olanlarda
5mg ba�lanmas� ve en az bir hafta kullan�mdan sonra en y�ksek doz olan 10 mg�a
��kar�lmas� �nerilir. Klirens alkali idrar ile anlaml� olarak azal�r. (ila�,
diyet)<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Ciddi hepatik yetmezlik durumunda dikkatli kullan�lmal�,
doz art��� daha yava� yap�lmal�d�r, b�l�nm�� dozlarda verilebilir ve yak�n
takip edilmelidir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Antipsikotik �la�lar�n <span
class=GramE>Dahili</span> Yan Etkileri<o:p></o:p></span></b></p>

<pre style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'><span
style='mso-tab-count:1'>�������������� </span><o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>�kinci ku�ak antipsikotiklerle ili�kili ortak yan etkiler aras�nda kilo al�m� ve ilgili metabolik etkiler, hipotansiyon, sedasyon, antikolinerjik <span
class=GramE>semptomlar</span>, hiperprolaktinemi, ekstrapiramidal semptomlar (EPS), kardiyak etkiler, kardiyomiyopatiler, kataraktlar ve cinsel i�lev bozuklu�u yer al�r. Nadir fakat ciddi yan etkiler, tardiv diskinezi, n�roleptik malign <span
class=GramE>sendrom</span>, n�betler, agran�lositoz, hipersensitivite reaksiyonlar� ve �zellikle demans ile ili�kili psikozu olan ya�l� eri�kin hastalarda t�m bu nedenlere ba�l� mortalite riski artmaktad�r.<o:p></o:p></span></pre>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Metabolik yan
etkiler: </span></i><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>�kinci ku�ak
antipsikotiklerin yayg�n yan etkisi kilo art��� ve bununla ili�kili metabolik
etkileridir. <span style='color:#212121'>Kilo al�m�, diyabet ve dislipidemi, i</span>kinci
ku�ak antipsikotiklerle <span style='color:#212121'>ili�kili metabolik <span
class=GramE>sendromun</span> bile�enleridir. Bu <span class=GramE>semptomlara</span>
neden olan mekanizma tamamen a��k de�ildir, ancak bu ila�larla hem i�tah art���
hem de de�i�en metabolik kontrol i�in kan�t vard�r.</span><u><o:p></o:p></u></span></p>

<pre style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Klozapin ve olanzapin, di�er antipsikotiklere g�re anlaml� derecede daha y�ksek risk ta��makta iken, aripiprazol, lurasidon, pimavanserin ve ziprasidon en d���k riskle ili�kilidir. Bu <span
class=GramE>semptomlar�n</span> potansiyel morbiditesi nedeniyle antipsikotik ila�lar� alan hastalarda rutin k�sa ve uzun s�reli kilo, bel �evresi, kan bas�nc�, a�l�k glikozu ve lipit profili takibi �nerilmektedir.<o:p></o:p></span></pre>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Endokrin yan etkiler:</span></i><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'> </span><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";mso-fareast-font-family:
"Times New Roman";mso-fareast-theme-font:minor-fareast'>Hiperprolaktinemi</span><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>: <span style='color:#212121'>Prolaktin y�kselmesi-
Erkeklerde ve kad�nlarda prolaktin salg�lanmas�, b�y�k �l��de, hipofiz bezi
�zerindeki tromroinfundibular dopaminin inhibit�r etkisi ile kontrol edilir.
Hipofiz dopamin resept�rlerinin direkt <span class=GramE>blokaj�</span>,
prolaktin sekresyonuna izin verir. Artm�� prolaktin d�zeylerinin klinik
sonu�lar� aras�nda jinekomasti, galaktore, adet d�zensizlikleri, cinsel i�lev
bozuklu�u ve infertilite, k�smen azalt�lm�� �strojen ve testosteron d�zeylerine
arac�l�k eder. </span><u><o:p></o:p></u></span></p>

<pre style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>�kinci ku�ak antipsikotikler <span
style='color:#212121'>aras�nda risperidon ve paliperidon en y�ksek oranda prolaktin ve daha az derecede asenapin, olanzapin ve ziprasidon ile ili�kilidir. Aripiprazol, brekspiprazol, kariprazin, klozapin, iloperidon, lurasidon, pimavanserin ve ketiyapin ile prolaktin d�zeylerinde �ok az de�i�iklik olur veya hi� de�i�mez. Risperidon ayr�ca, di�er antipsikotiklerle kar��la�t�r�ld���nda belirgin bir �ekilde artm�� hipofiz adenomu (1000 hasta i�in 0,5) ile ili�kili bulunmu�tur.<o:p></o:p></span></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Risperidon ve paliperidon kullanan hastalar�n 12 hafta boyunca her vizitte ve daha sonra y�lda bir cinsel fonksiyon de�i�ikli�i ve anormal laktasyon varl��� sorgulanmal�d�r. Hastada cinsel i�lev bozuklu�u veya galaktore bulgular� geli�irse, serum prolaktin seviyesi �l��lmelidir. <o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></i></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Seks�el yan etkiler:</span></i><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'> <span
style='color:#212121'>Cinsel aktivitenin t�m a�amalar�nda disfonksiyon (libido, uyar�lma ve orgazm) antipsikotik tedavide s�k g�r�l�r. 2011 y�l�nda yap�lan bir meta-analizde i</span>kinci ku�ak antipsikotiklerden<span
style='color:#212121'>; klozapin, olanzapin veya risperidon alan hastalar�n y�zde 40 ila 60'�nda cinsel yan etkiler g�r�ld��� ve aripiprazol, ketiyapin ve ziprasidonda y�zdelerin daha d���k oldu�unu ancak yine de %16 ila 27 aras�nda anlaml� oranlarda ya�and��� saptanm��t�r. </span>Daha yak�n zamanda yap�lan bir �al��mada p<span
style='color:#212121'>aliperidon ve risperidon alan hastalar�n %60 ila 70'inde cinsel yan etki ya�and���, olanzapin, ketiyapin ve ziprasidon alanlar�n %50 ila 60'�nda, klozapin alanlar�n %50'den az�nda ve aripiprazol alanlar�n %16 ila 27�sinde cinsel yan etkiler ya�and��� tespit edilmi�tir. Klinisyenler, ba�lang��ta ve en az y�lda bir kez cinsel i�levsellik ile ilgili zorluklar� �zellikle sormal�d�rlar.</span><u><o:p></o:p></u></span></pre>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></i></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><i
style='mso-bidi-font-style:normal'><span style='font-size:10.0pt;mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Kardiyovask�ler yan
etkiler:</span></i><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'> <span style='color:#212121'>QTc
intervali uzamas� ve ani �l�m kardiyak yan etkilerdir. </span>�kinci ku�ak
antipsikotiklerin <span style='color:#212121'>bir�o�unun QT aral���n�n
uzamas�na neden oldu�u bilinmektedir.<span style='mso-spacerun:yes'>� </span>QT
uzamas�, �torsade de pointes� ve potansiyel olarak �l�mc�l aritmilerin riskini
art�r�r. Antipsikotik tedavi s�ras�nda 500 msn'den daha fazla bir d�zeltilmi�
QT aral��� (QTc) veya QTc'de 60 msn veya daha fazla bir art�� �torsade de
pointes� i�in anlaml� risk oldu�unu g�stermektedir.</span><sup><span
style='color:red'> </span></sup><span style='color:#212121'>Spesifik ikinci
ku�ak antipsikotikler ve QT intervali uzamas� ile ili�kileri �unlard�r:</span><u><o:p></o:p></u></span></p>

<pre style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:
normal'><span style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></i></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>�loperidon</span></i><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'> </span></b><span style='mso-bidi-font-size:8.0pt;line-height:
150%;font-family:"Tahoma","sans-serif";color:#212121'>ve<b style='mso-bidi-font-weight:
normal'> </b><i style='mso-bidi-font-style:normal'>ziprasidon</i><b
style='mso-bidi-font-weight:normal'>,</b> di�er ikinci ku�ak antipsikotiklere g�re �nerilen en y�ksek oral dozlarda QTc'de s�ras�yla 9 msn ve 10 msn ortalama art�� ile daha fazla QT uzamas� riskine sahiptir.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Her iki ila� da do�rudan kardiyak �l�mle ili�kilendirilmemi�tir, ancak �nceden var olan QT uzamas�, di�er kardiyovask�ler hastal�klar, hipokalemi veya QT aral���n� uzatan di�er ila�larla e�zamanl� kullan�m� gibi di�er risk fakt�rleri ile birlikte vakalar bildirilmi�tir.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Ba�lamadan �nce bilinen risk fakt�rleri olan hastalarda ilac�n s�rekli bir tedavi d�zeyine ula�mas� ve yeni bir kardiyak <span
class=GramE>semptomun</span> ortaya ��kmas� durumunda bir elektrokardiyogram (EKG) �nerilmektedir.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></i></pre><pre style='text-align:justify;
line-height:150%'><i style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Ketiyapin,</span></i><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'> doz a��m� vakalar�nda QT uzamas� ile ili�kilidir ve<i
style='mso-bidi-font-style:normal'> asenapin</i><b style='mso-bidi-font-weight:
normal'> </b>ve<i style='mso-bidi-font-style:normal'> paliperidon </i>gibi kardiyak riski olan hastalarda kullan�m� ile ilgili bir uyar� ifadesi ta��maktad�r.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></i></pre><pre style='text-align:justify;
line-height:150%'><i style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Olanzapin</span></i><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'> </span></b><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>ve<b style='mso-bidi-font-weight:normal'> </b><i
style='mso-bidi-font-style:normal'>risperidonun</i> her biri hafif QT uzamas� ile ili�kilidir, ancak bu konuya �zel bir dikkat g�sterilmemi�tir.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></i></pre><pre style='text-align:justify;
line-height:150%'><i style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Lurasidon, aripiprazol,</span></i><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'> </span></b><i
style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>brekspiprazol ve kariprazin,</span></i><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'> kardiyak aritmilere en az neden olan ila�lard�r, ancak hi�bir kardiyak risk fakt�r� olmayan bir hastada aripiprazol ile QT uzamas� ve kardiyak �l�m bildirilmi�tir. <o:p></o:p></span></pre>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>Antipsikotik kullanan ve kardiyak risk fakt�r� olmayan
hastalarda rutin EKG izlemi �nerilmez. <span style='color:#212121'>QT aral���n�
uzatt��� bilinen di�er ila�lar� alan ki�iler de <span class=GramE>dahil</span>
olmak �zere, kardiyak risk fakt�rleri olan hastalarda hi�biri tamamen risksiz
de�ildir ve uygun dikkat g�sterilmelidir.</span><o:p></o:p></span></p>

<pre style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:
normal'><span style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></i></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>Miyokardit ve kardiyomiyopati:</span></i><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'> <i
style='mso-bidi-font-style:normal'>Klozapin,</i> �o�u kez ilk birka� hafta veya ay i�inde �l�mc�l olan miyokardit ve kardiyomiyopati vakalar� ile ili�kilendirilmi�tir.</span><sup><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:red'> </span></sup><span style='mso-bidi-font-size:8.0pt;line-height:
150%;font-family:"Tahoma","sans-serif";color:#212121'>Klozapin ile y�ll�k miyokardit insidans� geni� bir aral�kta bildirilmi�tir ve �l�m oran� y�zde 0,01-0,1 aras�ndad�r.<u><o:p></o:p></u></span></pre><pre
style='line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></i></pre><pre style='line-height:150%'><i
style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Ketiapin, risperidon ve ziprasidon</span></i><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'> ile nadir olarak miyokardit ve kardiyomiyopati bildirilmi�tir.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></i></pre><pre style='text-align:justify;
line-height:150%'><i style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Ortostatik hipotansiyon:</span></i><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'> Alfa-adrenerjik <span class=GramE>blokaj</span>, ikinci ku�ak antipsikotiklerin neden oldu�u ortostatik hipotansiyonun olas� mekanizmas�d�r. Genellikle, ortostatik ta�ikardi e�lik eder, her ikisi de en s�k ila�lara maruz kalman�n ilk birka� g�n�nde veya doz art�r�ld���nda g�r�l�r. Kan bas�nc� ve kalp at�m h�z�ndaki de�i�iklikler en s�k klozapin, iloperidon, ketiyapin ve paliperidon ve daha az s�kl�kla olanzapin, risperidon ve ziprasidon ile g�r�l�r. Nadiren aripiprazol, asenapin, brekspiprazol, kariprazin, lurasidon ve pimavanserin ile ortaya ��karlar. Semptomlar genellikle benign ve kendini s�n�rlay�c�d�r, ancak baz� durumlarda, tek bir g�nl�k dozun iki veya �� k���k doza b�l�nmesi, doz titrasyon h�z�n�n yava�lat�lmas� veya ila�ta de�i�iklik yap�lmas� gerekebilir. </span><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'>Kan bas�nc� ve kalp at�m h�z� tedavi ba�lang�c�nda, 3. ayda ve daha sonra y�lda bir takip edilmelidir.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'><o:p>&nbsp;</o:p></span></i></pre><pre style='text-align:justify;
line-height:150%'><i style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:black'>Hematolojik yan etkiler:</span></i><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'> Klozapin ile n�tropeni, l�kopeni ve agran�lositoz belgelenmi�tir. </span><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'>Bu �l�mc�l durum, tedavinin ilk birka� ay�nda, �nceden d���k h�cre say�m� olan hastalarda ve daha �nce ilaca ba�l� kan diskrazisi olanlarda daha s�k g�r�l�r. Klozapin ile tedavi edilen hastalar�n yakla��k %3'�nde l�kositoz ve yakla��k %1'inde agran�lositoz geli�ebilir. Klozapin kullanan hastalar�n n�tropeni i�in rutin olarak izlenmesi ve ciddi vakalarda ilac�n kesilmesini gerekir. Di�er antipsikotikler ile bu bulgular daha d���k oranlarda g�r�l�r.<span style='mso-spacerun:yes'>� </span>L�kositoz ve n�tropeni risperidon alan hastalar�n %4'�nde, paliperidon veya ketiapin alanlar�n %2'sinde ve di�er ikinci ku�ak antipsikotikleri alan hastalar�n %1'inden daha az�nda ortaya ��kmaktad�r. �iddetli n�tropeni veya agran�lositoz vakalar� bildirilmi�tir ancak nadirdir. Di�er antipsikotikleri alan daha �nceden ilaca ba�l� l�kositopenisi olan veya �nceden d���k bir l�kosit say�m�na veya d���k n�trofil say�m�na sahip olan hastalar i�in, tedavinin ilk birka� ay�nda izleme yap�lmas� �nerilmektedir. Spesifik bir takip aral��� �nerilmemesine ra�men, n�trofil say�m�n�n bazalde, 1 -2 hafta sonra ve 3-6 ay sonra yap�lmas� makul yakla��m olacakt�r. <u><o:p></o:p></u></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'><o:p>&nbsp;</o:p></span></i></pre><pre style='text-align:justify;
line-height:150%'><i style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Antikolinerjik etkiler:</span></i><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'> A��z kurulu�u, konstipasyon, bulan�k g�rme veya �riner retansiyon izlenebilir. Klozapin kullan�m�nda ise a��z kurulu�undan ziyade sialore g�r�l�r.<span style='mso-spacerun:yes'>� </span>Klozapin sekonder antipsikotikler i�inde muskarinik resept�rler i�in en g��l� afiniteye sahiptir ve yan etkiler bu ila�la en s�k ve �iddetlidir. Di�er sekonder antipsikotikler aras�nda olanzapin ve ketiyapin geri kalan ila�lardan daha y�ksek antikolinerjik problemlere sahiptir. S�kl�kla profilaktik ajanlar da dahil olmak �zere kab�zl���n <span
class=GramE>agresif</span> tedavisi, fekal impaksiyon veya ba��rsak perforasyonu gibi ciddi yan etkilerden ka��nmak i�in gerekli olabilir. Antikolinerjik etki en fazla olandan en az olana s�ras�yla klozapin ve olanzapin, risperidon, ketiyapin ve haloperidoldur.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'><o:p>&nbsp;</o:p></span></i></pre><pre style='text-align:justify;
line-height:150%'><i style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:black'>Sedasyon:</span></i><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:#212121'> Klozapin ve ketiyapin ile hastalar�n yar�s�nda sedasyon �n plana ��kmaktad�r. Asenapin, lurasidon, olanzapin ve ziprasidon ile sedasyon %10 ila 25 <span
class=GramE>aral���nda</span> oranlara sahiptir. <u><o:p></o:p></u></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Aripiprazol, brekspiprazol, kariprazin, paliperidon, pimavanserin ve risperidon gibi di�er ila�lar, hastalar�n %10'undan az�nda sedasyona neden olurlar. Aripiprazol ile hastalar�n %18'inde uykusuzluk rapor edilmi� olup bu oran sersemlik i�in rapor edilen de�erin �� kat�d�r.<span style='mso-spacerun:yes'>� </span>Antipsikotikler i�inde sedatif etkisi en fazla olandan en az olana s�raland���nda ketiyapin, klozapin ve olanzapin, risperidon ve haloperidoldur.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Hastalar ilk birka� tedavi dozu ile uyu�ukluk konusunda uyar�lmal� ve ilk izlem ziyareti s�ras�nda yan etki hakk�nda sorular sorulmal�d�r. Tedavide erken d�nemde sedasyon ge�iren hastalara periyodik olarak tekrar sorulmal�d�r.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'><o:p>&nbsp;</o:p></span></i></pre><pre style='text-align:justify;
line-height:150%'><i style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:black'>D��meler:</span></i><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'> </span><span style='mso-bidi-font-size:8.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:#212121'>FDA</span><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'> (Food and drug administration)</span><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>, 2017'de antipsikotik ila�lar�n uyku hali, post�ral hipotansiyon ve/veya motor ve duyusal instabilite sonucu d��melere ve k�r�klara neden olabilece�i konusunda uyar�da bulunmu�tur. Bu etkileri �iddetlendirebilecek durumu olan ya da ila� kullanan hastalar i�in, FDA antipsikotik tedavisi ba�lad���nda ve uzun s�reli antipsikotiklere devam eden hastalarda tekrarlayan bir risk de�erlendirmesi yap�lmas�n� �nermi�tir.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><i style='mso-bidi-font-style:normal'><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'><o:p>&nbsp;</o:p></span></i></pre><pre style='text-align:justify;
line-height:150%'><i style='mso-bidi-font-style:normal'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:black'>Artm�� mortalite riski:</span></i><span
style='mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
color:black'> </span><span style='mso-bidi-font-size:8.0pt;line-height:150%;
font-family:"Tahoma","sans-serif";color:#212121'>2005'ten beri FDA, ikinci ku�ak antipsikotiklerin, demansla ili�kili psikozu olan ya�l� eri�kin hastalar�n t�m nedenlere ba�l� �l�m�nde 1,6 ila 1,7 kat art��la �black box� uyar�s�n� gerektirdi�ini belirtmi�tir. Bu hastalar aras�nda <span
class=GramE>spesifik</span> �l�m nedenleri kalp hastal�klar� (%25), SVH (%8), pulmoner hastal�k (%8), kanser (%7) ve diyabet (%3) idi. Ya�l� bunama hastalar� ile s�n�rl� b�y�k bir pop�lasyona dayal� kohort �al��mas�nda, ikinci ku�ak antipsikotiklerden aripiprazol, olanzapin, risperidon ve ziprasidon aras�nda hi�bir fark bulunmam��, fakat ketiyapin % 20 daha d���k bir risk olu�turmu�tur.<o:p></o:p></span></pre><pre
style='text-align:justify;line-height:150%'><span style='mso-bidi-font-size:
8.0pt;line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></pre>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Steroidler<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Glukokortikoidlerin
yan etkileri hem doz hem de s�reye ba�l�d�r. Glukokortikoidlerin etkilerine glukokortikoid
resept�rleri arac�l�k eder ve bu ajanlar�n terap�tik etkilerinde de rol oynayan
hem genomik hem de nongenomik mekanizmalardan kaynaklan�r.<span
style='mso-spacerun:yes'>� </span>Glukokortikoid resept�r�ndeki ve
glukokortikoid metabolizmas�ndaki genetik polimorfizmler, g�zlenen glukokortikoid
toksisitelerindeki heterojenli�i a��klayabilir.</span><span style='font-size:
10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>
<span style='color:#212121;background:white'>Glukokortikoidlerin bir�ok organ
sistemi �zerinde olumsuz etkileri vard�r.</span><span style='color:#212121'> <span
style='background:white'>Dermatolojik ve g�r�n�m �zerine g�r�len yan etkiler;
purpura, ekimoz, ciltte incelme, kilo art���, Cushingoid g�r�n�m, akne,
hirsutizm, </span>y�zde eritem ve strialard�r. Oftalmolojik yan etkiler
aras�nda posterior subkaps�ler katarakt, y�ksek g�z i�i bas�nc�/glokom ve
egzoftalmus bulunmaktad�r.</span> <span style='color:#212121'>Kardiyovask�ler
sistem yan etkileri; s�v� retansiyonu, hipertansiyon, premat�re arteroskleroz
ve aritmilerdir. </span><span style='mso-spacerun:yes'>�</span><span
style='color:#212121'>Sindirim sistemi yan etkileri; gastrit, peptik �lser
hastal���, steatohepatit, visseral perforasyondur.</span> <span
style='color:#212121'>Kas iskelet sistemine ait yan etkiler osteoporoz,
avask�ler nekroz ve miyopati olarak bildirilmi�tir.</span> <span
style='color:#212121'>N�ropsikiyatrik yan etkiler aras�nda �fori,
disfori/depresyon, uykusuzluk, akatizi, mani/psikoz, ps�dot�mor serebri
bulunmaktad�r.</span> <span style='color:#212121'>Metabolik ve endokrin sisteme
ait g�r�lebilecek yan etkiler hiperglisemi, hipotalamo-hipofiz-adrenal
yetmezliktir.</span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'>Artan infeksiyon
riski �l�mc�l sonu�lara varabilen yan etkidir.<span style='mso-spacerun:yes'>�
</span>HBsAg veya HBV DNA (+) olgularda kullan�mlar� HBV aktivasyonu nedeniyle
fulminan hepatitle sonu�lanabilece�inden, tedaviye ba�lamadan �nce HBsAg,
anti-HBs, anti-HBc IgG ve gerekli olgularda HBV DNA bak�lmal� ve gerekli
olgulara antiviral profilaksi ba�lanmal�d�r. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt;
background:white'><span style='font-size:10.0pt;mso-bidi-font-size:8.0pt;
line-height:150%;font-family:"Tahoma","sans-serif";color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
class=GramE><b style='mso-bidi-font-weight:normal'><span style='font-size:16.0pt;
mso-bidi-font-size:10.0pt;font-family:"Tahoma","sans-serif";text-transform:
uppercase'>DAhiliyede</span></b></span><b style='mso-bidi-font-weight:normal'><span
style='font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family:"Tahoma","sans-serif";
text-transform:uppercase'> s�k kullan�lan ila�lar�n n�rolojik hastal�klar�n
klini�i �zerine olan yan etkilerinin y�netimi<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'>Hiperglisemi-hipoglisemi, hipoksi,
hiperkarbi, hipotansiyon-hipertansiyon, dehidratasyon, elektrolit
dengesizlikleri, metabolik asidoz-alkaloz, hipotiroidi-hipertiroidi, b�brek
yetersizli�i, karaci�er yetersizli�i, anemi, n�trisyonel eksiklikler gibi
sistemik veya metabolik bozukluklar�n normal n�ronal i�levi bozabilece�i
bilinmektedir. Bu sistemik veya metabolik bozukluklara neden olabilecek
ila�lar, mevcut n�rolojik hastal���n k�t�le�mesi durumunda mutlaka g�zden
ge�irilmeli, gerekli d�zenlemeler yap�lmal� ve �nlemler al�nmal�d�r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify;line-height:
150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
  <td width=626 valign=top style='width:469.8pt;border:solid windowtext 1.0pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%'><b
  style='mso-bidi-font-weight:normal'><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>Tablo 5. N�rolojik hastal�klarda klinik bozulmaya
  katk�da bulunabilecek-etkileyebilecek ila�lar<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:54.2pt'>
  <td width=626 valign=top style='width:469.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:54.2pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%'><span
  style='font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Glisemi
  d�zeyini etkileyen ila�lar<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpFirst style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l5 level1 lfo36'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>�<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>Hipoglisemi: oral antidiyabetikler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpLast style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l5 level1 lfo36'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>�<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>Hiperglisemi: steroidler<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:54.2pt'>
  <td width=626 valign=top style='width:469.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:54.2pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%'><span
  style='font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Kan
  bas�nc�n� etkileyen ila�lar<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpFirst style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l20 level1 lfo38'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>�<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>Hipotansiyon: antihipertansifler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpLast style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l20 level1 lfo38'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>�<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>Hipertansiyon: steroid, siklosporin,<span
  style='mso-spacerun:yes'>� </span>-NSA�<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;height:54.2pt'>
  <td width=626 valign=top style='width:469.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:54.2pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%'><span
  style='font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Elektrolitleri
  etkileyen ila�lar<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpFirst style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l4 level1 lfo40'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>�<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>Di�retikler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpLast style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l4 level1 lfo40'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>�<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>�</span>(ACE�/ARB)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;height:54.2pt'>
  <td width=626 valign=top style='width:469.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:54.2pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%'><span
  style='font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>S�v�
  durumunu etkileyen ila�lar<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpFirst style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l1 level1 lfo42'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>�<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>Di�retikler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpLast style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l1 level1 lfo42'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>�<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>Steroidler, NSA�<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;height:72.65pt'>
  <td width=626 valign=top style='width:469.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:72.65pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%'><span
  style='font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Karaci�er-b�brek
  toksisitesi yapabilen ila�lar<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpFirst style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l9 level1 lfo44'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>�<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>Statinler<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-align:justify;text-indent:
  -18.0pt;line-height:150%;mso-list:l9 level1 lfo44'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>�<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>ACE�/ARB<o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpLast style='text-align:justify;text-indent:-18.0pt;
  line-height:150%;mso-list:l9 level1 lfo44'><![if !supportLists]><span
  style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
  Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>�<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span style='font-family:"Tahoma","sans-serif";
  mso-fareast-language:EN-US'>NSA�<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;mso-yfti-lastrow:yes'>
  <td width=626 valign=top style='width:469.8pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;line-height:150%'><span
  style='font-family:"Tahoma","sans-serif";mso-fareast-language:EN-US'>Anemi
  yapabilen ila�lar <o:p></o:p></span></p>
  <p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt;line-height:
  150%;mso-list:l2 level1 lfo46;background:white'><![if !supportLists]><span
  class=MsoSubtleEmphasis><span style='font-size:14.0pt;mso-bidi-font-size:
  12.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;color:black;mso-themecolor:text1;font-style:normal;
  mso-bidi-font-style:italic'><span style='mso-list:Ignore'>�<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span></span><![endif]><span class=MsoSubtleEmphasis><span
  style='font-family:"Verdana","sans-serif";color:black;mso-themecolor:text1;
  mso-fareast-language:EN-US;font-style:normal;mso-bidi-font-style:italic'>Metotreksat&nbsp;</span></span><span
  class=MsoSubtleEmphasis><span style='font-family:"Verdana","sans-serif";
  mso-fareast-font-family:"Times New Roman";mso-fareast-theme-font:major-fareast;
  color:black;mso-themecolor:text1;mso-fareast-language:EN-US;font-style:normal;
  mso-bidi-font-style:italic'>&nbsp;</span></span><span
  class=MsoSubtleEmphasis><span style='font-family:"Verdana","sans-serif";
  color:black;mso-themecolor:text1;font-style:normal;mso-bidi-font-style:italic'><o:p></o:p></span></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l2 level1 lfo46;background:white'><![if !supportLists]><span
  class=MsoSubtleEmphasis><span style='font-size:14.0pt;mso-bidi-font-size:
  12.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;color:black;mso-themecolor:text1;mso-fareast-language:
  EN-US;font-style:normal;mso-bidi-font-style:italic'><span style='mso-list:
  Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span></span><![endif]><span class=MsoSubtleEmphasis><span
  style='font-family:"Verdana","sans-serif";color:black;mso-themecolor:text1;
  mso-fareast-language:EN-US;font-style:normal;mso-bidi-font-style:italic'>Trimetoprim&nbsp;</span></span><span
  class=MsoSubtleEmphasis><span style='font-family:"Verdana","sans-serif";
  mso-fareast-font-family:"Times New Roman";mso-fareast-theme-font:major-fareast;
  color:black;mso-themecolor:text1;mso-fareast-language:EN-US;font-style:normal;
  mso-bidi-font-style:italic'>&nbsp;</span></span><span
  class=MsoSubtleEmphasis><span style='font-family:"Verdana","sans-serif";
  color:black;mso-themecolor:text1;mso-fareast-language:EN-US;font-style:normal;
  mso-bidi-font-style:italic'><o:p></o:p></span></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l2 level1 lfo46;background:white'><![if !supportLists]><span
  class=MsoSubtleEmphasis><span style='font-size:14.0pt;mso-bidi-font-size:
  12.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;color:black;mso-themecolor:text1;mso-fareast-language:
  EN-US;font-style:normal;mso-bidi-font-style:italic'><span style='mso-list:
  Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span></span><![endif]><span class=MsoSubtleEmphasis><span
  style='font-family:"Verdana","sans-serif";color:black;mso-themecolor:text1;
  mso-fareast-language:EN-US;font-style:normal;mso-bidi-font-style:italic'>Hidroksi�re&nbsp;</span></span><span
  class=MsoSubtleEmphasis><span style='font-family:"Verdana","sans-serif";
  mso-fareast-font-family:"Times New Roman";mso-fareast-theme-font:major-fareast;
  color:black;mso-themecolor:text1;mso-fareast-language:EN-US;font-style:normal;
  mso-bidi-font-style:italic'>&nbsp;</span></span><span
  class=MsoSubtleEmphasis><span style='font-family:"Verdana","sans-serif";
  color:black;mso-themecolor:text1;mso-fareast-language:EN-US;font-style:normal;
  mso-bidi-font-style:italic'><o:p></o:p></span></span></p>
  <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;line-height:
  150%;mso-list:l2 level1 lfo46;background:white'><![if !supportLists]><span
  class=MsoSubtleEmphasis><span style='font-size:14.0pt;mso-bidi-font-size:
  12.0pt;line-height:150%;font-family:Symbol;mso-fareast-font-family:Symbol;
  mso-bidi-font-family:Symbol;color:black;mso-themecolor:text1;mso-fareast-language:
  EN-US;font-style:normal;mso-bidi-font-style:italic'><span style='mso-list:
  Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span></span><![endif]><span class=MsoSubtleEmphasis><span
  style='font-family:"Verdana","sans-serif";color:black;mso-themecolor:text1;
  mso-fareast-language:EN-US;font-style:normal;mso-bidi-font-style:italic'>Zidovudin&nbsp;</span></span><span
  class=MsoSubtleEmphasis><span style='font-family:"Verdana","sans-serif";
  mso-fareast-font-family:"Times New Roman";mso-fareast-theme-font:major-fareast;
  color:black;mso-themecolor:text1;mso-fareast-language:EN-US;font-style:normal;
  mso-bidi-font-style:italic'>&nbsp;</span></span><span
  class=MsoSubtleEmphasis><span style='font-family:"Verdana","sans-serif";
  color:black;mso-themecolor:text1;mso-fareast-language:EN-US;font-style:normal;
  mso-bidi-font-style:italic'><o:p></o:p></span></span></p>
  <p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt;line-height:
  150%;mso-list:l2 level1 lfo46;background:white'><![if !supportLists]><span
  style='font-size:14.0pt;mso-bidi-font-size:12.0pt;line-height:150%;
  font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
  style='mso-list:Ignore'>�<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span></span><![endif]><span class=MsoSubtleEmphasis><span
  style='font-family:"Verdana","sans-serif";color:black;mso-themecolor:text1;
  mso-fareast-language:EN-US;font-style:normal;mso-bidi-font-style:italic'>5-Florourasil</span></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:8.0pt;line-height:150%;font-family:
"Tahoma","sans-serif"'>NSA�: nonsteroid antiinflamatuar ila�lar, ACE�/ARB:
Anjiotensin d�n��t�r�c� enzim inhibit�rleri/anjiotensin resept�r blokerleri<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:16.0pt;mso-bidi-font-size:
12.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:16.0pt;mso-bidi-font-size:
10.0pt;font-family:"Tahoma","sans-serif";text-transform:uppercase'>N�rolojik
Hastal��� Olan Ya�l�daki Sistemik Hastal�klar�n Y�netimi<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='font-family:"Tahoma","sans-serif"'>Hipertansiyon
<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Hipertansif
olgular�n ��� 50 ya� �st�ndedir. Altm�� ya� �st� bireylerde hipertansiyon
prevalans� %60-80� dir. </span><span style='font-family:"Tahoma","sans-serif"'>N�rolojik
hastal��� olanlarda kan bas�nc� kontrol� olduk�a �nem arz etmektedir.
Hipertansiyonun inme i�in maj�r risk fakt�r� oldu�u bilinmektedir. �te yandan
inmeli hastalarda serebral hipoperf�zyon riski nedeniyle anlaml�
hipotansiyondan da ka��n�lmal�d�r. Benzer �ekilde hipertansiyon vask�ler demans
i�in bir risk fakt�r�d�r. Hipotansiyon veya hipertansiyon kaynakl� serebral
perf�zyondaki bozulma kognitif fonksiyonda bozulmaya neden olmaktad�r. �te
yandan PH�de veya otonom n�ropatilerde otonom fonksiyonlardaki bozulma nedeni
ile hipertansiyon tedavisinin s�k <span class=GramE>komplikasyonlar�ndan</span>
olan ortostatik hipotansiyon riski di�er hastalara g�re daha fazlad�r.<b
style='mso-bidi-font-weight:normal'> </b></span><span style='mso-bidi-font-size:
10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Hipertansiyon tedavi
hedefleri ile ilgili son d�nemde yeni g�ncellemeler yap�lm��t�r. 2018 Avrupa
Kardiyoloji Derne�i hipertansiyon tan� ve tedavi k�lavuzunda 65-80 ya� aras�
bireylerde diyabet, koroner arter hastal��� ve kronik b�brek hastal���ndan ba��ms�z
olarak &gt;140 /90mmHg�n�n �zerinde (ofis tabanl� kan bas�nc� �l��m� ile), 80
ya� �st�nde ise 160/90 mmHg�n�n �st�nde tedavi ba�lanmas� �nerilir. Seksen ya�
�zerinde hipertansiyon tedavisi iyi tolere ediliyor ise tansiyon d���r�c�
tedavinin kesilmemesi �nerilir. 2017 ACC/AHA (American Cardiology
Collage/American Heart Association) hipertansiyon k�lavuzuna g�re 65 ya� �st�
bireylerde hedef sistolik kan bas�nc� &lt;130 mmHg (ambulatuar kan bas�nc�
monit�rizasyonu ile) olarak ifade edilmektedir T�m diyabetiklerde <u>&gt;</u>130/80
mmHg ile ila� tedavisi ba�lanmas� �nerilmektedir. Bu hedefler b�y�k �l��de
zinde ya�l�lar i�in ge�erlidir. Komorbidite y�k� fazla olan veya s�n�rl� ya�am
s�resi beklenen olgularda, klinik de�erlendirme/hasta tercihi ve tak�m
yakla��m� ile kan bas�nc� hedefleri bireyselle�tirilmelidir. Ya�l�da
hipertansiyon tedavisinde �nemli s�n�rlama yapan sebepler ortostatik
hipotansiyon, postprandial hipotansiyon ve mental fonksiyonlarda k�t�le�medir. </span><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Ortostatik
hipotansiyonu, kognitif y�k�m�, fonksiyonel k�s�tl�l���, d���k ya�am beklentisi
(&lt;2 y�l) veya d��me riski y�ksek olan ya�l�larda s�k� kan bas�nc� kontrol�
(&lt;140/90 mmHg) uygun de�ildir.</span><b style='mso-bidi-font-weight:normal'><span
style='font-family:"Tahoma","sans-serif"'> <o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Ortostatik
hipotansiyonu (sistolik kan bas�nc�nda <u>&gt;</u>20 mmHg d���� veya diastolik
kan bas�nc�nda <u>&gt;</u>10 mmHg d����) olanlarda t�m antihipertansifler doz
azalt�m� a��s�ndan de�erlendirilmelidir. Ortostatik hipotansiyon y�netiminde
sekonder fakt�rler d��lanmal� ve �ncelikli olarak non-farmakolojik yakla��mlar
uygulanmal�d�r. Bu yakla��mlarla cevap al�namayan hastalarda ila� tedavisi
denenebilir. <span style='color:black'><span style='mso-spacerun:yes'>�</span></span><span
class=GramE><span style='color:black;mso-themecolor:text1'>Non-farmakolojik
yakla��mlar aras�nda aya�a yava� kalkmak, alt </span>ekstremite diren�
egzersizleri, varis �orab� giymek, yeterli s�v� al�m� [2�2,5 L/g�n], alkolden
ka��nmak, az ve s�k yemek yemek, yeterli tuz al�m� [&gt;8g], karbonhidrattan
zengin yiyeceklerden uzak durmak, s�cak havada yo�un egzersizden ka��nmak,
yatarken ba�� 45 derece y�ksekte tutmak bulunmaktad�r. </span>�lkemiz i�in
�zg�n olarak geli�tirilen TIME ila� kullan�m� <span class=GramE>kriterlerinde</span>
ya�l�larda hipertansiyon tedavisi ile ilgili dikkat edilmesi gereken noktalar
vurgulanm��t�r.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:14.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Hiperlipidemi<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'>Belgelenmi� aterosklerotik koroner
arter hastal��� (ge�irilmi� akut koroner <span class=GramE>sendrom</span>,
koroner anjiyografide plak varl���), SVH (ge�irilmi� iskemik SVH/T�A veya
intrakraniyal/ekstrakraniyal ateroskleroz varl���) veya periferik arter
hastal��� olan hastalarda sekonder korunma ama�l� statin tedavisi ba�lanmas�
�nerilmektedir.<span style='mso-spacerun:yes'>� </span>Diabetes mellitus
varl���nda LDL d�zeyi &gt;100 mg/dl olmas� durumunda, e�lik eden en az bir kardiyovask�ler
hastal�k risk fakt�r� (hipertansiyon, ailede kardiyovask�ler hastal�k �yk�s�,
sigara kullan�m�, alb�min�ri gibi) varsa primer kardiyovask�ler korunma i�in
statin tedavisi ba�lanmas� g�ncel k�lavuzlarda �nerilmektedir. Ya�am beklentisi
2 y�ldan d���k olan hastalarda, terminal demans� olanlarda, 85 ya� �st�
hastalarda statinden beklenen faydalan�m d���kt�r; statin yan etkileri
(miyopati, hepatik) daha fazlad�r. Bu hastalarda statin kullan�m�na olgu
baz�nda, hasta/hasta yak�n� bilgilendirmesi ile karar verilmelidir. </span><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>�lkemiz
i�in �zg�n olarak geli�tirilen TIME ila� kullan�m� <span class=GramE>kriterlerinde</span>
ya�l�larda hiperlipidemi tedavisi ile ilgili dikkat edilmesi gereken noktalar
vurgulanm��t�r.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Diabetes mellitus</span></b><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:14.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'><o:p></o:p></span></b></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif";color:black'>Fonksiyonel, kognitif
kapasitesi normal ve ya�am beklentisi, tedaviden yararlanmay� sa�layacak �l�u&#776;de
uzun (�rn. &gt;10 y�l) olan ya�l� hastalarda glisemik kontrol hedefleri, gen�
diyabetliler gibidir. Bu hastalarda Hemoglobin A1C (HbA1c) &#8804;%7, a�l�k ve
��u&#776;n �ncesi plazma glukozu 80-130 mg/dl, gece plazma glukozu 90-150 mg/dl
olarak hedeflenmelidir. �oklu kronik hastal��� olan, hafif-orta derecede
kognitif bozuklu�u olan ya�l�larda ya�am su&#776;resi k�salm��t�r. Bu grup
hastada HbA1c d�zeyi %7,1 ila 8 aras�nda, a�l�k ve ��u&#776;n �ncesi plazma
glukozu 90-150, gece plazma glukozu 100-180 mg/dl olarak hedeflenmelidir.</span><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:14.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'> </span></b><span
style='font-family:"Tahoma","sans-serif";color:black'>Komplikasyonlar�
ilerlemi�, e�lik eden �nemli sa�l�k sorunlar� bulunan, ya�am beklentisi k�sa,
k�r�lgan ve fonksiyonel ya da kognitif kapasitesi s�n�rl� olan ileri ya�taki
diyabetlilerde glisemik ve metabolik hedefler daha esnek tutulmal�d�r. Bu hastalar
i�in HbA1c &gt;%8,5 aras�nda ve a�l�k veya preprandiyal plazma glukozu 100-180
mg/dl, gece plazma glukozu 110-200 mg/dl olmas� �nerilmektedir. Bu grup
hastalarda hipoglisemiden korunma temel hedef olmal� ve tedavide karma��k
olmayan, uygulamas� kolay ve basit ila�lar tercih edilmelidir. �zellikle insu&#776;lin
tedavisi gerektiren hastalarda insu&#776;line ba�lanmadan �nce kognitif
sorunlar de�erlendirilmelidir. </span><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'><o:p></o:p></span></b></p>

<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;
text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'>Diyabet komplikasyonlar�n�n
fonksiyonel kapasiteyi s�n�rlayabilece�i unutulmamal� ve <span class=GramE>komplikasyon</span>
taramalar� g�ncel yakla��mlara uygun olarak yap�lmal�d�r. Bununla beraber ya�am
beklentisi �ok s�n�rl� olan hastalarda <span class=GramE>komplikasyon</span>
taramas� ve erken tedavisinden sa�lanacak ek yararlar�n g�r�lmesi m�mk�n
olamayaca��ndan t�m tarama programlar�n�n uygulanmas� gerekmeyebilir.</span><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:14.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'><o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;font-family:"Tahoma","sans-serif"'>Hipotiroidi-Hipertiroidi<o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-family:"Tahoma","sans-serif"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:10.0pt;line-height:150%;font-family:"Tahoma","sans-serif"'>Ya�l�
hastalarda tiroid hastal�klar� s�k g�r�lmektedir ve tedavi edilmezse ciddi
sorunlara neden olabilmektedir. Ya�l�larda tiroid hastal�klar�n�n tan� ve
tedavisi, <span class=GramE>semptomlar�n</span> tipik olmamas�, normal
de�erlerin gen� eri�kinlere g�re farkl�l�k g�stermesi, komorbiditeler ve
tedavileri nedeniyle hastal���n seyrinin daha ciddi olmas� ve tedavisinin
zorla�mas� gibi bir�ok fakt�r nedeniyle zor olabilmektedir. Ya�l�da
hipotiroidizm dikkat, haf�za, <span class=GramE>konsantrasyon</span> gibi
kognitif fonksiyonlarda bozulmaya neden olabilir. Ayr�ca ciddi hipotiroidizm
depresyon ve demans �eklinde ortaya ��kabilir. �tirodizmin sa�lanmas� ile bu
bulgular genellikle normale d�ner. Ya�l� hastalar tiroid hormon fazlal���na
daha hassaslard�r bu nedenle d���k dozla ba�lan�p doz ayarlamas� dikkatli
yap�lmal�d�r. �yatrojenik tirotoksikoz �zellikle atrial fibrilasyon ve
osteoporotik k�r�klara neden olabilece�i i�in hassas titrasyon �nemlidir.
Ya�l�da TSH d�zeylerinin 4-6 mIU/L tutulmas� �nerilmektedir. Seksen ya�
�zerindeki ya�l�larda ise TSH hedef d�zeyi daha y�ksek d�zeylerde olabilir
ancak TSH 10 mIU/L�yi ge�memelidir.</span><span style='font-family:"Tahoma","sans-serif"'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Subklinik hipotiroidisi olan ya�l�larda (TSH: 4-10 mIU/L;
sT4: N), tiroid hormonu replasman tedavisi ek yarar� olmad���, atrial fibrilasyon
ve osteoporoz gibi potansiyel yan etki riski nedeniyle �nerilmemektedir. Ayr�ca
yetmi� ya� �zerinde subklinik hipotiroidide mortalite daha azd�r ve replasman
ba�lanmas�n�n mortalite �zerinde ek faydas� yoktur. Yetmi� ya� �zerinde
subklinik hipotiroidide TSH &lt;10 mU/L ise takip ve 6 ay sonra TSH kontrol�
�nerilmektedir. </span><span style='font-family:"Tahoma","sans-serif"'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'>Hipertiroidik ya�l� bireylerin 2/3��nde gen� eri�kinlere
benzer <span class=GramE>semptomlar</span> (tremor, anksiyete, �arp�nt�, kilo
kayb�, s�cak intolerans� gibi sempatik hiperaktivite semptomlar�) g�r�l�rken
1/3��nde apatetik hipertiroidizm g�r�l�r. Bu hastalar ba�l�ca atrial
fibrilasyon ve kalp yetersizli�i gibi kardiyak bulgular ve a��klanamayan kilo
kayb� ile ba�vurabilirler. Hipertiroidi saptanan ya�l�larda etyolojiyi
ara�t�rmaya y�nelik uygun tetkikler istenmeli ve k�sa zamanda tedavi
edilmelidir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='mso-bidi-font-size:14.0pt;line-height:150%;font-family:"Tahoma","sans-serif";
background:white'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;color:#212121'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:10.0pt;
line-height:150%;color:#212121'>Kaynaklar: <o:p></o:p></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'>Cruz-Jentoft AJ, Bahat G,
Bauer J, Boirie Y, Bruy�re O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer
AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing
Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2),
and the Extended Group for <span class=GramE>EWGSOP2 .</span> Sarcopenia:
revised European consensus on definition and diagnosis. Age Ageing. 2018 Oct
12. doi: <span class=GramE>10.1093</span>/ageing/afy169. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'>Burgos R, Bret�n I,
Cereda E, Desport JC, Dziewas R, Genton L, Gomes F, J�sus P, Leischker A,
Muscaritoli M, Poulia KA, Preiser JC, Van der Marck M, Wirth R,Singer P,
Bischoff SC. ESPEN guideline clinical nutrition in neurology. Clin Nutr 2018;<span
class=GramE>37:354</span>-396. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'>Bauer J, Biolo G,
Cederholm T, Cesari M, Cruz-Jentoft AJ, Morley JE, Phillips S, Sieber C, Stehle
P, Teta D, Visvanathan R, Volpi E, Boirie Y. Evidence-based recommendations for
<span class=GramE>optimal</span> dietary protein intake in older people: a
position paper from the PROT-AGE Study Group. J Am Med Dir Assoc. 2013;<span
class=GramE>14:542</span>-59 <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'>Inouye SK, Westendorp RG,
Saczynski JS. Delirium in elderly people. Lancet. 2014;383(9920):911-22. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'>Chang JT, <span
class=GramE>Morton</span> SC, Rubenstein LZ, Mojica WA, Maglione M, Suttorp MJ,
Roth EA, Shekelle PG. Interventions for the prevention of falls in older
adults: systematic review and meta-analysis of randomised clinical trials. BMJ.
2004;328(7441):680<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'>Sternberg SA, Wershof
Schwartz A, Karunananthan S, Bergman H, Mark Clarfield A. The identification of
frailty: a systematic literature review. J Am Geriatr Soc. 2011;<span
class=GramE>59:2129</span>-38<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:#212121'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'>Gauthier S. Cholinergic
adverse effects of cholinesterase inhibitors in Alzheimer's disease:
epidemiology and management. Drugs Aging.2001;<span class=GramE>18:853</span>-62.
<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;line-height:150%;color:black;
mso-themecolor:text1'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;line-height:150%;color:black;
mso-themecolor:text1'>Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical
antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. <span
class=GramE>2009 ;360</span>:225-35<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;line-height:150%;color:black;
mso-themecolor:text1'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'>Volkert D, Beck AM,
Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, Kiesswetter E, Maggio M,
Raynaud-Simon A, Sieber CC, Sobotka L, van Asselt D, Wirth R, Bischoff SC.
ESPEN guideline on clinical nutrition and hydration in geriatrics. Clin Nutr.
2018; pii: S0261-5614(18)30210-3. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><sup><span
style='color:red'><o:p>&nbsp;</o:p></span></sup></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
class=GramE><span style='font-size:10.0pt;line-height:150%;color:black'>Morley
JE, Argiles JM, Evans WJ, Bhasin S, Cella D, Deutz NE, Doehner W, Fearon KC, Ferrucci
L, Hellerstein MK, Kalantar-Zadeh K, Lochs H, MacDonald N, Mulligan K,
Muscaritoli M, Ponikowski P, Posthauer ME, Rossi Fanelli F, Schambelan M,
Schols AM, Schuster MW, Anker SD; Society for Sarcopenia, Cachexia, and Wasting
Disease. </span></span><span style='font-size:10.0pt;line-height:150%;
color:black'>Nutritional recommendations for the management of sarcopenia. J Am
Med Dir Assoc. 2010;<span class=GramE>11:391</span>-6. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:150%;color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
class=GramE><span style='font-size:10.0pt;line-height:200%;color:black'>Cederholm
T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, Baptista
G, Barazzoni R, Blaauw R, Coats A, Crivelli A, Evans DC, Gramlich L,
Fuchs-Tarlovsky V, Keller H, Llido L, Malone A, Mogensen KM, Morley JE,
Muscaritoli M, Nyulasi I, Pirlich M, Pisprasert V, de van der Schueren MAE,
Siltharm S, Singer P, Tappenden K, Velasco N, Waitzberg D, Yamwong P, Yu J, Van
Gossum A, Compher C; GLIM Core Leadership Committee; GLIM Working Group. </span></span><span
style='font-size:10.0pt;line-height:200%;color:black'>GLIM criteria for the
diagnosis of malnutrition - A consensus report from the <span class=GramE>global</span>
clinical nutrition community. Clin Nutr. 2018; pii: S0261-5614(18)31344-X. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:200%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;line-height:200%;color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;line-height:150%;tab-stops:45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;line-height:150%'>Ya�l�l�kta
Endokrinolojik Hastal�klar�n Tedavi K�lavuzu, T�rkiye Endokrinoloji Ve
Metabolizma Derne�i, 2018 ISBN: 978-605-4011-29-2 1. Bask�: May�s 2018<o:p></o:p></span></p>

</div>

</body>

</html>
